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Resumo 
 
Em cada dez novos casos de cancro diagnosticados, no mundo, por ano, um é cancro de 
mama. Apesar do aumento da sobrevivência nos países mais desenvolvidos (e com alta 
incidência), relacionado com a existência de rastreio, diagnóstico rápido e melhoria no 
tratamento, o cancro da mama continua a ser a principal causa de morte por cancro em 
mulheres.  
A investigação das últimas décadas tem-se centrado fundamentalmente no tumor e na 
sua genómina considerando-o como uma entidade independente do organismo. Mesmo 
sendo a terapêutica individualizada um dos objectivos major desta pesquisa, as 
características do individuo têm sido poucas poucas vezes valorizadas. 
A hipótese principal deste trabalho foi a de que o tumor é um microsistema a evoluir num 
macrosistema hospedeiro devendo existir uma interdependência entre estes. O conceito 
da influência do macroambiente na evolução tumoral é consistente com a teoria 
Darwiniana da evolução que postula que a seleção é uma propriedade essencial dos 
sistemas biológicos. Isto é, assim como as forças ambientais poderão explicar os padrões 
de incidência do cancro da mama na população mundial, também os factores do 
hospedeiro poderão selecionar os fenótipos do tumor. De facto, dados recentes indicam 
que alguns factores de risco conhecidos para o cancro da mama são condições 
sistémicas como a obesidade ou a diabetes. A prevalência epidémica da obesidade e das 
suas comorbilidades têm sido investigadas como possíveis razões para o aumento da 
incidência do cancro nas sociedades ocidentais. No entanto, apesar de as alterações do 
perfil lipídico, nomeadamente a hipercolesterolémia, serem também prevalentes nestas 
regiões o papel do metabolismo lipídico sistémico no cancro da mama permanece por 
esclarecer. 
Os lípidos são fundamentais para as células, onde actuam quer como constituintes 
celulares quer como moléculas de sinalização. O colesterol, especificamente, é um 
componente essencial das membranas celulares onde se concentra nos denominados 
“lipid rafts”, microdomínios da membrana envolvidos na polaridade da célula, migração, 
proliferação, sobrevivência e angiogénese. O colesterol é também o precursor obrigatório 
das hormonas esteróides como o estrogénio e progesterona, sendo a vasta maioria dos 
tumores de mama hormono-sensíveis. 
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Até agora,a maioria dos estudos publicados sobre relação entre o colesterol e o cancro 
da mama tentaram demonstrar causalidade entre os níveis séricos e a incidência de 
cancro. Raros estudos exploraram a eventual associação com a agressividade tumoral ou 
com a sua progressão. Portanto, a importância do colesterol plasmático na progressão do 
cancro da mama é desconhecida. Esta Tese visou estudar o papel do colesterol 
sistémico na progressão do cancro da mama e os mecanismos moleculares 
subjacentes 
Para tal foi desenhado um estudo observacional prospectivo que seguiu um coorte de 
mulheres com cancro de mama (estadios I-III), sem tratamento prévio. Os resultados 
mostraram que o nível de LDL-C no momento do diagnóstico se correlaciona 
positivamente com o tamanho e estadio do tumor. Aos 2 anos de seguimento, mulheres 
com níveis de LDL-C mais elevados no diagnóstico tiveram menor tempo livre de doença. 
Estes dados apontam o LDL-C como um biomarcador de agressividade tumoral (factor de 
prognóstico) e um possível alvo terapêutico (factor preditivo). 
Para provar a relação causal do ambiente enriquecido em colesterol na progressão do 
tumor foram usados modelos bem estabelecidos in vitro e in vivo que permitiram 
demonstrar que a sinalização mediada pelo LDL-C induz fenótipos tumorais, semelhantes 
aos observados nos doentes com cancro de mama e caracterizados por maior 
proliferação e capacidade invasora. As células expostas a concentrações maiores de 
LDL-C apresentam características genotípicas distintas, compatíveis com um fenótipo 
mais agressivo, como confirmado por análise de expressão génica. Experimentalmente 
foi demonstrado que a expressão tumoral do ABCA1 (principal exportador celular de 
cholesterol) num ambiente enriquecido em colesterol é um marcador do fenótipo induzido 
pelo LDL-C. 
Em conjunto, os resultados desta tese ilustram a influência do metabolismo sistémico na 
progressão do cancro da mama e sugerem que o perfil lipídico deve ser avaliado em 
todos os doentes com este diagnóstico. Sendo a hipercolesterolémia tão prevalente nas 
sociedades ocidentais com uma distribuição global paralela à incidência do cancro da 
mama, é de esperar que a modulação do perfil lipídico nestes doentes tenha um impacto 
elevado como estratégia de prevenção (secundária). Isto parece particularmente 
relevante para os doentes com tumores não hormono-sensíveis já que não existem 
outras formas de quimioprevenção. 
Palavras-chave: cancro da mama; colesterol, LDL-C 
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Abstract 
One in ten of all new cancers diagnosed worldwide, each year, is a breast cancer. Despite 
the more favorable survival of breast cancer patients in (high-incidence) developed 
regions due to screening, faster diagnosis and improved treatment, it remains the most 
frequent cause of cancer-related death in women.  
The research of the last decades focused primarily on tumor genomics considering the 
tumor as an entity independent of the organism. Although the personalized therapy has 
been the ultimate goal of this aproach, host characteristics were seldom valued. 
Our working hypothesis states that the tumor is a microsystem evolving within a host 
macrosystem and an- interdependence between them must exist. The concept of the 
influence of the macroenvironment in tumor development is consistent with the Darwinian 
theory of evolution that postulates selection as a fundamental property of biological 
systems. As environmental forces may explain breast cancer incidence patterns in the 
world population, host environmental factors may drive breast cancer phenotypes. Recent 
data indicate that some known risk factors for breast cancer are indeed systemic 
conditions such as obesity or diabetes. The epidemic prevalence of obesity and its 
associated comorbidities have been investigated as possible reasons for the increased 
incidence of cancer in Western societies. Although altered lipid profiles, including 
hypercholesterolemia, are extremely prevalent in these areas the role of systemic lipid 
metabolism in breast cancer is poorly understood. 
Lipids are fundamental to cells, where they act either as constituents of the cell or as cell 
signaling molecules. Cholesterol, in particular, is an essential component of cell 
membrane bilayer, where it concentrates on the so-called lipid rafts-membrane 
microdomains which are involved in cell polarity, migration, proliferation, survival and 
angiogenesis. Cholesterol is also an obligatory precursor of steroid hormones, such as 
estrogen and progesterone, being the vast majority of breast tumors hormone responsive. 
To date, most studies have seek to find a causal relation between cancer incidence and 
cholesterol plasma levels, however, fewer studies adressed a possible link in tumor 
aggressiveness or on its progression. Thus, for now, the importance of plasma cholesterol 
in breast cancer progression is largely unknown.  
This Thesis aimed to study the role of systemic cholesterol in breast cancer 
progression and the underlying molecular mechanisms.  
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To do that, an observational prospective study was designed to follow a cohort of women 
with breast cancer (stages I-III), without previous treatment. Results show that plasma 
LDL-C at diagnosis positively correlates with tumor size and stage. At 2 years of follow up, 
higher levels of LDL-C were associated with reduced disease-free survival. These data 
indicate LDL-C as a biomarker of tumor aggressiveness (prognostic factor) and a possible 
therapeutic target (predictive factor). 
To demonstrate a causal implication of cholesterol-enriched environment in tumor 
progression, well established in vitro and in vivo models were used. Results revealed that 
LDL-C signaling induces a tumor phenotype, also observed in breast cancer patients 
characterized by increased cell proliferation and invasion. Cells exposed to higher LDL-C 
concentrations have distinct genetic expression, supporting an aggressive phenotype, as 
confirmed by gene expression analysis. It was also experimentally shown that tumor 
ABCA1 (main cellular membrane cholesterol exporter) expression in cholesterol-enriched 
environment is a marker of LDL-C induced phenotype. 
Together, the results of this thesis illustrate the influence of systemic metabolism in breast 
cancer progression and suggest that lipid profile must be assessed in all breast cancer 
patients. Being hypercholesterolemia so prevalent in Western societies with a global 
incidence pattern superimposing that of breast cancer, the modulation of cholesterol 
plasma levels are expected to have a major impact in (secondary) prevention. This seems 
particularly relevant for patients with hormone unresponsive tumors, for which no 
chemopreventive strategy exists. 
 
Key words: breast cancer, cholesterol, LDL-C 
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ECM: extracellular matrix 
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HIF-1: hypoxia-inducible factor 1 
HMGR: hidroxi-3-methyl-glutaril-CoA reductase  
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IGF-1R: insulin-like growth factor 1 receptor 
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JNK: jun amino-terminal kinase 
Ki-67: antigen identified by monoclonal antibody Ki-67 
LDL (=LDL-C): low-density lipoprotein  
LDLR: low-density lipoprotein receptor 
LRP1: low density lipoprotein receptor-related protein 1 
LVI: lymphovascular invasion 
LXR: liver X receptors α (LXRα) and β (LXRβ)
 
MAPK: mitogen activated protein kinase 
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mTOR: mammalian target of rapamycin 
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PDGFR: platelet-derived growth factor receptor 
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PI3K: phosphoinositide 3-kinase 
PLC: phospholipase C 
PR: progesterone receptor 
PTEN: phosphatase and tensin homolog 
PUFA: polyunsaturated fatty acids  
RB: retinoblastoma-associated gene 
Rb: retinoblastoma-associated protein 
RE: endoplasmasmic reticulum 
RIPA: radioimmunoprecipitation assay 
RNA: ribonucleic acid 
ROS/RNS: reactive oxygen species/reactive nitrogen species  
RR: relative risk; 
RTC: randomized control trials  
SCAP: sterol regulatory element-binding protein cleavage activating protein 
SDF-1: stromal cell-derived factor 1 
SDS: sodium dodecyl sulfate 
SEM: standard error of the mean 
SFK: Src family of kinases  
Shh Sonic hedgehog protein 
siRNA: small interfering ribonucleic acid 
SOS: son of sevenless  
SR-A1/2: scavenger receptors class A  
SR-BI: scavenger receptors class B 
SREBP: sterol regulatory element-binding protein 
TC: total cholesterol 
TGFα: transforming growth factor alfa 
TGF-β: transforming growth factor beta 
Tie-2: angiopoietin receptor 2 
TNF: tumor necrosis factor 
TP53: tumor suppressor protein p53 gene 
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 uPAR: urokinase-type plasminogen activator receptor 
VEGF-A: vascular endothelial growth factor-A  
VLDL: very low-density lipoprotein  
WHO: World Health Organization 
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General Introduction  
 
The general introduction of this Thesis is organized in two parts. The first one reviews the 
actual knowledge of breast cancer ethiopathogenesis and highligths some gaps in breast 
cancer research. The second part, briefly describes cholesterol functions and metabolism 
exploring published data on the relationship between cholesterol and breast cancer.  
I. Breast cancer–The problem 
Incidence and mortality  
Cancer and cardiovascular diseases are the leading causes of death in the West1,2 and 
are dramatically rising in Asian countries3,4. 
During 2012, there were over 3,4 million new cases of cancer, in Europe (excluding skin 
non-melanoma cancers) (Graphic 1). The most common cancer site was breast (464,000 
cases, 13,5% of all cancer cases) and among women, breast cancer was the leading 
cause of death (131,000, 16,8% of all cancer)5 
 
Graphic 1: Estimated number of new cases from cancer by site in Europe in 2012. 
( Data from J. Ferlay et al, ,20136.) 
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In Portugal, breast cancer is the most frequent cancer in women, and despite being the 
cancer specific site (excluding skin cancers) responsible for the largest volume of 
oncologic treatments, including oncologic surgery, it still is the first cause of cancer-related 
death7. 
Faster diagnosis and progresses in systemic treatment have improved survival rates in 
the last three decades8,9,10, but advanced cases (stage IV) have 5-year survival rate of 
25%11. Identifying cases that will progress and that should be treated aggressively 
remains a major problem. 
 
Etiopathogenesis 
Breast cancer has been attributed to a combination of genetic susceptibility and other 
patient factors including age, reproductive, hormonal and lifestyle features. 
Age  
Breast cancer is extremely rare among women younger than 20 years old and is 
uncommon among women younger than 30 years old. Incidence increases sharply with 
age, being two thirds of invasive breast cancers found in women older than 55 
years11(Graphic 2). 
 
 
Graphic 2: Percentage of new cases of breast cancer, by age. 
 Percentage of new cases in females of all races, 2007-2011. Data from Surveillance, Epidemiology and End 
Results Program (www.seer.cancer.gov)
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Genetic factors 
By 1980, a significant body of evidence supported the presence of inherited factors 
responsible for familial clustering of breast cancer12, and scientific efforts shifted to 
determine its inheritance pattern. Thirty years later, high-penetrance cancer susceptibility 
genes appear directly responsible for only 5-10% of all breast cancers. BRCA1 and 
BRCA2 gene mutations are the most common and well-studied genes associated with 
inherited breast cancer and account for almost all these cases13. Mutations in p53 (Li-
Fraumeni syndrome14), PTEN (Cowden syndrome15), CHEK216, STKI/LKB1 (Peutz-
Jeghers syndrome17), ATM18, MSH2/MLH1 (Muir-Torre syndrome19), PALB220, BRIP121, 
were also described in breast cancer families but are less common. 
The search for low penetrance alleles, either by candidate gene approach or genome 
wide association studies, did not produce major clinical impact. Apart from the 
identification of some loci strongly associated with breast cancer risk22,23,24, the 
understanding how this knowledge can be applied clinically, is still missing. On the other 
hand, the identification of small interfering ribonucleic acids (siRNA) uncovers a new level 
of regulation of gene expression. Ribonucleic acids (RNAs) are the direct products of 
genes, and these small RNAs, also called micro RNAs (miRNAs) can bind to other 
specific messenger ribonucleic acid (mRNA) molecules and either increase or decrease 
their activity, resulting in gene silencing via translational repression or target degradation, 
thus, preventing protein expression25. It is now believed that as much as 92% of gene 
expression is regulated by siRNAs26. In breast cancer miRNAs show differential 
expression across molecular subtypes, and show both oncogenic and tumor-suppressive 
roles dependent on the context27. 
Non-genetic factors 
Reproductive factors, hormonal factors and nutritional/lifestyle are considered non-genetic 
breast cancer risk factors. Whereas the causal effect of some of them is accepted, their 
individual strength and how they correlated with each other is more difficult to define.  
Reproductive factors 
Early age menarche28, late menopause29 and nuliparity28, have all been consistently 
associated with increased risk of breast cancer28. Most studies point the early onset of 
ovulatory menstrual cycles and the greater lifetime exposure to endogenous hormones to 
be the reason of such association30. First pregnancy leads to proliferation of breast cells, 
which results in differentiation into mature cells prepared to lactation. After differentiation, 
epithelial cells have a longer cell cycle and spend more time in the G1 phase allowing for 
DNA repair31. In the same trend, lactation may be a protective factor because breast-
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feeding results in further terminal differentiation of the breast epithelium and delays the 
return of ovulatory menstrual cycles after pregnancy. 
Hormonal factors 
Several lines of evidence have long suggested that sex hormones play a central role in 
the etiology of breast cancer. In animals, estrogens, progesterone, and prolactin all 
promote mammary tumors. Data from randomized controlled trials (RTC) have confirmed 
the epidemiologic relations of hormone therapy to increased risk of breast cancer and 
estrogen plus progestin therapy is now classified as a human carcinogen32,33,34. 
Conversely, hormonal manipulations, such as anti-estrogens and aromatase inhibitors are 
useful in the treatment of breast cancer and in reducing breast cancer incidence in high 
risk women35,36,37.. 
Nutrition/ lifestyle factors 
Around the world, nutritional factors have been prominent among the hypothesized 
environmental determinants of breast cancer incidence and in the large increase in rates 
of migrant populations from low-incidence to high-incidence countries38,39. The dominant 
hypothesis has been that high-fat intake increases the risk of breast cancer. In agreement, 
overweight and obesity were clearly associated with increased incidence of breast cancer 
in postmenopausal women and a higher mortality rates40,41,42,43. Studies specifically 
addressing high-fat diet in breast cancer risk, showed increased occurrence of mammary 
tumors in rodents44,45 although some of these studies loses the strong association when 
adjusted to energy intake46. Human ecological studies evidences that fat consumption per 
capita is highly correlated with breast cancer mortality rates47; and intervention studies 
show that the implementation of weight loss and low fat intake programs reduce breast 
cancer risk in 9% between interventional and control groups48. 
Other dietary elements possibly associated to breast cancer, include a positive 
association with alcohol consume49 and a negative association with vitamin D50,51,52 intake.  
Physical exercise is suggested as protective53, through body mass index (BMI) reduction, 
menarche delay, sex hormones and insulin-like growth factors lowering and by improving 
immune function54, 55. 
Other factors 
Other variables searched for a relation with breast cancer risk include; proliferative breast 
diseases, ionizing radiations, active and passive smoking, silicone breast implants, 
diabetes mellitus, thyroid cancer, non-steroid anti-inflammatory drugs (NSAID’s), statins 
and antidepressants use. As for comproved risk factors, the relative weight of each factor 
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is hard to predict in the individual case (Table 1) and for some of them the literature is 
very scarce. 
Proliferative breast diseases without atypia slightly increases the risk of breast cancer 
while atypical hyperplasia represents a moderate increased risk of breast cancer applying 
for both glands even when it is only unilateral56.  
Ionizing radiation to the chest, in cumulative doses at young age, substantially increases 
breast cancer risk. Evidence on this topic comes from atomic bomb survivors57, 
therapeutic58 and occupational59 radiation use studies. The regular diagnostic radiation 
use, such as the mammographic screening, shows no significant increased risk of breast 
cancer60. 
Recent studies have shown the association of type 2 diabetes with the incidence of breast 
cancer61,62,63 and cancer-specific mortality. This association was most pronounced in 
postmenopausal women and ER-positive disease63. This effect is attributed to insulin, 
which acts as a breast cancer cell growth factor64,65. But because many other conditions 
lead to hyperinsulinemia, further studies on the relationship between breast cancer and 
insulin resistance are warranted. Nevertheless, clinical trials with oral anti-diabetics drugs 
are in course66. 
Table 1: Risk factors for breast cancer and approximate strength of association 
Reproductive 
Factors 
Hormonal 
Factors 
Nutritional/Lifestyle 
Factors 
Others 
Factors 
Early age at 
menarche + 
 
Oral contraceptives 
use (current vs 
none) + 
Obesity (BMI>30vs>25) 
Premenopausal – 
Postmenopausal + 
Family history 
(mother and sister) 
+++ 
Age at first birth 
(>35vs<20) ++ 
 
Estrogen 
replacement (10 
years vs none) + 
Adult weight gain 
(postmenopausal) ++ 
Family history (1
st
–
degree relative) ++ 
No. of births (0 vs 1 
child) + 
 
Hormone 
replacement (>5 
years vs none) ++ 
Alcohol (one or more 
drink vs none) + 
Jewish heritage 
(yes vs no) + 
Age at menopause 
(5-years increment) 
+ 
↑ blood estr./andr 
(post menopause) 
+++ 
Physical activity 
(>3hours/week) - 
Ionizing radiation 
(yes vs no) + 
Breast-feeding 
(>1year vs none) - 
High blood prolactin 
++ 
Monounsaturated fat (vs 
saturated fat) - 
Benign breast 
disease ++ 
- no risk; +low risk; ++moderate risk; +++high risk  
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Although the relative strength of known or suspected breast cancer risk factors are 
modest in magnitude (RR are usually in the range of 1.3 to 1,8) the impact of risk factors 
control could be very large. When considering (primary) prevention, it is important to 
remember that even small changes at individual level can produce substantial changes in 
population rates of disease67. A recent study estimates that up to 27% of breast cancer-
related deaths would be avoided with control of key behavioral and environmental risk 
factors such as alcohol use, overweight and obesity and physical inactivity68.  
Nevertheless, only about 30% of breast cancers are estimated to be explained by known 
risk factors69, leading to the hypothesis that other environmental factors could play a major 
role. On the other hand, mechanisms linking known and suspected risk factors to the 
initiation and development of breast cancer are poorly understood. Therefore, there may 
still be a large amount of unknown risk factors to breast cancer etiopathogenesis. 
Phenotypes 
Invasive breast cancers are a heterogeneous group of lesions differing with regard to their 
clinical presentation, imagiological appearance, pathological features, gene expression 
profiling and biological behavior.  
The phenotype is usually based on the histological characteristics of the tumor, enclosing 
a range of genotypes and biological behaviors. In clinical practice, the phenotype is used 
to define therapy and prognosis.  
Based on World Health Organization (WHO)70, the most widely used histological 
classification system of breast cancers, the most common histological type is invasive 
(infiltrating) ductal carcinoma (53-70%), recently denominated invasive carcinoma, not 
otherwise specified (NOS). The other types comprises a group of invasive breast cancers 
with specific or special histological features: invasive lobular carcinoma (5-16%), medullar 
(3-9%), tubular (1-3%), mucinous (1-2%), and other rare types71,72,73. Non-epithelial breast 
cancers such as sarcomas or lymphomas are even rarer. 
The routine pathologic examination of invasive breast cancers defines the histological 
type and the grade. Histological grade is based on the degree of differentiation of the 
tumor tissue. For breast cancer the most reproduced system is the Nottingham (Elston-
Ellis) grade system74. It refers to the semi-quantitative evaluation of three morphological 
characteristics: degree of tubule or gland formation, nuclear pleomorphism and mitotic 
count. The final score shows a very strong correlation with prognosis; patients with grade I 
tumors have a significantly better survival than those with grade II and III tumors75. 
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Additionally, three immunohistochemical markers (estrogen receptor (ER), progesterone 
receptor (PR) and human epidermal growth factor receptor 2 (ERBB2 or Her-2/neu 
receptor or HER2)) are generally used to identify biological properties. And in the last 
years, proliferative markers such as Ki67 are also used to determine tumor index 
proliferation rate, since it was demonstrated to have correlation with prognosis76. 
The tumor subgroups identified by immunohistochemistry closely resemble the molecular 
subtypes, defined by Sorlie et al, based on gene expression profiling studies: Luminal A, 
Luminal B, HER2 type and basal-like77.  
Luminal A and luminal B cancers generally have a good prognosis and show high 
expression of hormone receptors and associated genes. Together, these two subtypes 
account for approximately 70% of all breast cancers. The luminal B cancers tend to be 
higher grade than the luminal A and some of them may overexpress HER2. Both luminal 
A and luminal B cancers usually respond to hormone therapy, with luminal A cancers 
showing the improved response. Response of the luminal cancers to chemotherapy is 
variable, with the luminal B cancers generally showing better response.  
The HER2 type cancers show high expression of HER2 and low expression of ER and 
associated genes. They account for approximately 15% of all breast cancers and are 
generally ER or PR negative. HER2 cancers are more likely to be high grade and have 
positive lymph nodes. These cancers show the best response to trastuzumab and to 
anthracycline-based chemotherapy but, overall have a poor survival prognosis.  
The basal-like breast cancers show high expression of basal epithelial genes and basal 
cytokeratins, low expression of ER and ER associated genes as well as low expression of 
HER2. They constitute approximately 15% of all breast cancers and are often referred to 
as triple negative cancers, because they are invariably ER, PR, and HER2 negative. The 
basal-like tumor phenotype is especially common in African-American women and is also 
the most common phenotype of BRCA1-associated breast cancers. Basal-like cancers 
have a poor prognosis and are not amenable to treatment with either hormonal or 
biological therapy. 
. 
Prognostic and predictive markers  
Despite usefulness of pathological characteristics, in which clinical practice and 
therapeutic decision are based, they do not linearly correlate with tumor biology and 
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behavior. In order to define prognosis and predict therapeutic response, clinicians classify 
a newly diagnosed breast cancer through stage and a panel of associated factors.  
The American Joint Committee on Cancer (AJCC) system is the most used to stage 
tumors. It is both a clinical and pathological staging and is based on the TNM system, in 
which T refers to tumor, N to regional lymph nodes, and M to distant metastasis78 
At present, the prognostic and predictive factors of primary breast cancers used in clinical 
practice are79: 
1. Axillary lymph node status, including micrometastasis (Nmic) 
2. Tumor size 
3. Histological subtype 
4. Histological grade 
5. Proliferation indices, including mitotic index 
6. Estrogen and progesterone receptor status (mainly as predictive markers of response 
to hormonal therapies)  
7. HER2 amplification or overexpression (mainly as a predictive marker of response to 
trastuzumab and possibly as predictive of benefit from anthracyclines) 
8. Multiparameter-based markers (mainly as prognostic indicator of recurrence risk). 
The identification of a single biomarker to predict prognosis and response to therapy 
would be a major step forward in oncology. However, one of the hallmarks of cancer is the 
redundancy of cellular pathways, leading this single biomarker difficult to obtain. 
In the last decades technology for individualizing therapy on the basis of gene arrays for 
tumor characteristics has bloomed and was heralded to dictate the future individualized 
therapy. For instance, gene arrays, also termed gene expression arrays or DNA 
microarrays, are a method to simultaneously determine the expression levels of up to 
25,000 human genes in a tumor or normal tissue simultaneously. Among several gene 
expression based prognosticators80,81,82 only few was validated, but they do not replace 
traditional prognostic factors. Even the most validated assays have been studied only in 
relatively small datasets or as subsets of larger clinical trials and many of them have not 
been validated at all on independent test sets. Moreover, the field of breast cancer 
therapy is rapidly changing and the natural history of breast cancer can be very long. In 
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these circumstances the evidence on prognosis and efficacy of a given approach can be 
obsolete during development of validation studies.  
On opposition relation of tumor with other host pathological or physiological pathways has 
barely been explored. For example, the effectiveness of certain drugs, such as tamoxifen 
and the chemotherapy irinotecan, is mediated by metabolism of cytochrome P450 
enzymes, mainly in the liver. Based on genetic polymorphisms the activity of such enzyme 
complex have considerable inter-individual variability83. This aspect may contribute to the 
observed variability in the response to hormone therapy. This underlines the dependency 
of the host and how systemic characteristics need to be considered for tumor biology 
interpretation and treatment strategy. 
The future of prognostication and prediction may rely on the integration of classic 
biomarkers, such as ER status and stage, with genomic biomarkers and individual 
characteristics.  
 
Tumor biology  
Normal cells became neoplastic and lead to the onset of cancer by progressively 
acquiring hallmark capabilities such as: sustained proliferative signaling, cell death 
resistance, evasion to growth suppressors, replicative immortality and angiogenic and 
invasion (metastastatic) potential. Reprogramming energy metabolism and evasion from 
immune destruction are now being considered as emerging hallmarks84.  
Breast cancer proliferation genetics and signaling pathways 
Proliferation signals are conveyed in large part by growth factors that bind cell-surface 
receptors, typically containing intracellular tyrosine kinase domains. These emit signals 
via branched intracellular signaling pathways that regulate cell cycle, progression and 
proliferation. Often, these signals influence other cell-biological properties, such as cell 
survival and energy metabolism.  
 
Cancer cells may produce growth factor ligands themselves, resulting in autocrine 
proliferative stimulation or, alternatively send signals to stimulate normal cells within the 
supporting tumor-associated stroma, which supply cancer cells with various growth 
factors85,86. Receptor signaling can also be deregulated by elevating the levels of receptor 
proteins at the cancer cell surface, rendering such cells hyperresponsive. Growth factor 
independence may also derive from the structural alterations in the receptor molecules or 
constitutive activation of elements of signaling pathways operating downstream of these 
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receptors. Given that a number of distinct downstream signaling pathways radiate from a 
ligand-stimulated receptor, the activation of one or another of these downstream pathways 
may only recapitulate a subset of the regulatory instructions transmitted by an activated 
receptor. In breast cancer, some of these mechanisms have been demonstrated. 
Estrogen and progesterone induce proliferation and differentiation of normal breast 
epithelium. Their effects are mediated trough ER and PR, respectively. ER is highly 
elevated in nearly all precursors87,88 and drugs targeting this receptor (e.g. tamoxifen) 
reduce breast cancer by 50%36,89. Nuclear/genomic ER can activate growth factor 
pathways by increasing the expression of ligands (transforming growth factor α-TGFα, 
amphiregulin), receptors (insulin-like growth factor 1 receptor -IGF-1R), or other signaling 
intermediate molecules (insulin receptor substrate-1) which are estrogen regulated and 
important for growth factor activity90. In addition to the genomic activity, ER has a non-
genomic action by membrane initiated steroid signaling91. Membrane ER may exist as a 
cytoplasmic entity tethered to the inner face of the plasma membrane bilayer through 
binding to proteins of lipid rafts, scaffold or adaptor proteins92,93, or possibly associating 
with other membrane receptors, such as IGF-1R94,95 epidermal growth factor receptor 
(EGFR)96, or ERBB292,97.  
 
ERBB2 (also known as neu oncogene or HER2) amplification, with resultant ERBB2 
protein overexpression, has been shown to play a role in sustaining multiple cancer 
pathways, including self-sufficiency in growth signals, sustained angiogenesis, increased 
cell division, and enhanced invasion98,99,100. ERBB2 receptor (amplifications or 
overexpression)101 are present in 15-20% of breast cancers and inhibition of ERBB2 
membrane signaling in these cancer cells through administration of humanized anti-
ERBB2 antibodies (trastuzumab) or administration of small molecule inhibitors of ERBB2 
tyrosine kinase activity (lapatinib) is associated with improved patient outcomes for 
women with both primary and metastatic disease102,103,104. 
Constitutive activation of signaling circuits usually triggered by activated growth factor 
receptors is also a cancer cell mechanism to proliferate. Mutations in the phosphoinositide 
3-kinase (PI3K) pathway are frequent in breast cancer, causing resistance to ERBB2-
targeting agents and, possibly, to hormonal agents as well. Multiple PI3K inhibitors are 
currently under development, including pure PI3K inhibitors, compounds that block both 
PI3K and mammalian target of rapamycin receptor (mTOR) (dual inhibitors), pure catalytic 
mTOR inhibitors, and inhibitors that block Akt105. 
Disruptions of negative-feedback mechanisms that attenuate proliferative signaling are 
another way of tumor cell perpetuates proliferation. Defects in ras GTPase, phosphatase 
and tensin homolog (PTEN) phosphatase and mTOR kinase are examples105 (Figure 1). 
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Figure 1: Major pathways regulating proliferation of breast cancer cells. 
Abbreviations: CBP:CREB binding protein; ER:estrogen receptor; ERE:estrogen-responsive element; HER2: 
human epidermal growth factor receptor 2; MAPK:mitogen-activated protein kinase; MEK:mitogen-activated 
protein kinase/extracellular signal–related kinase kinase; mTOR:mammalian target of rapamycin; 
PI3K:phosphoinositide-3kinase; SOS:son of sevenless. (Adaptated from Di Cosimo S et al, Management of 
breast cancer with targeted agents: Importance of heterogenicity,2010
106
)  
 
In addition, evading growth suppressors will also promote proliferation. The two 
prototypical tumor suppressors encode retinoblastoma-associated protein (Rb) and tumor 
suppressor protein p53 (p53). TP53 (p53 gene) mutations are common in precursors 
lesions and breast cancer and are supposed to be the cause of 1% of hereditary 
cases13,107. 
Growth factor–dependent and hormone-dependent signaling are not the only important 
signal transduction pathways that derive from the cell surface. Two important classes of 
adhesion-dependent signals also play roles in cell growth, differentiation, and survival, as 
well as in motility and invasion of breast cancer cells: integrin and cadherin adhesion 
molecules108,109. 
Integrins carry signals from the extracellular matrix into the cell. Integrins signal cells 
through many pathways, but one that has received considerable current interest is the 
focal adhesion kinase (Fak)-Src pathway. Activation of these two tyrosine-kinase–
encoding oncoproteins activates the PI3K and Akt candidate oncoproteins, leading to 
multiple aspects of malignant behavior108,109. Of considerable interest, the tumor-
suppressive phosphatase PTEN acts on Fak, PI3K, and Akt as its substrates to suppress 
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survival and induce apoptosis. However, mutations of PTEN do not appear to be 
particularly common in sporadic breast cancer110,111. 
 
One of the functions of E-cadherin is to restrict cell motility, but it also diminishes the 
cytoplasmic pool of the important proliferation-modulating βcatenin transcription factor. 
The tumor-suppressive E-cadherin gene is commonly silenced by DNA methylation or 
mutation in breast cancer, releasing βcatenin to potentially up-regulate expression of the 
c-myc protooncogene (v-myc avian myelocytomatosis viral oncogene homolog)112,113. The 
βcatenin pathway may also be up-regulated by growth factor pathways, such as epidermal 
growth factor (EGF), hyperglycemic-glycogenolytic factor, and WNT (wingless) 
signaling114. 
Cell death mechanisms 
By 2000, it was widely accepted that cancer cells require unlimited replicative potential in 
order to generate macroscopic tumors. However, a balance between replication and death 
is required and involved in cancer progression. Cell death can occur by several 
mechanism including apoptosis or oncosis. 
The concept that programmed cell death by apoptosis serves as a natural barrier to 
cancer development has been established by compelling functional studies 115,116,117. The 
apoptotic machinery is composed of both upstream regulators and downstream effector 
components115. The regulators, in turn, are divided into two major circuits, one receiving 
and processing extracellular death-inducing signals (the extrinsic apoptotic program, 
involving for example the Fas ligand/Fas receptor), and the other sensing and integrating 
a variety of signals of intracellular origin (the intrinsic program). Each one culminates in 
the activation of a normally latent proteases (caspases 8 and 9), that proceed to initiate a 
cascade of proteolysis involving effector caspases responsible for the execution phase of 
apoptosis, in which the cell is progressively disassembled and then consumed, both by its 
neighbors and by professional phagocytic cells. The ‘‘apoptotic trigger’’ that conveys 
signals between the regulators and effectors is controlled by counterbalancing pro- and 
anti-apoptotic members of the Bcl-2 family of regulatory proteins115. Although the cellular 
conditions that trigger apoptosis remain to be fully enumerated, several abnormality 
sensors that play key roles in tumor development have been identified115,116. Most notable 
is DNA damage sensor that functions via the p53 tumor suppressor protein118. As referred 
previously, mutations in p53 leads tumor cells to evade growth suppression.  
Trigger apoptosis signaling circuit is the mechanism of action of some anticancer therapy 
but is also a response to various physiological stresses that cancer cells experience 
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during the course of tumorigenesis and is substantially elevated in proliferative lesion such 
as higher grade DCIS119,120. This exposes that much more remains to elucidate about this 
process.  
 
In contrast to apoptosis, cells dying by oncosis (commonly denominated necrosis, which 
refers just to the pathological aspect of cell death) become bloated and explode, releasing 
their contents into the local tissue microenvironment. Although oncosis has historically 
been viewed much like organismic death, as a form of system-wide exhaustion and 
breakdown, the conceptual landscape is changing: cell death by necrosis is clearly under 
genetic control in some circumstances, rather than being a random and undirected 
process121,122. Perhaps more important, necrotic cell death releases pro-inflammatory 
signals into the surrounding tissue microenvironment, in contrast to apoptosis and 
autophagy, which do not. Consequently, necrotic cells can recruit inflammatory cells of the 
immune system. Multiple lines of evidence indicate that immune inflammatory cells can 
promote tumor progression, given that such cells are capable of fostering angiogenesis, 
cancer cell proliferation, and invasiveness123,121. 
Autophagy is a process by which cells clear damaged or superfluous proteins and 
organelles. The recycling of these intracellular constituents also serves as an alternative 
energy source during periods of metabolic stress to maintain homeostasis and viability. 
Although not a cell death process, recent evidence suggests that autophagy provides a 
protective function to limit tumor necrosis and inflammation, and to mitigate genome 
damage in response to metabolic stress and defects in apoptosis124. The mechanism 
behind this has not been totally determined but is expected to be an anticancer target in 
near future125. 
Tumor neo-vascularization 
Like normal tissues, tumors require sustenance in the form of nutrients and oxygen as 
well as an ability to evacuate metabolic wastes and carbon dioxide. The tumor-associated 
neovasculature, generated by the process of angiogenesis, addresses these needs. 
During embryogenesis, the development of the vasculature involves the generation of new 
endothelial cells and their assembly into tubes (vasculogenesis) in addition to the 
sprouting (angiogenesis) of new vessels from existing ones. Following this 
morphogenesis, the normal vasculature becomes largely quiescent. In the adult, in 
physiological processes such as wound healing and female reproductive cycling, 
angiogenesis is turned on, but only transiently. In contrast, during tumor progression, an 
‘‘angiogenic switch’’ is almost always activated and remains on, causing normally 
quiescent vasculature to continually sprout new vessels that help to sustain expanding 
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neoplastic growth126. A compelling body of evidence indicates that the angiogenic switch 
is governed by factors that either induce or oppose angiogenesis127,128. The well-known 
prototypes of angiogenesis inducers and inhibitors are vascular endothelial growth factor-
A (VEGF-A) and thrombospondin-1, respectively129. Histological studies of premalignant, 
noninvasive lesions, including dysplasias and in situ carcinomas arising in a variety of 
organs, have revealed the early triggering of the angiogenic switch126. Although 
angiogenesis is well documented in breast cancer progression anti-angiogenic drugs 
failed to show the expected clinical success130. 
Cancer metabolism 
The chronic and often uncontrolled cell proliferation that represents the essence of 
neoplastic disease involves not only deregulated control of cell proliferation but also 
corresponding adjustments of energy metabolism in order to fuel cell growth and division. 
The existence of this metabolic switch in cancer cells was recognized since the pioneering 
work of Otto Warburg in the first half of the twentieth century131. Despite this feature has 
received little or no attention for decades, it has been the object of major research effort in 
recent years132,133.  
Cancer cells exhibit increased nutrient uptake 
Cancer cells increase their glucose uptake, but instead of oxidizing most of this glucose to 
efficiently generate adenosine 5′-triphosphate (ATP) by oxidative phosphorylation, they 
ferment the excess glucose to lactate. This phenomenon is observed even in the 
presence of oxygen, and is referred as the Warburg effect or aerobic glycolysis134,135(for 
review of molecular mechanism136)(Figure 2). Previously, aerobic glycolysis was 
suggested to be a consequence of mitochondrial damage131 or an adaptive response to 
tumor hypoxia137. However, mitochondria remain functional in most tumors, and aerobic 
glycolysis is observed in cancer cells even in normoxia134,135. 
Aerobic glycolysis, may allow individual cancer cells to increase uptake and incorporation 
of nutrients into the biomass (nucleotides, amino acids, and lipids) and facilitate the 
construction of new cells. According; 1) several signaling pathways implicated in cell 
proliferation also regulate metabolic pathways that incorporate nutrients into biomass; and 
2) certain cancer-associated mutations enable cancer cells to metabolize nutrients in a 
manner conducive to proliferation rather than efficient ATP production. In support of this 
idea, aerobic glycolysis is a characteristic of many rapidly proliferating normal tissues and 
microorganisms134. Satisfying the metabolic needs of proliferation and redox control 
beyond ATP production may be advantages of aerobic glycolysis138. Moreover, studies 
have shown that lactate, a metabolite of aerobic glycolysis is also mediating the malignant 
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transformation and selection of surrounding cells leading to tumor progression and 
invasion139,140. 
Although glucose catabolism through aerobic glycolysis has in large part been recognized 
a hallmark of cancer, it alone cannot explain all the metabolic changes necessary to 
support the requirements of cell growth141. Many normal mammalian tissues use nutrients 
other than glucose, and consumption of alternative fuel sources is observed in some 
cancer cells. Glutamine is the most abundant amino acid in both serum and cell culture 
medium, and glutamine is an important source of nitrogen for cells138,142. The carbon 
skeleton of glutamine can be oxidized to generate ATP and replenish citrate cycle 
intermediates. Finally, in some contexts reductive glutamine metabolism can provide 
carbon for lipid synthesis143,144. Indeed, after glucose, glutamine is the nutrient most highly 
consumed by cancer cells in tissue culture142,145. Emerging evidence suggests that other 
nutrients, including fatty acids and other amino acids, can also play key roles in some 
contexts 145,146,147. 
Increased nutrient uptake is exploited in the clinic as a way to image tumors. F-18 fluoro-
2-deoxyglucose PET (FDG-PET) is used to visualize tumors activity. This technique 
serves as a measure of glucose uptake in patient tissues by coupling positron-emitting 18F 
to an analog of glucose that is taken up and trapped in cells by phosphorylation but is not 
subject to further metabolism148. FDG-PET is most useful clinically as a staging tool and 
can also be used to monitor therapy response149. PET scanning to monitor uptake of other 
nutrients, such as glutamine and glutamate analogs has also been described in research 
settings149.  
Cancer cells use 
different metabolic 
programs 
While cancer 
metabolism is often 
considered as a 
property that differs 
from normal cell 
metabolism, there is 
evidence that tumor 
cells exhibit a 
diversity of metabolic 
phenotypes150,145,151,15
 
Figure 2: Glucose catabolism in normal and tumor cells 
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2,153. Heterogeneous expression of metabolic genes is observed across tissue types, and 
the metabolic network of an individual tumor more closely resembles that of the normal 
tissue from which the tumor arose than it does with other tumors that develop in different 
organ sites150. This expression pattern may reflect the propensity of cancer cells to adapt 
the pre-existing metabolic network to support their needs.  
Indeed, the metabolic phenotype of tumors must be a function of both the genetic lesion 
driving tumorigenesis and the tissue from which the cancer arose152. Expression of 
oncogenes promotes increased consumption of glucose, glutamine, and proteins and can 
reprogram metabolism to support cell growth and proliferation146,154,155,156. Increasing 
evidence indicates that tumor suppressor genes function in part through effects on 
metabolism157, and the combination of genetic mutations in specific tissues facilitates 
altered metabolic regulation to support abnormal tissue growth.  
Tumor cell metabolism is influenced by external factors 
Altered tumor metabolism is not simply the final outcome of some combination of cell 
genetic modifications. Instead, a non-genetic component in the form of the tumor 
microenvironment must additionally be considered as part of the equation that influences 
metabolic changes in cancer cells158(Figure 3). Solid tumors are poorly vascularized, and 
therefore their surrounding environment can expose distinct regions of the tumor to spatial 
and temporal gradients of oxygenation, pH, and nutrient availability159. For example, 
fluctuating oxygen gradients across the microenvironment can drive sporadic hypoxia, the 
stabilization of hypoxia-inducible factor 1 (HIF1), and a corresponding induction of the 
HIF1-induced transcriptional program160. Regardless of whether HIF1-induced 
transcriptional effects are promoted through inappropriate genetic regulation or in 
response to hypoxic stress, one of its downstream consequences remains the conversion 
of a large percentage of glycolytic pyruvate to secreted lactate. The secreted lactate in 
turn triggers additional metabolic responses as a result of local acidification within the 
tumor microenvironment. It has also been suggested that this lactate-driven acidification 
can promote both tumor invasion and immune evasion161,162, which are among the other 
denoted hallmarks of cancer. Moreover, lactate secretion may have a functional role 
within a larger system of metabolic cooperation and symbiosis between cells in the 
microenvironment. Described as a “2-compartment” model of tumor metabolism, the 
symbiosis is characterized as the potential for anabolic malignant cells to extract high-
energy metabolites (lactate, glutamine, and fatty acids) from adjacent catabolic cells 
(within the tumor or neighboring stromal cells) through a network of nutrient sharing that 
can stimulate tumor proliferation and metastasis163,164.  
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Studies reporting 2-compartment tumor metabolism have recently emerged in the context 
of breast cancer cells and their neighboring fibroblasts165,166,167, as well as for ovarian 
cancer cells and their neighboring adipocytes168. However, the complex interplay between 
genetics, microenvironment, and tissue heterogeneity is poorly understood. In addition, 
whole body metabolic regulation can affect tumor tissue metabolism, and patients with 
cancer often have perturbations in whole body metabolism169. Altered organismal 
metabolism can affect cancer outcomes as evidenced by the relationships between 
cachexia170,171, obesity40 or diabetes61 and poor patient survival.  
Powerful homeostatic mechanisms exist at the organismal level to maintain a relatively 
constant supply of nutrients available to both normal and malignant tissues. This complex 
system cannot be understood from cell cultures studies or simple models and remains a 
challenge for the field (Figure 3).  
 
Figure 3: Determinants of the tumor metabolic phenotype. 
The metabolic phenotype of tumor cells is controlled by intrinsic genetic mutations and external responses to 
the tumor environment. Oncogenic signaling pathways controlling growth and survival are often activated by 
the loss of tumor suppressors (such as p53) or the activation of oncoproteins (such as PI3K). The resulting 
altered signaling modifies cellular metabolism to match the requirements of the cell division. Abnormal 
microenvironment conditions such as hypoxia, low pH and or nutrient deprivation elicit responses from tumor 
cells, including autophagy, which further affect metabolic activity. These adaptations optimize tumor 
metabolism for proliferation by providing appropriate levels of energy in the form of ATP, biosynthetic capacity 
and the maintenance of balanced redox status. The influence of the systemic metabolism on this microsystem 
is not known. AMPK: AMP-activated protein kinase; HIF-1: hypoxia-inducible factor 1.  
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Cancer cells in primary tumors are surrounded by a complex 
microenvironment comprising numerous cells including 
endothelial cells of the blood and lymphatic circulation, 
pericytes, stromal fibroblasts and a variety of bone marrow-
derived cells (BMDC), including macrophages, neutrophils, 
myeloid-derived suppressor cells, TIE2-expressing monocytes 
and mesenchymal stem cells. (Adapted from Joyce,JA et al, 
Microenvironmental regulation of metastasis, 2009)  
Evading the immune system 
The long-standing theory of immune surveillance proposes that cells and tissues are 
constantly monitored by an ever-alert immune system, and that such immune surveillance 
is responsible for recognizing and eliminating the vast majority of incipient cancer cells 
and thus emerging tumors. According to this logic, solid tumors that do appear have 
somehow managed to avoid detection by the various components of the immune system 
or have been able to limit the extent of immunological killing, thereby evading eradication. 
Although the supposed mutual dependencies of the immune system, other cancer 
hallmarks and systemic metabolism, this topic will not be further developed (for review172). 
Tumor environment 
The microenvironmental influence on tumor progression is well recognized and is known 
to contribute to cancers 
heterogeneity (for review173). 
Homeostasis in normal tissues 
requires a tightly controlled 
balance of cell proliferation and 
death, which is achieved and 
maintained through intercellular 
communication. An important 
regulator of normal cell behavior 
and tissue hemostasis is the 
surrounding extracellular matrix 
(ECM). The ECM has many 
functions, including acting as 
physical scaffold faciliting 
interactions between different cell 
types, providing survival and 
differentiation signals. Maintaining 
organ homeostasis can prevent neoplastic transformation in normal tissues by ensuring 
stable tissue structure, mediated by tight junction proteins and cell adhesion molecules 
such as integrins and E-cadherin174,175. During early tumor development, however the 
protective constrains of the microenvironment are overridden by conditions such as 
chronic inflammation, and local tissue microenvironment shifts to a growth-promoting 
state. 
Figure 4: Primary tumor microenvironment 
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It is now well established that primary tumors comprise a multitude of stromal cell types in 
addition to cancer cells176 (Figure 4). Although the majority of cell-cell interaction is still 
unknown, there is increasing evidence that the microenvironment induces important 
signals to tumor cells to develop mesenchymal properties (called epithelial to 
mesenchymal transition (EMT), see below), intravasation, survival in circulation and also 
tropism and proliferation in metastatic distant sites173.  
 
Figure 5: Selective pressures and steps from primary tumor growth to metastasis 
Cancer is initiated by cell intrinsic oncogenic changes. Early events involve mutations of breast stem cells. 
These mutations can be inherited (e.g. mutations in BRAC1, BRAC2 or P53) or acquired as consequence of 
some exposure carcinogenic. Microenvironmental factors such as hypoxia, low pH, immune cells, and stromal 
cells have important roles in tumor progression. Bone marrow-derived cells (BMDC) not only home to the 
primary site to aid primary tumor growth, but also home to future distant sites of metastasis to form a pre-
metastatic niche
179
. Together with new accomplices, angiogenesis, lymphangiogenesis, and invasion toward 
chemotactic gradients occur. Intravasation gives rise to circulating tumor cells and starts the metastatic 
cascade. Survival of these circulating cells necessitates resisting mechanical stress and cell-mediated toxicity. 
Sites of extravasation are biased by circulatory patterns, mechanical forces, and chemotactic gradients. 
Familiar challenges and elements faced in distant organs may allow growth. Alternatively, some selective 
pressures in metastatic sites will not be familiar and will limit full colonization, resulting in dormancy. However, 
these new selective pressures that are organ-specific can drive the acquisition of further genetic alterations. If 
successful, full colonization will occur. During all this process, systemic pressures may act in other to inhibit or 
facilitate tumor progression (green). In breast cancer, the target variables may include elements such as 
immune system, hormonal and metabolic resources availability.(Figure adapted from DeVita eta al, Cancer: 
Principles and Practice of Oncology,9
th
 edition, Charper 9) 
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This “ecosystem” is contained within a macroenvironment system whose selective 
pressures are often forgotten (Figure 5). Illustrating the influence of such selective 
pressures are the partial responses to systemic therapy and the emerging resistance of 
some tumor subclones. Likewise, the association of a systemic condition and specific 
cancer phenotypes, such as obesity and ER negative breast cancers177,178 or the fact that 
systemic estrogens stimulate ER positive breast cancers32,33, support this notion of a 
macroenvironmental control of cancer progression. 
Currently, the phenotype of the primary tumor and clinical staging are used to define 
prognosis and therapy. Great efforts have been made to integrate genotypic 
characteristics (genotype) in clinical guidelines; however, the systemic properties of the 
host, important in tumor progression and response to therapy have not been taken into 
account in this equation. 
 
 
Tumor dissemination 
How cancer cells invade surrounding tissues and disseminate to distant organs 
(metastasis) has been a matter of debate for decades.  
Metastasis is the leading cause of breast cancer-related death180. One of the primary aims 
in cancer clinical management is to prevent or decrease the risk of metastasis. How this 
objective is approached is shaped by empiricism and perceptions about how metastasis 
proceeds because no single explanation of the full complexity of the metastatic process 
has been proven to be correct or complete. 
Numerous prerequisites are needed for cells to become metastatic: 1) Invasion and 
motility–Tumor cells may undergo a epithelial to mesenchymal transition (EMT) to become 
motile, a fundamental property of metastatic cells, and use their migratory and invasive 
properties in order to burrow through surrounding extracellular stroma and to enter blood 
and lymphatics vessels; 2) Intravasation and survival in the circulation-Once tumor cells 
enter the circulation, or intravasate, they must be able to withstand the physical shear 
forces and the hostility of sentinel immune cells. Solid tumors are not adapted to survive 
as single cells without attachments and often interact with each other or blood elements to 
form intravascular tumor emboli.); 3) Arrest and extravasation-Once arrested in the 
capillary system of distant organs, tumor cells must extravasate, or exit the circulation, 
into foreign parenchyma. This may happen by physical means whereby intravascular 
growth causes eventual disruption of small capillaries, or escape may be regulated via 
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invasive properties acquired by tumor cells; 4) Growth in distant organs-Successful 
adaptation to the new microenvironment results in sustained growth.  
Normal epithelial cells, such as breast ductal cells, are displayed in a tissue structure 
maintained by cell-cell interactions. These involve tight junctions, cadherin based 
adherens junctions that are connected to the actin cytoskeleton, gap junctions that allow 
direct chemical interactions between neighboring cells, and desmosomes connected to 
the intermediate filament cytoskeleton, and cell-ECM interactions mediated by integrins 
and other molecules. The cell-cell and cell-ECM contacts also define tissue polarity181, 
which allows different functions for the apical and basal surfaces. 
Epithelial to mesenchymal transition is a biologic process that allows these cells to 
undergo multiple biochemical changes that enable them to assume a mesenchymal cell 
phenotype, which includes enhanced migratory capacity, invasiveness, elevated 
resistance to apoptosis, and greatly increased production of ECM component182. This 
initiates the invasive and metastatic behavior of epithelial cancers, but EMT mechanisms 
are also recognized in physiological conditions such as during embryogenesis or tissue 
regeneration183. 
A number of distinct molecular processes are engaged in order to initiate an EMT and 
enable it to reach completion. These include activation of transcription factors (Snail, Slug, 
zinc finger E-box binding homeobox 1 (ZEB1), Twist, Goosecoid, and 
FOXC2184,185,186,187,188), expression of specific cell-surface proteins (SMA, FSP1, vimentin, 
and desmin189, β4integrin, α5β1integrin, vβ6integrin190), reorganization and expression of 
cytoskeletal proteins191,192, production of ECM-degrading enzymes, and changes in the 
expression of specific miRNAs 193,194, 195. 
Every day millions of cells are released into the peripheral circulation196 but if and how an 
extravasated tumor population grows in a distant organ still an enigma. From all of the 
steps in the metastatic cascade, the ability to grow in distant organs has the greatest 
clinical impact. Clinically, many patients treated by local excision of a primary cancer but 
with micrometastatic disease at the time of diagnosis will show a long latency period 
before distant disease develops. The ability of the tumor to adapt or to co-opt new growth 
signals may determine whether distant relapse occurs early or lately. 
Moreover, the spread of cancer cells from the primary tumor and the colonization of a 
distant organ, does not seem to occur in random fashion197. Breast tumors usually 
metastasize to bone, lung, pleura, liver and, less frequently, to brain and the adrenal 
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gland. ER-positive tumors preferentially spread to bone while ER-negative tumors 
metastize more aggressively to visceral organs198,199.  
The clinical data for breast cancer has inspired a long-standing debate on whether 
metastasis follows a traditional progression model or a predetermination paradigm, also 
known as the Halsted model versus the Fisher model for metastasis200. Both models seek 
to justify and explain clinical data looking at the benefit of aggressive local treatment of the 
primary tumor and draining lymph nodes versus the early use of adjuvant systemic 
chemotherapy. Although more anatomic than cellular in nature, the Halsted model looked 
at breast cancer as a progressive disease that orderly spread pattern from primary site, to 
regional lymph nodes, to distant organs. This orderly progression would make complete 
eradication of the primary and regional tumor burden sufficient to stop metastasis. 
Screening programs, radical versus more limited surgical excisions and the use of 
adjuvant radiation to the surgical bed can be justified on the basis of the idea that cancers 
caught early are less likely to spread. 
In contrast, Fisher hypothesized that whether distant relapse occurs in breast cancer is 
predetermined from the onset of tumorigenesis. This view emphasizes breast cancer as a 
systemic disease and the importance of adjuvant systemic chemotherapy.  
The data from randomized trials for adjuvant treatment and from breast cancer screening 
programs do not clearly rule out one model or the other201.  
To reconcile the clinical data, Hellman201 proposed that breast cancer is best considered a 
spectrum of diseases bound by predetermination models and traditional progression 
models. In fact, in clinical practice, the lack of evidence favors the acceptance of this large 
spectrum.  
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II. Dyslipidemia-The problem  
 
As mentioned earlier, breast cancer arises from a combination of genetic and 
environmental factors; including those from the external environment and the individual-
host environment.  
The incidence of female breast cancer varies markedly around the world. It is highest in 
the United States, Western and Northern Europe, intermediate in Southern and Eastern 
Europe and South America, and lowest in Asia and Africa202(Figure 6). Since the 1950, 
breast cancer rates have nearly doubled in traditionally low-risk countries such as 
Japan203, Singapore204, and urban areas of China205. Dramatic changes in lifestyle, namely 
in reproductive behavior and nutritional status occur as these regions make the transition 
toward a Western-style economy203,204. Because of unfavorable trends in these countries, 
the international gap in breast cancer incidence has narrowed since 1970.  
 
As evidenced by WHO and local databases statistics (Eurostat, CDC), cancer and 
cardiovascular diseases are the leading causes of death in Europe2 and USA1 and are 
increasing in Asian countries3,4. It is reasonable to question if there are some 
environmental factors responsible for those distributions patterns.  
Lipid profile alteration, namely dyslipidemia, is a top risk factor to cardiovascular 
diseases206,207, 208. It is very common in Western countries209 and is raising in Asia210, 
being lipid lowering drugs one of the most used drugs in the world1.  
Dyslipidemia is a broad term that refers to a number of lipid disorders. Most (80%) of them 
are related to diet and lifestyle, although familial disorders (20%) are also important. The 
basic categories of dyslipidemias include: elevated low-density lipoprotein cholesterol 
(LDL-C), low high-density lipoprotein cholesterol (HDL-C), excess lipoprotein(a), 
hypertriglyceridemia, atherogenic dyslipidemia, and mixed lipid disorders. Most patients 
with cardiovascular diseases have mixed dyslipidemia (elevated LDL-C and low HDL-
C)211. In 2008 the global prevalence of raised cholesterol among adults (≥ 5.0 mmol/l) was 
39% (37% for males and 40% for females) and had slightly changed between 1980 and 
2008. The prevalence of elevated total cholesterol was highest in the WHO Region of 
Europe (54% for both sexes), followed by the WHO Region of the Americas (48% for both 
sexes). The WHO African Region and the WHO South East Asian Region showed the 
lowest percentages (22.6% for AFR and 29.0% for SEAR). 
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Figure 6: Breast Cancer Incidence, Worldwide in 2008 
(Data from Ferlay J et al GLOBOCAN 2008, 2010) 
 
Curiously, the world incidences pattern of raised cholesterol (Figure 7) parallels the breast 
cancer incidence (Figure 6). 
 
Figure 7: Mean blood cholesterol, ages 25+, age standardized, females 2008 
(Data from WHO, 2011) 
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Overall, raised cholesterol is globally estimated to cause 2.6 million deaths (4.5 per cent 
of the total number of deaths) and 29.7 million DALYS*, or 2 per cent of total DALYS 
(*DALY- disability-adjusted life year is a measure of overall disease burden expressed as 
the number of years lost due to ill-health, disability or early death)206.  
Despite the epidemiologic importance of dyslipidemia, the role of systemic cholesterol 
metabolism in breast cancer is poorly understood. 
 
Cholesterol and cholesterol metabolism  
 
Cholesterol is a molecule virtually present in all cells and its metabolism is conserved from 
yeasts to humans, denoting the importance of cholesterol equilibrium to sustain normal 
functions in eukaryotic cells212. 
Perhaps the most important role of cholesterol is being an essential structural element of 
the membranes of all eukaryotic cells and subcellular particles. At plasmatic membranes it 
occupies the spaces between the polar head groups of the phospholipid molecular bilayer, 
reducing its fluidity and accumulates in microdomains called lipid rafts (for review213). In 
addition to its structural role, cholesterol is an obligatory precursor of steroid hormones 
(progesterone, estradiol, testosterone, glucocorticoids and mineralocorticoids) and vitamin 
D214. Cholesterol metabolism gives also origin to oxysterols and bile acids (Figure 8). 
 
Figure 8: Cholesterol metabolism products. 
Cholesterol incorporates cell membranes and its metabolism origins steroid hormones, vitamin D
214
, 
oxysterols and bile acids (Adapted from Yiannis A. et al, 2001
215 
) 
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Cholesterol metabolism 
The cholesterol molecule is an alicyclic compound and in terms of physical properties, is a 
lipid with very low solubility in water. For this reason, only about 30% of total plasma 
cholesterol occurs free; approximately 70% of cholesterol circulates as a component of 
lipoproteins. In lipoprotein particles the hydrophobic lipid core is surrounded by an 
amphipathic monolayer of phospholipids and specific apolipoproteins (reviewed by 
Ginsburg et al216 and Bachorik et al217). 
Lipoproteins share common lipid and apolipoprotein components, but apolipoproteins and 
the amounts of cholesterol, triglyceride, and phospholipids vary between lipoprotein 
particles. Consequently, lipoproteins can be identified based on molecular mass, chemical 
composition, physicochemical and flotation characteristics or electrophoretic mobility. The 
main lipoproteins are commonly classified according to their hydrated densities as follows: 
chylomicrons (density < 0.95 g/ml), very low-density lipoprotein (VLDL, density 0.95–1.006 
g/ml), intermediate-density lipoprotein (IDL, density 1.006–1.019 g/ml), low-density 
lipoprotein (LDL-C, density 1.019–1.063 g/ml) and high-density lipoprotein (HDL-C, 
density 1.063–1.210 g/ml). Chylomicrons and VLDL particles are mainly transporting 
triglycerides, whereas cholesterol is carried by LDL (LDL-C) and HDL (HDL–C) particles. 
At birth, serum cholesterol levels are similar throughout the world, typically around 80 
mg/dL (2 mmol/ l)218. In adults, it spreads in the range of 100-300 mg/dL (2.5–7.5 mmol/L). 
In many Asian countries, adult levels are often less than 200 mg/ dL (5 mmol/ L), however 
levels have been raising in the last decades in urban areas, whereas in Europe and the 
USA they are generally higher than 200 mg/dL (5 mmol/L)3. 
 
Plasma cholesterol is derived from the diet or can be de novo synthesized in the body. 
Intestinal cholesterol absorption and the enterohepatic cycle  
Cholesterol enters the intestine from diet sources (200-500 mg/day), bile (800–1200 
mg/day) and from shed intestinal epithelial cells (300 mg/day). Some 30–60% of intestinal 
cholesterol is absorbed. Cholesterol can be excreted as fractions of bile salts (250 mg), 
intestinal cholesterol which are not absorbed (550 mg), and in sebum (100 mg). 
Nevertheless, a total of some 900 mg must therefore be returned to the liver daily, derived 
from the diet or endogenous synthesis219. 
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The absorption and transport of cholesterol in the body involves coordinated combinations 
of lipoproteins and receptors, as depicted in Figure 9. 
Basically cholesterol is absorved from the intestine in chylomicrons and transported to the 
liver and peripheral tissues in LDL-C. Reverse transportation from peripherical tissues is 
made mainly by HDL-C.  
 
 
Figure 9: Overview of lipoprotein metabolism 
Cholesterol (C) is from dietary is absorved, together with fatty acid (FA), into chylomicrons (CM). CM remnants 
(CMR) are taken up by hepatic low-density lipoprotein receptor (LDLR), in the absence of LDLR they are 
taken up by LDLR-related protein-1 (LRP1). In hepatocytes, triglycerides (TG) are packaged with cholesterol 
and the APOB isoform B100 into very (VLDL); the TG contained in VLDL are hydrolyzed by LPL, releasing FA 
and VLDL remnants (IDL) that are hydrolyzed by hepatic lipase (HL), thereby yielding LDL-C. In hepatocytes, 
cholesterol is recycled or synthesized de novo, with 3-hydroxy-3-methylglutaryl coenzyme A reductase 
(HMGR) being rate-limiting. LDL-C transports cholesterol from the liver to the periphery. LDL-C is 
endocytosed by peripheral cells and hepatocytes by LDLR, assisted by an adaptor protein (AP). Proprotein 
convertase subtilisin/kexin type 9 (PCSK9), when complexed to LDLR, short-circuits recycling of LDLR from 
the endosome, leading to its degradation (X). HDL-C, via APOA-I (A1), mediates reverse cholesterol transport 
by interacting with ATP-binding cassette A1 (ABCA1) and ABCG1 transporters on non-hepatic cells. Lecithin-
cholesterol acyltransferase (LCAT) esterifies cholesterol so it can be used in HDL-C cholesterol, which enters 
hepatocytes via scavenger receptor class B type I (SRB1). (Adapted from Hegele, RA,  2009
220
) 
 
 
Cholesterol synthesis 
Cholesterol de novo biosynthesis occurs virtually in all cells, although, this capacity is 
greatest in liver, intestine, adrenal cortex and reproductive tissues. 
 
The cholesterol biosynthesis is carefully regulated. When the amount of dietary 
cholesterol is reduced, cholesterol synthesis is increased in liver and intestine to supply 
the needs of other tissues in the form of lipoproteins. When the amount of dietary 
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Figure 10: Cholesterol biosynthesis pathway 
cholesterol 
increases, 
cholesterol 
synthesis in liver 
and intestine is 
almost totally 
suppressed. Thus, 
the rate of de novo 
cholesterol 
synthesis is 
inversely related to 
the amount of 
dietary cholesterol 
taken up by the 
body221. Hidroxi-3-
methyl-glutaril-CoA 
reductase (HMGR) 
is located on the 
RE and catalyzes 
the conversion of 
HMG-CoA to 
mevalonic acid 
(Figure 10). This is the committed step and the rate-limiting reaction in cholesterol 
biosynthesis. HMGR is subject to both short-term and long-term control222. Long-term 
effects are mediated by alterations in its rate of synthesis and degradation. Short-term 
effects involve allosteric effects and alterations in its state of phosphorylation. Squalene 
synthase catalyses the first commited step in sterol synthesis, since the squalene 
produced from farnesyl pyrophosphate is converted exclusively into cholesterol and its 
derivatives (bile acids, vitamin D, steroid hormones), via a complex, multistep pathway223.  
 
The LDL-C-C receptors 
LDL-C receptor is mainly expressed in the liver, but it is also present on the surface of 
nearly all normal cells where the uptake of plasma LDL-C provides cholesterol for 
membrane synthesis and other requirements. After binding lipoprotein, the lipoprotein-
receptor complex is internalized by endocytosis. LDL-C dissociates from the receptor, 
which returns to the cell surface and is again able to bind lipoproteins. Within lysosomes, 
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cholesterol esters of LDL-C are converted to free cholesterol by acid lipase and 
apolipoproteins are degraded to amino acids. Free cholesterol is delivered to the 
cytoplasm. Synthesis of LDLR is suppressed when the cell is replete in cholesterol.  
The clearance of LDL-C from plasma is primarily mediated by LDLR224,225. In addition, 
some of LDL-C may be removed by LRP1226, scavenger receptors, which are responsible 
for the clearance of modified LDL-C [Scavenger Receptors class A (SR-A1/2) and B (SR-
BI)]227, ox-LDL receptor (OLR1)228), or by non-receptor-mediated internalization229.  
Intracellular cholesterol homeostasis 
Despite being a cholesterol-poor organelle, the endoplasmatic reticulum (RE) is the 
crucial regulatory compartment in cholesterol homeostasis. The RE is the primary site of 
cholesterol synthesis and esterification, and recent data indicate that excessive free 
cholesterol may exert its cytotoxic effects via RE perturbation230. 
 
Figure 11: Schematic representation of the intracellular cholesterol homeostasis. 
Extracellular cholesterol enters the cell via the LDLR. Transport to the endoplasmic reticulum (RE) occurs via 
endosomal system. Once at the ER, excess cholesterol is converted to cholesterol ester by ACAT-1. If 
intracellular cholesterol levels drop, the N-terminus of SREBP is released and enters the cell nucleus, 
resulting in transcription of mRNA to increase cholesterol production and increase receptors for extracellular 
cholesterol. If intracellular cholesterol is in excess, HMGR is degraded and LDLR expression down regulated.  
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To avoid cytotoxicity, free cholesterol is esterified by acetyl-coenzyme A acetyltransferase 
1 (ACAT-1) and stored in the cell. When intracellular cholesterol rises, the synthesis is 
inhibited through degradation of HMGR and the up take is limited by low expression of 
LDLR.  Conversely, when cell requires high levels of cholesterol, its synthesis and up take 
are up regulated231(Figure 11).  
The homeostatic mechanism whereby cellular cholesterol levels exert negative feedback 
on cholesterol synthesis is mediated by Sterol Regulatory Element-Binding Protein 
(SREBP) transcription factors232. There are 3 SREBPs: SREBP-2 primarily activates 
genes involved in cholesterol synthesis, whereas SREBP-1a and SREBP-1c have greater 
effects on genes involved in fatty acid synthesis. SREBPs are synthesized inactive RE 
transmembrane proteins. When cholesterol is abundant, SREBPs remain in the RE 
associated with the escort protein SCAP (SREBP cleavage activating protein) and the RE 
retention protein Insig233. Low cholesterol causes a conformational change in the sterol-
sensing domain of SCAP234, dissociating Insig and allowing SREBP-SCAP to reach the 
Golgi. Two proteases in the Golgi release the active form of SREBP, which translocates to 
the nucleus to activate transcription of target genes.  
Cholesterol synthesis is also regulated post transcriptionally: high cholesterol accelerates 
degradation of HMGR, the rate-limiting enzyme in cholesterol synthesis, by promoting 
association of its sterol-sensing domain with Insig235. The final enzyme of cholesterol 
synthesis, 7-dehydrocholesterol reductase (DHCR7), also has a sterol-sensing domain 
and may be similarly regulated236.  
Cells with high rates of cholesterol synthesis or accumulation may export cholesterol to 
cells with increased requirements. The main cholesterol exporters in human cells are 
ATP-binding cassette protein A1 (ABCA1) and G1 (ABCG1). ABCA1 is responsible for the 
efflux of both phospholipids and free cholesterol and its transcription is mediated by the 
nuclear receptors LXRα and LXRβ237,238,239 whose ligands are sterol metabolites such as 
22-, 24-, 27- hydroxycholesterol and 24-25-epoxycholesterol240,241. ABCA1 is also post 
transcriptionally regulated. Several proteins including α1syntrophin, β1syntrophin, 
calmodulin and apolipoprotein A1 have been reported to interact with ABCA1 and 
implicated in reduction of the rate of ABCA1 degradation242,243, 244,245. 
In synthesis, the regulation of cholesterol metabolism occurs both at cellular and systemic 
level. The systemic pool of cholesterol results from the balance between the cholesterol 
up take from diet, de novo synthesis, mainly in the liver, and the adipose tissue storage. 
The communication is mediated by lipoproteins. The intracellular cholesterol is highly 
controlled through the coordination of cellular synthesis, up take from the bloodstream, 
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and storage. This equilibrium involves some key elements such as HMGR, LDLR, ACAT-1 
and ABCA1.  
Cholesterol biological functions 
Lipid rafts 
Methods to determine the cholesterol content of various cellular membranes are subject to 
technical limitations, but it is commonly cited that 65% to 80% of total cellular cholesterol 
is in the plasma membrane, whereas only 0,1% to 2% is in RE246,247,248. In the cell 
membrane, cholesterol is specially localized in sub-domains called lipid rafts213,249,250.  
These microdomains cluster together proteins involved in the regulation of crucial cellular 
processes251,252 including cell fate, cell signaling and traffic and cell migratory potential. 
The structure and function of lipid raft domains depend on their lipid and protein 
compositions. Two major types of rafts have been distinguished: planar non caveolar and 
caveolae that form tube-like invaginations of plasma membrane (Table 2). 
Table 2: Lipid and protein composition of caveolae and non-caveolae lipid rafts 
Lipid Rafts 
Types 
Lipids 
Protein 
Markers 
Receptor 
Proteins 
Signaling 
Proteins 
 
Non-caveolar 
lipid rafts 
 
 
Cholesterol 
Glycosphingolipid 
Sphingomyelin 
Ganglioside GM1 
Ganglioside GM3 
 
Flotilin-1 
Flotilin-2 
Fas 
EGFR 
ERBB2 
IGF-R1 
CD44 
ER 
 
Ras 
Src 
ERK2 
Shc 
 
Caveolae 
lipid rafts 
 
 
Cholesterol 
Glycosphingolipid 
Sphingomyelin 
Ganglioside GM1 
 
Caveolin-1, 
Caveolin-2 
Caveolin-3 
Fas 
EGFR 
ERBB2 
IGF-R1 
CD44 
ER 
uPAR 
MMP-1,2,9 
 
Ras 
Src 
eNOS 
PI3 kinase 
Phospholipase 
C 
 
        Adapted from Nohara el al
250
 and Patra et al
253
. (For legend see Abbreviations.) 
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Physiologically, lipid rafts contribute to the spatial organization of membrane and, in 
consequence, to polarization of epithelial cells. This polarization seems to be fundamental 
to membrane trafficking of cellular components between cell compartments and exchange 
of cellular components between organelles254,255. Lipid raft-mediated trafficking of lipids 
and proteins facilitates dynamic regulation of cellular signaling cascades256. Rafts can also 
control cell signaling by altering the function of their affiliated proteins. Accumulating 
evidence suggests that raft associated proteins behave differently whether localized inside 
or outside of rafts. Modified signal transduction following lipid raft/caveolae disruption has 
been reported in the case of several signaling cascades involving ERK257, EGFR258,259, 
IGF-R1260, and platelet-derived growth factor receptor (PDGFR)261. Finally, some lipid rafts 
are actively involved in endocytosis, which promotes internalization of receptors and 
signaling molecules262. Internalization of ligands or receptors modifies downstream signal 
transduction, and is associated with the perturbation of extracellular ligand-driven 
signaling events via transient receptor desensitization. Lipid rafts and caveolin-1 have also 
been shown to be crucial for the formation of invadopodia, membrane protrusions that 
penetrate the surrounding matrix through a combination of matrix remodeling and physical 
force263.  
Cholesterol as a progesterone and estrogen precursor 
Cholesterol is the precursor of all classes of steroid hormones: glucocorticoids (e.g. 
cortisol), mineralocorticoids (e.g. aldosterone), and sex hormones (androgen, estrogen, 
and progesterone). Synthesis and secretion occur in the adrenal cortex (cortisol, 
aldosterone, and androgens), ovaries and placenta (estrogen and progesterone), and 
testes (testosterone). Estrogen is also produced peripherally in adipose tissue, which is an 
important source of estrogen in postmenopausal women 
Steroid hormones are transported by the blood from their sites of synthesis to their target 
organs. Because of their hydrophobicity, they must be complexed with specific steroid-
carrier plasma proteins or albumin264. 
Steroid hormones are crucial substances for the proper function of the body. The 
mineralocorticoids largely function to regulate the excretion of salt and water by kidney. 
The glucocorticoids affect carbohydrate, protein, and lipid metabolism in manner nearly 
opposite to that of insulin, and influence a wide variety of other vital functions including 
inflammatory reactions and the capacity to cope with stress. Both androgen and estrogen 
affect sexual development and function. They regulate sexual differentiation, the 
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secondary sex characteristics, and sexual behavior patterns. Progesterone mediates the 
menstrual cycle and pregnancy events264. 
Steroids can act through two basic mechanisms: genomic and non-genomic. The classical 
genomic action is mediated by specific intracellular receptors, whereas the primary target 
for the non-genomic one is the cell membrane. The final hormonal effect in a target tissue 
is dependent on the cross talk between different nuclear steroid receptors and on 
expression of receptor isoforms265. 
Oxysterols 
Most oxysterols arise from cholesterol by autoxidation or by specific microsomal or 
mitochondrial oxidations, usually involving cytochrome P450.  
Plasma oxysterol levels are increased in hypercholesterolemic humans266,267, as well as in 
hypercholesterolemic fed mice268,269 compared to non-hypercholesterolemic controls. 
However, reports describing the occurrence and levels of oxysterols in plasma, low-
density lipoproteins, various tissues, and food products are hampered by low physiological 
concentrations (0.01– 0.1mM) relative to cholesterol (5,000mM) and the absence of a 
comprehensive set of authentic standards. 
Oxygenated derivatives of cholesterol (oxysterols) present a remarkably diverse profile of 
biological activities, including effects on sphingolipid metabolism, platelet aggregation, 
apoptosis, and protein prenylation. The most notable oxysterol activities center around the 
regulation of cholesterol homeostasis, which appears to be controlled in part by a complex 
series of interactions of oxysterol ligands with various receptors, such as the oxysterol 
binding protein, the cellular nucleic acid binding protein, the sterol regulatory element 
binding protein (SRBP), the liver X receptor (LXR), and the low-density lipoprotein 
receptor (LDLR) (for review 270).  
The precise identification of the endogenous oxysterol ligands and elucidation of their 
metabolism are topics of importance considering their potential physiological role. 
However, studies of this matter are limited by difficulties in the separation and 
identification of the various oxysterols and the susceptibility of cholesterol to autoxidation 
when conserved ex-vivo. This may produces artifactual oxysterols with potent activities 
when used in experimental studies leading to wrong interpretations of endogenous 
oxysterols functions271. 
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Oxysterols are oxidized derivatives of cholesterol and play various regulatory roles in 
normal cellular processes such as cholesterol homeostasis by acting as intermediates in 
cholesterol catabolism.  
 
Cholesterol and cholesterol metabolism in (breast) cancer cells 
In normal cells lipogenesis activity is low due to transcriptional regulation of the key genes 
involved in lipid biosynthesis. By contrast, in tumor cells, increased signaling activity of 
growth factor or steroid hormone receptors via PI3K/Akt and MAPK/ERK1/2272, HIF-1, 
p53273 and Sonic hedgehog (Shh)274 pathways modulate and activate SREBP-1, the main 
regulatory component of lipogenesis. Overexpression of SREBP1 and 2 and lipogenic 
enzymes was observed in a number of carcinomas, namely breast cancer275,276 and was 
described to correlate with disease severity, increased risk of recurrence and lower 
chance of survival277. Also analyses of microarray transcriptional profiling demonstrate an 
overexpression of cholesterol gene pathways in chemotherapeutic resistant cancer 
cells278. 
Active sterol biosynthesis is an essential component of proliferating cells since cholesterol 
is fundamental as a building block for biological membranes. Moreover, the early steps of 
cholesterol biosynthesis provide cells with compounds essential for cell growth and 
division, such as mevalonic acid, farnesyl pyrophosphate and geranylgeranyl 
pyrophosphate important for PI3K, Akt, Ras and other GTPases signaling (Figure 10)279. 
Besides increasing its synthesis, cancer cells can also uptake cholesterol from the 
bloodstream thought lipoprotein receptors located in the cell surface. High LDLR 
expression has been shown in breast cancers280. 
However the ability of breast cancer cell to synthetize / up take cholesterol may be 
diverse281. In vitro studies using MCF-7 and MDA MB 231 cell lines metabolomics show 
that ER positive cell lines have up regulation of enzymes from cholesterol biosynthetic 
pathway, compared to ER negative cell lines282. This may underline the estrogen 
dependency, but also discloses that ER negative cells are more dependent on exogenous 
than on endogenous cholesterol. In accordance, Wang et al283, recently showed that 
genes from lipid metabolism are differently expressed in ER positive and ER negative 
breast cancers, as well as in contralateral unaffected breast of ER positive and ER 
negative breast cancer patients. These intriguing findings strongly implicates lipid 
metabolism in breast cancer initiation and eventually in the generation of different tumor 
phenotypes. 
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The promotion of lipogenic and the lipid-consuming behaviors appears to be dependent of 
proliferating and survival signaling pathways which provide metabolic advantage to cancer 
cells (Figure 12). However, despite the utility of cholesterol, excessive intracellular 
accumulation is deleterious284,285, 286,287.  
 
Figure 12: Regulation of cholesterol homeostasis and cancer signaling pathways. 
An increased demand for de novo cholesterol biosynthesis is regulated via signaling inputs from cell surface 
growth factor receptors (e.g. ERBB2, EGFR or IGF-R) that induce transcriptional activity SREBP. Excess of 
cholesterol will suppress SREBP via its inhibitory interaction with SCAP. The alternative to de novo 
biosynthesis is cholesterol importation via LDLR. LDLR has to undergo lysosomal degradation in order to 
liberate cholesterol from the endocytosed lipid particles. Oxidized cholesterol species bind to LXR that is a 
heterodimeric transcriptional factor for various regulatory proteins including cholesterol efflux pumps, ABCA1. 
How tumor cell regulate intracellular cholesterol content is not completed understood. (Adapted from Gorin et 
al, 2012 
293
) 
 
In normal cells, free cholesterol is stored after esterification288 and the intracellular excess 
increases expression and translocation of ABC membrane exporters, such as ABCA1 or 
ABCG1. Loss of function mutations in ABCA1 gene causes Tangier disease and familial 
hypolipoproteinemia, both cardiovascular conditions characterized by abnormally low 
levels of HDL-C and atherosclerosis289 and were recently implicated in cancer cell 
survival290. Several studies suggest that ABCA1 and ABCG1 not only export cholesterol 
but also generates special membrane meso-domains291 by promoting lipid redistribution 
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which could modulate raft dependent cell signaling291,292,291. The role of this mechanism in 
cancer is unknown. 
Physiologically, the intracellular cholesterol is regulated by coordination of import/ export 
machinery (lipoprotein receptors and ABC exporters, as well as HMGR, are under 
transcriptional influence of SREBP, sensitive to intracellular levels of cholesterol (Figure 
12) and also by systemic homeostasis. In cancer cells, is not known how this equilibrium is 
regulated and simultaneously the metabolic advantage ensured. Furthermore, there is no 
knowledge how tumor cell metabolism is or not influenced by the systemic cholesterol 
metabolism. 
The elements constituting lipid rafts have been shown to be involved in key processes in 
cancer cells, namely apoptosis, cell cycle, metabolism and migration. 
Abnormal signaling by growth factor receptors can facilitate tumor proliferation and 
growth. Lipid rafts modulate the signaling functions of several growth factor receptors, 
including EGFR, ERBB2, ER, IGF-1R and sigma receptors. 
EGFR function in particular is largely dependent on its affiliation with lipid rafts251,294,295,296. 
Oncogenic ERBB2 dimerization in breast cancer cells takes place in lipid rafts297 and 
forced exclusion of ERBB2 from rafts has been shown to decrease dimerization and 
tyrosine phosphorylation297. Another possible avenue of ERBB2 signaling regulation by 
lipid rafts relates to protein trafficking. ERBB2 is endocytosed and recycled back to the 
cell membrane298 which maintains its overexpression at the cell membrane of breast 
cancer cells. Modulation of lipid metabolism may control ERBB2 overexpression by 
influence its endocytosis and redistribution in the cell membrane299.  
Another protein known to localize in lipid rafts is the ER92. Estrogen signaling, non-
genomic mediated, is linked to lipid rafts, where ER co-localizes with ERBB receptors to 
modulate growth events92. Both these receptors may be activated by membrane-bound 
ER300, resulting in MAPK-dependent ER phosphorylation301. As these receptors are 
reportedly lipid raft-affiliated, interference of this union with lipid rafts may prove to be 
useful in targeting endocrine resistance in breast cancer. 
IGF-1R is another tyrosine kinase receptor whose activation leads to proliferation and 
differentiation via MAPK and PI3K/Akt pathways302. IGF-1R activity has been linked to 
lipid raft affiliation, particularly caveolae. Stable expression of caveolin-1 in MCF7 breast 
cancer cells, while decreasing cell attachment303, results in enhanced matrix-independent 
cell survival via up regulation of IGF-1R and subsequent activation of p53 and p21304. 
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Caveolin-1 further drives IGF-1R-induced recruitment of β1-integrin into lipid rafts305, 
which could in turn regulate the influence of β1integrin on cell fate306.  
Sigma receptors are a novel family of receptors whose physiological and 
pathophysiological roles are only beginning to emerge. Their inhibit proliferation, induce 
apoptosis and can decrease cell adhesion in mammary carcinoma cell lines307. Sigma 
receptors were proposed to have the ability to remodel lipid rafts by modulating raft 
cholesterol levels via cholesterol-binding motifs308 and thereby modify lipid rafts signaling. 
Defects in apoptosis allow tumor cells to escape growth-inhibitory signals and to progress 
through the cell cycle. Perhaps the best-characterized death receptor is Fas (CD95 or 
APO-1), which has been implicated in the apoptotic events that drive physiological 
remodeling of the mammary gland after breast feeding309. Down-regulation of Fas has 
also been associated with poor prognosis in breast cancer patients310, and inhibition of 
Fas activity has been linked to drug resistance311. Recent studies have shown that Fas is 
translocated into lipid rafts, where apoptotic receptor aggregation takes place312 and 
cholesterol depletion, in lipid rafts, was shown to abolish apoptosis313,314. Acquired 
resistance of breast cancer cells to Fas-induced apoptosis may alternatively result from 
activation of survival pathways, such as the PI3K pathway. Its engagement leads to 
activation of the Akt, which negatively regulates apoptosis by inactivating pro-apoptotic 
proteins such as Bad and caspase-9315. Lipid raft localization of Akt has been implicated in 
facilitating its activation316,317.  
Cancer cells often activate pathways that reduce adhesion and promote cell migration, 
increasing the likelihood of the metastatic spread of breast cancer. Kinases play a 
significant role in regulating cell adhesion and migration. The Src family of kinases (SFK) 
integrates signal transduction from many tyrosine kinases receptor, including EGFR, IGF-
1R and ERBB2318,319 to multiple downstream targets including PI3K, Ras and FAK319. SFK 
activation has been linked to lipid rafts in breast cancer cells320, fuelling speculation that 
selective targeting of raft-affiliated SFK may offer a potent therapy. 
As mentioned before, lipid rafts and caveolin-1 are crucial for the formation of 
invadopodia, by clustering together proteins involved in actin cytoskeleton organization, 
signaling, cell-ECM adhesion and membrane remodeling321. Invasive potential has also 
been linked with the raft-affiliated proteins caveolin-1 and matrix metalloproteinase 14 
(MMP14) in both breast322 and prostate323 cancer cells. In fact caveolin-1 and MMP14 
have been shown to co-associate and been co-trafficked in invasive breast cancer cell 
lines324. Accordingly, a reduction in ECM degradation activity of MMP14 has been 
reported in MDA-MB-231 cells following disruption of lipid rafts by cholesterol depletion or 
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after knockdown of caveolin-1 in MMP14-overexpressiong MDAMB- 231 cells324. Together 
these results highlight that lipid rafts and caveolin-1 are important for invadopodia function 
in breast cancer cells. 
MMP14 is not the only lipid raft-affiliated proteinase implicated in breast cancer 
progression. Aberrant expression of MMP2 and MMP9, that are localized in rafts during 
cancer cell migration253, have been associated with high-grade breast cancer325.  
Similarly, urokinase-type plasminogen activator (uPA) and its receptor (uPAR) have been 
linked to breast cancer progression and metastasis253,326, and are also localized to lipid 
rafts during cancer cell migration326. A recent study investigating the importance of lipid 
rafts in regulating uPAR and MMP9 functionality in breast cancer has demonstrated that 
cholesterol depletion reduces co-localization of uPAR and MMP9 with lipid rafts and 
significantly decreases their total protein and mRNA levels327. Lipid raft disruption in 
breast cancer cells resulted in reduced amounts of active Src, FAK, Akt and ERK and 
increased uPAR co-localization with lysosomal markers, reverted with cholesterol 
repletion327. This is in agreement with previous observations of differences in MMP9-
driven cell migration according to its sub-cellular localization inside or outside rafts325. 
A proposed marker for breast cancer stem cells is CD44328,329 a multi-functional lipid raft-
affiliated transmembrane glycoprotein. CD44 is the major receptor for the ECM 
component hyaluronan330; but it can also act as a co-receptor for growth factors331,332 and 
organize the actin cytoskeleton through cytoplasmic linker proteins333. CD44 abnormalities 
have been associated with aggressive histological features of breast cancer334,335, and the 
association of CD44 with MMP9 in breast tumor cells promotes tumor cell migration and 
invasion336.  
Thus lipid rafts are fundamental to breast cancer pathogenesis and some current 
treatments to breast cancer target lipid rafts. One key example is cisplatin, whose 
mechanism of action is incompletely understood, but which has been described to exert 
some of its actions through modulation of ceramide lipid rafts. Also some derivatives of 
doxorubicin, an anthracycline widely used in breast cancer adjuvant chemotherapy, 
promote their actions by activating lipid raft-associated pathways337.  
Furthermore, lipid rafts are readily modified by diet and nutrition259,338. It has been 
described that in vivo polyunsaturated fatty acids (PUFA) supplementation affects lipid raft 
composition by depleting up to 50% of cholesterol and by altering lipid raft/caveolae 
protein composition. In comparison to chemical disruption of lipid rafts (e.g. with methyl-β- 
cyclodextrin and nystatin), PUFA treatment is very selective and depletes only membrane 
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cholesterol without affecting other cell sources of cholesterol339. By this mechanism 
PUFAs have been shown to decrease cell proliferation and induce apoptotic cell death 
probably by decreasing Akt/nuclear factor kappa-light-chain-enhancer of activated B 
(NFĸB) signal transduction340.  
Among cholesterol metabolism products, progesterone and estrogen were extensively 
proved to be breast cancer promoters32,33. Both genomic and non-genomic actions have 
been involved in breast cancer development but also have been important therapeutic 
targets. Estrogen receptors inhibitors (e.g. tamoxifen) and aromatase inhibitors are 
extensively used in treatment of patients with ER positive breast cancers and in primary 
prevention of high risk patients. 35,36,37 
The investigation of the role of oxysterols in cancer is just beginning, but, in vitro and in 
vivo studies have suggested that oxysterols may play critical roles in multiple stages of 
carcinogenesis. First, they may be involved in tumor initiation by enhancing the production 
of reactive oxygen species/reactive nitrogen species (ROS/RNS). Second, tumor 
promotion may be enhanced by oxysterols through up regulated expression of proteins 
such as cyclooxygenase 2 (COX-2) leading to the alteration of cellular features. In 
addition, certain oxysterols can support cancer progression through the induction of 
migration. Oxysterols may exert their effect by binding to specific proteins and activating 
signaling cascades341. Very recently, has been shown that 27-hydroxycholesterol 
increases ER-dependent growth and LXR-dependent metastasis in mouse models of 
breast cancer linking hypercholesterolemia to breast cancer pathophysiology342  
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Cholesterol and breast cancer  
 
Lipid profile and breast cancer risk 
 
Prospective studies on the relationship between total cholesterol and cancer risk have 
been limited and contradictory. 
Initial studies have reported that cancer incidence343,344,345,346, 347,348,349,350,351,352,353,354 and 
cancer mortality346,350,355,356,357,358,359,354,360,361 were higher in individuals with lower baseline 
levels of TC.  While this inverse association  was seen in the majority of the earlier 
studies, others found higher cancer risk in those with high TC concentrations362,363,364, nor 
relation at all 365,366,367,368,369,370,371,372 or U-shaped association, with low as well as high TC 
levels373. Some authors speculated that rather than reflecting a true causal relationship, 
the higher cancer risk seen for low TC may be attributable to an effect of preclinical 
cancer. In other words, reflects the metabolic depression of TC due to undiagnosed 
malignant lesions347,374. The positive association of cancer and high blood cholesterol is 
more consistent from the biological point of view. 
To better clarify this issue, the association of cholesterol dietary intake and cancer risk 
was tested. Hu et al375 showed a positive relation of high cholesterol consumption and 
stomach, colon, rectum, pancreas postmenopausal breast, kidney, bladder cancer, non-
Hodgkin lymphoma  and leukemia.  
However, while the majority of these studies are in accordance with these positive 
associations, some studies did not find any association or revealed contradictory findings. 
Such as a study376 described an association of low cholesterol intake and colorectal 
cancer in the Portuguese population (for review375). Recent analysis377,378 suggested that 
depending on cancer site, plasma cholesterol levels may have different associations with 
cancer 379,377. 
Concerning breast cancer, prospective studies showed positive association between TC 
levels and breast cancer  incidence377,363,380 and decreased overall survival381. Other 
studies showed no  association382,379,383,384,385,369, or even inverse correlations between TC 
levels and incidence of premenopausal breast cancer348,386,387; and a protective effect of 
very high levels of TC364. 
LDL-C and HDL-C are lipoproteins responsible for cholesterol transportation, LDL-C from 
the liver to peripheral tissues and HDL-C for the reverse transportation220. Few studies 
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specifically addressed the relation of lipoproteins fractions. Regarding HDL-C, some show 
a positive association between low HDL-C levels and increased breast cancer 
risk379,388,389,390,391 and a protective effect of high HDL-C to premenopausal breast 
cancer392. Others authors  find no association393,394,395, and some even report a positive 
correlation between high HDL-C and breast cancer risk396,397. LDL-C is less studied and 
no association with breast cancer was known379,384. Triglycerides levels are not associated 
with risk in prospective studies except, when in combination with low HDL-C385,392.  
Different study design, study populations and endpoints, duration of follow up, timing of 
cholesterol measurements, tumor stage and histological type, and differences in statistical 
adjustment for confounding variables may account for the disparity in the results of these 
studies. 
 
Lipid profile in breast cancer patients 
 
The lipid profile is the pattern of lipids levels measured in the plasma of a person and 
usually includes TC, LDL-C, HDL-C and triglycerides. When compared to non-breast 
cancer patients, alterations in lipid profile are very often seen among breast cancer 
patients (Table 3 
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Table 3: Alterations in lipid profile of breast cancer patients 
Author, year Study population Results* 
  TC LDL-C HDL-C TAG 
Bani,1986
398
 N= 48 BC patients 
N= 50 control 
↑ TC ↑ LDL-C ↓HDL-C 
 
↑ TAG 
Zielinski,1998 
399
 
N= 65 BC patients 
Group I: (N=51) 
metastatic 
Group II: (N=14) 
relapse after 
remission 
Group I: from 
32 patients 
with normal 
TC at 
baseline, 32 
had ↑ TC 
with disease 
progression. 
Group I: from 
9 patients 
with normal 
TC at 
baseline, had 
4 ↑ TC with 
disease 
progression 
NM NM Group I: from 
28 patients 
with normal 
TAG at 
baseline 22 
had TAG ↑ 
with disease 
progression. 
Group I: from 
8 patients 
with normal 
TC at 
baseline had 
4 TAG ↑ with 
disease 
progression 
Potischman,1999
400
 
N= 83 BC patients 
(in situ 6; Stage I 52; 
Stage II31; Stage III 
20; Stage IV 17) 
N= 113 control 
↓TC  
advanced 
stages 
NM NM NA 
Knapp, 1991
401
 N= 83 BC patients 
(Stage I 20; Stage 
II11; Stage III 5; 
Stage IV 47) 
↓TC  
advanced 
stages vs 
Stage I; 
↓TC  bone 
met vs liver 
or liver+bone 
met 
↓LDL-C  
bone 
met vs 
liver or 
liver+bo
ne met 
↓HDL-C 
advance
d stages 
vs 
Stages 
I-III 
↑ TAG 
advanced 
stages vs 
Stages I-III 
Agur-Collins, 
1998
402
 
N=58 BC patients 
N= 105 control 
(afro-american 
women) 
NA NA NA 
 
↑ TAG 
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Ray, 2001
390
 N= 54 BC patients, 
untreated, Stages II-
IV 
N= 42 control 
↑ TC ↑ LDL-C ↓HDL-C ↑ TAG 
Hasija, 2005
403
 N= 100 BC patients, 
untreated Stages I-
IV) 
N= 50 control 
↑ TC ↑ LDL-C NA NM 
Lopez-Saez, 
2008
404
 
N= 250 BC patients, 
stages I-III) 
N= 204 control 
↑ TC 
(BC PM ) 
↑ LDL-C 
(BC PM) 
↓HDL-C 
 
↑ TAG 
 
Owiredu, 2009
405
 N= 100 BC patients 
N= 100 control 
↑ TC ↑ LDL-C 
(BC PM) 
NA ↑ TAG 
Abdelsalam,2012
406
 
N= 120 BC patients 
(Stage I 52; Stage 
II31; Stage III 20; 
Stage IV 17) 
N= 120 control 
↑ TC ↑ LDL-C NA NM 
Yadav, 2012
407
 N= 69 BC patients 
N= 70 control 
↑ TC ↑ LDL-C ↓HDL-C ↑ TAG 
* BC patients vs control (when applicable). NM: Not measured. NA: not statistically significant. TC: total 
cholesterol; LDL-C: low density lipoprotein; HDL-C: High density lipoprotein; TAG: triglycerides; met: 
metastasis; BC: breast cancer; PM: postmenopausal 
 
The raised TC plasma level is ubiquitous to all studies390,398,401, 403, 404, 406 with the exception 
to advanced cases in two studies400,401. When measured, triglycerides and LDL-C, were 
also constantly raised, while HDL-C level was consistently decreased.  
The differences observed in breast cancer ptients with tumors at different stages, as well 
as the modifications in lipid profiles in the Zielinski study399 underline that the relation of 
the tumor and cholesterol must be dynamic during the oncologic process.  
Furthermore, hormonal therapies used in breast cancer produce changes in lipid profile. 
Tamoxifen increases triglycerides levels and reduces TC and LDL-C levels408. Anatrozole 
is associated to a non-significant decrease in levels of TC, LDL-C and triglycerides and a 
significant increase in HDL-C409. Letrozole increases  significantly  TC, LDL-C and HDL-C, 
with return to baseline after 3 to 6 months410. Although considered safe from the 
cardiovascular point of view, these therapeutic agents can determine changes in lipid 
profile that may imply uncertain influence in tumor control.  
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Insights from experimental studies  
 
The influence of plasma cholesterol in breast cancer initiation, from an epidemiological 
point of view, has been the difficult to demonstrate, whereas controlled experimental 
studies suggest a role of cholesterol in breast cancer progression. 
Since only ER negative breast cancer cell lines display increased proliferation in the 
presence of LDL-C411,288, the pro-proliferative and migratory effect of LDL-C appears to be 
dependent on the status of the ER in breast cancer cell lines. 
ER basal like cells store more cholesterol esters that ER positive cells. Acetyl-coenzyme 
A acetyltransferase 1 is responsible for the storage of long chain fatty acids and 
cholesterol in cytoplasmatic lipid droplets. Acyl-CoA cholesterol acyltransferase inhibition 
reduces breast cancer cells proliferation, migration288, invasion and colony formation412,413. 
Inhibition of intracellular cholesterol transport also affects cellular proliferation414,415. 
The effect of HDL-C on breast cancer cells shows increased proliferation but no migration, 
invasion or metastasis416. On the contrary HDL-C from diabetic patients induced all these 
effects417,418,419. This result is apparently mediated through the scavenger receptor class 
B, type I (SR-BI)416,420.  
Recent animal studies evidenced a role of high fat diet (HFD) in breast cancer. Llaverias 
et al44, used a transgenic mammary tumor mice model (FVB/N mice expressing the 
polyoma middle T antigen (PyMTTg) under the control of the mouse mammary tumor 
virus long terminal repeat promoter) to show that  HFD mice fed  have more aggressive 
tumors (more tumors, higher histological grade and enhanced angiogenesis) and more 
lung metastasis. Alikhani et al421 used an apolipoprotein E (Apo E) deficient mice model. 
Since Apo E is major ligand to LDLR, these mice developed marked dyslipidemia when 
challenged with a high fat/ cholesterol diet showing elevated circulating cholesterol and 
triglyceride levels in the setting of normal glucose homeostasis and insulin sensitivity. 
Upon injection of two mouse mammary cancer cell lines MET-1 and Mvt-1, the mice 
developed larger tumors and more pulmonary metastasis than the wild-type mice. 
In the study by Kim et al45, 4-week-old, female BALB/c mice were fed HFD or control diet 
for 16 weeks. Subsequently, 4T1 mammary carcinoma cells were injected into the inguinal 
mammary fat pads of mice continuously fed on their respective diets. Results showed that 
the tumor weight, the number and volume of tumor nodules in the lung and liver as well as 
tumor-associated mortality were increased in the HFD group.  
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In all these mice trials, only Llaverias et al44 measured cholesterol plasma levels. They 
found that, in animals fed HFD, 12-week-old PyMTTg mice opposed to  4 and 8 weeks old 
has reduced serum cholesterol levels (P<0.05). As found in some clinical studies this 
observation is in accordance to the so called reverse causation effect of tumor in 
cholesterol levels. 
In line with these observations, Gomes et al demonstrated that elevated LDL-C promotes 
bone marrow derived cells (BMDC) mobilization by interfering with SDF-1:CXCR4 axis. 
These cells are known to play an important role in tumor progression either in the  tumor 
microenvironment422 or in metastatic niches at distant organs179.  
Very recently, the interest in the role of cholesterol in breast cancer was renewed by the 
hypothesis that a primary metabolite of cholesterol, oxysterol 27-hydroxycholesterol, 
promotes ER–positive BC growth in in vivo models342. In this setting cholesterol reduction 
would be a safe strategy to prevent and /treat breast cancer342,423,424,425.  
 
Statins use and breast cancer  
 
HMG-CoA reductase inhibitors (statins) block the rate-limiting step in cholesterol 
biosynthesis426. Statins can be classified, based on their solubility in hydrophilic (better 
solubility in water) or lipophilic (better solubility in fats) (Table 4). The hydrophilic statins 
are excreted from the body largely unmetabolized by the liver because hydrophilic nature 
prevents up take by extra-hepatic tissues. Lipophilic statins are broken down in the liver 
by the cytochrome P450 (CYP450) system and can be also up take by extra-hepatic 
tissues427. Hydrophilic statins tend to have fewer interactions with other drugs428.  
Table 4:Statins 
Classification by solubility Drug 
Water soluble (hydrophilic) pravastatin, pitavastatin and rosuvastatin 
Fat soluble (lipophilic) atorvastatin, fluvastatin, lovastatin and 
simvastatin 
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These drugs have become standard therapy to manage hypercholesterolemia and 
associated morbidities429. As such, statins are among the most commonly prescribed 
drugs worldwide. Their use has increased dramatically in the past decade and is likely to 
continue rising430. 
Statins may affect the occurrence or outcomes of diseases either by cholesterol reduction 
or by mechanisms outside of the cholesterol synthesis pathway431,432,433. Pre-clinical 
studies showed  that, contrary to concerns over the carcinogenicity of statins in the early 
animal models434, statins may in fact have a chemopreventive potential against 
cancer435,436,433. 
HMG-CoA reductase is the major rate-limiting enzyme of the mevalonate pathway. Statins  
inhibition of HMGR prevents the conversion of HMG-CoA to mevalonate, and thereby 
reduce levels of mevalonate and its downstream products435. Many products of the 
mevalonate pathway are necessary for critical cellular functions such as membrane 
integrity, cell signaling, protein synthesis, and cell cycle progression435,436. Disruptions of 
these processes in neoplastic cells by statins may result in control of tumor initiation, 
growth, and metastasis, which has been shown to inhibit cancer cell growth and lead to 
apoptotic cell death437,438,439. Most recently, the possible tumor suppressive activity of 
statins was linked to down regulation or inhibition of matrix metalloproteinases through 
prolonged lowering of circulating cholesterol. Metalloproteinases are enzymes able to 
degrade extracellular matrix components involved in tumor growth, invasion, and 
metastasis440. 
At the clinical level, the association of statins consumption and cancer risk has been 
widely searched, across RTC to statins in cardiovascular diseases. Results from two 
statins randomized control trials, have related an increase incidence of cancer risk with 
pravastatin use441,442, but  no other RTC or meta-analyses confirmed such effects and 
showed a neutral impact of statins443, 444,445,446,447,448,449,450,451.  
Importantly, those studies were designed to assess cardiovascular endpoints and 
therefore enclose many limitations to assess cancer risk. Relatively short follow-up times, 
short duration of statin use, no evaluation of dose-duration response, highly selected 
groups of patients in RCTs, and failure to account for multiple types of statins must be 
considered when interpreting results of all the meta-analyses. Mean follow-up in statin 
RCTs is generally 4–6 years and cancer is an endpoint that needs longer follow-up. Meta-
analyses of overall cancer risk are unlikely to be very sensitive as it is unlikely that statins 
alter the risk of all cancers. A true change in the risk of specific cancers may be masked 
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by the random variation in the association of statins with other cancers. Some authors 
also suggested that different pharmacokinetic properties of hydrophilic statins (e.g. 
pravastatin) versus hydrophobic statins (e.g. lovastatin, simvastatin) support opposing 
effects on cancer risk452,453. This may explain the increased risk of cancer found among 
pravastatin users in two of the large RCT441,442, and the protective effect seen in users of 
lipophilic statins in other studies454,455,456. However, the two published meta-analyses 
reported on statin type found no difference in risk by hydrophilic versus hydrophobic 
statins450,446. 
A very recent cohort study crossing statins prescription/ pharmacy dispense  and cancer 
related-mortality in Denmark National databases457, showed that statins use before cancer 
diagnosis  is associated with reduced cancer-related mortality. Although some limitations 
found and pointed by the authors and others458, such as lack of follow up and co-
morbidities data, the association seems to be plausible, in the study population. 
Concerning breast cancer, most studies383,459,460,461,462,463,464,465,466,467,468,469,470, including 
meta-analysis471,450,446,472,473,474 have reported no association between breast cancer 
incidence and statin use, although some reports suggested protective 
effect475,476,456,455,477,478 and one an inverse effect479 (Table 5). 
Two studies analyzed the association between post-diagnosis statin use and breast 
cancer recurrence. Kwan et al480 followed a cohort of approximately 2000 breast cancer 
survivors for a mean of 5 years and observed an association between lipophilic statin use 
and decreased cancer recurrence. While in this study the estimate was not measured 
precisely enough to provide strong evidence against a null association (hazard ratio [HR] 
= 0.67, 95% confidence interval [CI] = 0.39 to 1.13), Ahern et al481  following  a large 
Danish cohort of stage I-III breast cancer patients diagnosed between 1996-2003,  found 
that simvastatin use (but not hydrophilic statins) was associated with reduced breast 
cancer recurrence (10 y adjusted  HR 0,55 96CI 0,35-0,85). Others have found a 
protective effect higher in ER negative breast cancer478,482 and a putative potentiation of 
radiotherapy effect483,484,485. 
While there are many observational studies and meta-analyses published on statin use 
and breast cancer risk, the current data is unsatisfactory for recommending statins for 
primary breast cancer prevention and secondary prevention is not well studied.  
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Table 5: Epidemiologic studies on the association of statins use and breast cancer risk. 
Author, year Design*  Number of cases Results  
  
User 
Non-
user 
(point estimate (95% CI))** 
Blais, 2000
459
 CC 65 OR=0,67 (0,33–1,38) 
Coogan, 2002
479
 CC 33 828 OR=1,5 (1,0–2,3) 
Kaye, 2002
460
 CC 31 102 OR=1,0 (0,6–1,6) 
Beck, 2003
476
 Cohort 188 691 Ever use: OR=1,09 (0,93–1,28) 
Age <55 yrs: OR=0,81 (0,53–1,24) 
Age >55 yrs: OR=1,15 (0,97–1,37) 
Use ≥4 yrs: OR=0,26 (0,12–0,55) 
Cauley, 2003
475
 Cohort 6 234 RR=0,28 (0,09–0,86) 
Boudreau, 2004
455
 CC 112 849 Ever use: OR=0,9 (0,7–1,2) 
Use> 5 yrs: OR=0,7 (0,4–1,0) 
Graaf, 2004
461
 CC 467 OR=1,07 (0,65–1,74) 
Kaye, 2004
462
 CC 40 OR=0,9 (0,6–1,3) 
Kochhar, 2005
477
 CC 556 OR=0,49 (0,38–0,62) 
Eliassen, 2005
383
 Cohort 152 1,472 Current use: RR=0,91 (0,76–1,08) 
Friis, 2005
463
 Cohort 48 3,093 RR=1,02 (0,76–1,36) 
Cauley, 2006
456
 Cohort 297 4,086 Ever use: HR=0,91 (0,80–1,05) 
Hydrophobic statin use: HR=0,82 (0,70-
0,97) 
Setoguchi, 2007
464
 Cohort 203 65 HR=0,99 (0,74–1,33) 
Boudreau, 2007
467
 Cohort 130 2,577 Ever use: HR=1,07 (0,88–1,29) 
Use ≥5 yrs: HR=1,27 (0,89–1,81) 
Hydrophobic use: HR=1,01 (0,80–1,26) 
Coogan, 2007
465
 CC 69 
cases 
and 
controls 
1101 
cases and 
controls 
Ever use: OR=1,2 (0,8–1,8) 
Use ≤1 year: OR=1,0 (0,5–2,1) 
Use 1–5 year: OR=1,2 (0,7–2,1) 
Use ≥5 years: OR=1,5 (0,7–3,2) 
P for trend in duration: 0,1 
Hydrophobic statin use: OR=1,0 (0,6–
1,6) 
Friedman, 2007
468
 Cohort 881 - Ever use: HR=0, 9 (0,92–1,06) 
Use >5 yrs: HR=1,02 (0,86–1,21) 
Smeeth, 2008
469
 Cohort 324 2880 HR=1,17 (0,95–1,43) 
Kumar, 2008
478
 Cohort 387 1754 Use ≥ 1 yrs ER-: HR 0,63 (0,43-0,92) 
Use <1yr ER+: HR 1,25 (0,72-2,17) 
Haukka, 2010
470
 Cohort - - RR=1,01 (0,96–1,06) 
Woditscha, 2010 
466
 
CC 5,409 17,079 Lipophilic statins 
Use ≥ 2 yrs ER-: HR 0,98 (0,84-1,13) 
Use≥ 2 yrs ER+: HR 1,03 (0,97-1,10) 
Kawn , 2008
480
*** Cohort 367 1444 RR = 0.67; ( 0.39-1.13) 
P linear  for trend in duration: 0,02 
 
Ahern, 2011
481
*** Cohort 3282 15 487 Hydrophobic statin use 
HR: 0,55 (0,35-0,85) 
*CC=case control; **OR=odds ratio; RR= relative risk; HR=hazard ratio; CI=confidence interval; relative to 
non-users; *** recurrence risk. 
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Of the 27 ongoing studies registered in ClinicalTrials.gov examining associations between 
statin therapy and cancer risk or outcomes, nine are in breast cancer. Results of these on-
going trials will be a major contribution to the field. Such trials and epidemiologic studies 
are more feasible for cancer prognosis than incident risk due to the long latency period of 
cancer and thus, the long follow-up periods required. However, the prospect of reducing 
the incidence and burden of some of the most prevalent cancers with a safe, affordable, 
and tolerable medication that already reduces the risk of the leading cause of death, 
cardiovascular disease, warrants further exploration. 
Non-statin cholesterol lowering drugs are a heterogeneous group with varied mechanisms 
of action including fibrates, niacin, bile-acid resins and cholesterol absorption inhibitors. 
Few studies evaluated other cholesterol-lowering drugs and, in general, they are not 
associated with risk of cancer486 except cholestyramine, and fibrates434 in older animal 
studies, but human association was not demonstrated. 
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Hypothesis and Aims 
 
Based on epidemiological and experimental data we considered the hypothesis that 
systemic cholesterol metabolism influences breast cancer behavior by promoting tumor 
progression. 
 
To test our hypothesis we sought to:  
1) Determine an association of systemic cholesterol levels and breast cancer 
progression. 
For that we designed a clinical prospective study of women with early breast 
cancer to determine how lipid profile correlates with tumor features and 
progression. We also tested the hypothesis experimentally by using orthotopic 
breast cancer mouse models and in vitro breast cancer cell lines. 
 
2) Investigate the cellular and molecular mechanisms by which cholesterol can 
influence breast cancer pathophysiology. 
 
3)  Explore how assessment and control of the systemic cholesterol levels would 
improve breast cancer treatment and surveillance. 
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Chapter 1 
Plasma Level of LDL-Cholesterol is a Predictive Factor of Breast 
Tumor Aggressiveness1 
 
Introduction 
 
Cancer and cardiovascular diseases are the leading causes of death in Europe2 and USA1 
and their incidence is also increasing in Asia3,4. 
Breast cancer is the most frequent malignancy diagnosed each year in Europe and USA 
(age–adjusted incidence rate, 76-89,7 per 100,000)202, and still account for high mortality 
rate3. In Asia, incidence and mortality of breast cancer are lower (age–adjusted incidence 
rate, 22-30 per 100,000)202 but have been dramatically raising in the last decade3, 205. 
Lifestyle and diet are frequently indicated as reasons for the global distribution of breast 
cancer incidence38,39. Nevertheless, while hypercholesterolemia, mainly attributed to diet 
[high LDL-C and low HDL-C levels] was already shown to play a major role in the 
etiopathogenesis and incidence of cardiovascular diseases211, its influence in breast 
cancer is not completely understood. 
Several reasons suggest the possible involvement of cholesterol in breast cancer biology. 
Cholesterol is a structural component of cell membrane, specially localized in lipid rafts-
membrane microdomains that assemble the machinery of cell signaling pathways closely 
associate with malignant transformation due to their influence in organization of the 
cytoskeleton, cell polarity and angiogenesis256,487. Cholesterol is also a steroid hormone 
                                               
1 The results discussed in this chapter are published in Rodrigues Dos Santos C, Fonseca I, Dias S, Mendes 
de Almeida JC. Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor 
progression. BMC Cancer. 2014 Feb 26;14:132 (highly accessed paper), and were presented at 34
th
 Annual 
San Antonio Breast Cancer Symposium, 13
th
 Annual Meeting of the American Society of Breast Surgeons 
and VIII Congresso Nacional de Senelogia. 
Preliminary results of this study were published at Santos, CR; Mendes Almeida JC and Dias, S, Systemic 
LDL Promotes Breast Cancer Progression; Annals of Surgical Oncology, May 2012, Volume 19 (Issue 2 
Supplement);100-01. 
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precursor, namely estrogen and progesterone, and the vast majority of breast cancer is 
hormone responsive488. Moreover, the peak incidence of breast cancer occurs in the 
perimenopausal period489, when women dyslipidemia prevalence also increases490.  
However, clinical data searching for the association of cholesterol levels and breast 
cancer risk are scarce and have provided contradictory results. Prospective studies 
showed positive association between total cholesterol levels and both breast cancer 
incidence377,363,380 and overall mortality in breast cancer patients381; but also no 
association at all 382,379,383,384,369,385 or even inverse association between total cholesterol 
levels and incidence of premenopausal breast cancer348,386,387; as well as a protective 
effect of very high levels of total cholesterol364 were described. Studies specifically 
addressing the role of lipoproteins fractions are similarly contradictory. Regarding HDL-C, 
some shown a positive association between low HDL-C levels and breast cancer 
risk379,388,389,390,391 and a protective effect of high HDL-C with premenopausal breast 
cancer392; while others found no association393,394,395, and some even reported a positive 
correlation between high HDL-C and breast cancer risk396,397. LDL-C is less studied and 
no association with breast cancer was reported379,384. Triglycerides levels were no 
associated with risk in prospective studies except, in combination with low HDL-C385,392.  
Disparity in those results may be due to different study designs, study populations, 
endpoints, duration of follow up, timing of cholesterol measurements, tumor stage, tumor 
histological type, and differences in statistical adjustment for confounding variables. 
On the other hand, alterations in lipid profile are often seen among breast cancer patients, 
when compared to non-cancer controls. Increased total cholesterol levels were 
transversally seen in almost all studies390,398,403,404,406,405,407.400,401. Triglycerides and LDL-C, 
when measured, were also constantly elevated while HDL-C level was decreased 
390,398,403,404,406,405,407,402. Experimentally, lipoproteins were shown to induce cancer cells 
proliferation and migration in vitro411,288,416,491,417,418,419 and studies using genetic or diet 
induced hypercholesterolemic mouse models revealed a clear association between high 
lipid levels and breast cancer development44 and progression45,421.  
Thus, whereas the influence of plasma cholesterol in breast cancer risk has been difficult 
to demonstrate, the variations of lipid profile in breast cancer patients and the results from 
controlled experimental studies strongly support a role for cholesterol in breast cancer 
pathophysiology. 
At this point we hypothesized that host cholesterol-enriched systemic environment 
promotes breast tumor progression. To answer to this question we analyzed the 
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correlation of lipid profile with clinical and pathological characteristics of breast tumors in a 
cohort of breast cancer patients without previous treatment. 
Methods2 
Study population and data collection 
From January to December 2011, women, who underwent for operable breast cancer at 
the Breast Unit of Instituto Português de Oncologia de Lisboa, Francisco Gentil (IPOLFG), 
were prospectively assembled (Figure 13). 
 
Figure 13: Study Fluxogram 
 
Biospecimen collection and plasma lipid and lipoproteins assays  
Fasting lipid profile was measured at diagnosis, along with routine preoperative exams. 
Blood was collected into EDTA-coated tubes and the plasma levels of TC, LDL-C, HDL-C 
and triglycerides were measured automatically by electrophoresis (Architect ci8200 
analyzer; Abbott Diagnostics, Wiesbaden, Germany) at the certified Clinical Pathology 
Laboratory of IPOLFG. 
Hormonal receptors were measured using standardized immunohistochemistry. HER2 
was scored according to the WHO guidelines493 from 0 to 3+. All cases with 2+ score were 
                                               
2 The data collection was performed in collaboration with Breast Unit clinicians. Immunohistochemistry was 
performed by Pathological Department technicians and reviewed by Isabel Fonseca. Plasma lipids were 
measured by Clinical Pathology technicians.Assistance with statistical analysis was obtained from Nuno 
Cortez-Dias. The remainder tasks described in this chapter were performed by the candidate. 
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reevaluated using chromogenic in situ hybridation.  Immunohistochemical staining for Ki67 
was performed in a Dako Autostainer® (Dako, Glostrup, Denmark) using standard 
protocols, followed by counting positive cells in an automated cellular imaging system 
(ACIS®II, Dako, Glostrup, Denmark I). Technicians were blinded to the lipid profile status 
of the study participants. 
Statistical analysis 
Continuous variables are presented as mean (standard deviation) or median (interquartile 
range) if they have normal distribution or not, respectively. For categorical variables 
absolute values and frequencies are shown. Spearman rank correlations coefficients were 
calculated to examine correlations between continuous variables. Univariate analysis 
between lipid profile, breast cancer risk factors (menopausal status, BMI, age, family 
history, parity, breast feeding) and traditional prognostic factors (tumor size, positive 
lymph nodes, tumor grade, lymphovascular invasion, ER, PR, HER2 and Ki67) were 
performed using parametric tests to variables with normal distribution and non-parametric 
tests to variables without normal distribution. Patient subgroups were defined by LDL-C 
levels tertiles. Tumor characteristics (T stage, N Stage, immunohistochemical subtypes) 
were studied as categorical variables.   
Multivariate logistic regression to the risk of tumor T stage included the following 
variables: TC (by tertiles), LDL-C (by tertiles), triglycerides (3rd tertile), BMI (by tertiles) 
and age (by tertiles) by using stepwise conditional forward analysis. 
Likelihood ratio P values are reported to whole variables in the model. All P values are 
two-tailed. The statistical analysis was done using IBM SPSS Statistics for Windows, 
Version 19.0(Armonk, NY: IBM Corp. Released 2010). 
 
Results 
A total of 446 women were potential assembled to the study (Figure 13). Of those, 202 
were excluded for being on conflicting medications (n=134), because histological type 
(n=60) and previous treatments (n=9). Baseline demographic, clinical and tumor related 
characteristics of the study population (n=244) are listed in (Table 6). 
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Table 6: Clinical and tumor-related characteristics of the study population (N=244) 
Characteristics  No. of 
Patients 
%¹ 
Patient Characteristics 
   
   Age (Years), mean±SD (range) 58,2±13,3 (29-91) 
  
   Weight (Kg), median (interquartile range) 67 (60-76) 
  
   Height (cm), median (interquartile range) 160 (154-163) 
  
BMI (Kg/m
2
), median (interquartile range) 26,7 (23,5-30,44) 
  
   Menopausal  Status (yes) 
 
126 65,6 
   Gestation (yes) 
 
182 90,5
4    Breast-Feeding (yes)  
146 79,3 
   Oral Contraception/ HT (yes) 
 
96 55,6 
   Family History of BC♯(yes) 
 
56 27,5 
   TC (mg/dL), median (interquartile range) 209,5 (191-231)  
    HDL-C (mg/dL), median (interquartile 
range) 
53 (46-60) 
 
   LDL-C (mg/dL), median (interquartile 
range) 
128 (110-153) 
 
Triglycerides (mg/dL), median       
(interquartile range) 
94 (74,5-126) 
  
Tumor Characteristics 
  
 
   Histological Type IDC² 244 100 
 Tumor Size (mm), median  
(interquartile range) 
21 (14-30)   
   Tumor Stage (T) T1, ≤ 2cm 122 50 
 T2, 2-5cm 115 47,2 
 T3, >5cm 7 2,8 
   Tumor Grade G1 27 12,4 
 G2 134 61,5 
 G3 57 26,2 
    Subtypes ER/PR positive∞ 204 83,9 
 Triple negative 23 9,5 
 HER 2 
Typepositive 
16 6,6 
   LVI positive  61 29,2 
   Nodal Stage (N) N0 137 56,9 
 N1, 1-3 LN+ 72 29,9 
 N2, 4-9 LN+ 18 7,47 
 N3, ≥10 LN+ 14 5,8 
   Clinical Stage I 84 34,4 
 II 125 51,3 
 III 35 14,3 
   Bilaterality (yes)  10 4,1 
¹ frequency of known cases; ² IDC is presently named invasive carcinoma, NOS.∞ includes Luminal A 
and B. HT: Hormonal Therapy; BC: Breast Cancer; ♯ not in the first generation; BMI: Body Mass 
Index; HT: Hormonal therapy; TC: Total Cholesterol; LDL-C: Low Density Lipoprotein; HDL-C: High 
Density Lipoprotein IDC: Invasive Ductal Carcinoma; ER: Estrogen Receptor; PR: Progesterone 
Receptor; LVI: Lymphovascular Invasion; LN: Lymph Nodes.  
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Spearman correlations  
Exploratory correlations between lipid profile, age, BMI, primary tumor size and lymph 
node metastasis ratio (defined as the number of metastatic axillary lymph nodes over the 
total lymph nodes removed), showed that systemic levels of LDL-C and TC correlates 
positively with tumor size (Spearman r=0,199, P 0,002; Spearman r=0,145, P 0,025, 
respectively).  As expected, age correlates with BMI (Spearman r= 0,155, P 0,022) and 
triglycerides (Spearman r= 0,312, P <0, 0001) and BMI correlates with age, LDL-C 
(Spearman r=0,161, P 0,018), HDL (Spearman r=-0,157, P 0,021) and triglycerides 
(Spearman r=0,149, P 0,027).   
Plasma LDL-C level was significantly related to tumor T stage and prognostic groups of 
the AJCC78. There is no statistical difference in other parameters of lipid profile across 
tumor stages (Table 7). 
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Table 7: Lipid profile in tumor stage
1
 and in prognostic groups
2
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Univariate associations 
Population was stratified based on LDL-C level tertiles: LDL T1:LDL-C≤117mg/dl; LDL 
T2:144mg/dl≥LDL-C>117mg/dl; LDL T3:LDL-C>144mg/dl. Patients in the third LDL-C 
tertile have larger tumors (P 0,024) (Figure 14A), of higher differentiation grade (P 0,027), 
with higher proliferative rate (P 0,017), and higher likelihood of being diagnosed in 
advanced stages. This analysis does not demonstrated differences in lipid profiles 
between breast tumor immunohistochemical subtypes (Luminal A, Luminal B, Triple 
negative and HER2 type494). Nevertheless, tumors of patients in the third LDL-C tertile are 
more commonly HER2 positive, when compared to the others tertiles (P 0,002) (Figure 
14B). There are no differences, between LDL-C categories, concerning studied breast 
cancer risk factors (Table 8).  
 
Table 8: Patient characteristics in LDL-C levels tertiles 
Patient 
Characteristic 
LDL T1 
(LDL≤117mg/dl) 
N=82 
LDL T2 
(144mg/dl≥ 
LDL>117mg/dl) 
N=81 
LDL T3 
(LDL>144mg/dl) 
N= 81 
P value 
Age (years), median 
(interquartile range) 
60,14 (49,0-70,3) 58,3 (48,2-70,0) 58,2(50,9-64,2) 0,593 
Menopausal Status (+), 
 (N,%) 
64,7% 65,1% 67,2% 0,951 
Pregnancy History (+), 
 (N,%) 
94,2% 71,9% 88,3% 0,408 
Breast –feeding (+),  
(N,%) 
76,6% 51,9% 68,4% 0,079 
Oral contraception (+),  
/ HT (+), (N,%) 
51,6% 58,3% 53,7% 0,597 
Family History
♯
, (N,%) 40% 34,5% 25,5% 0,258 
BMI (Kg/m
2
), median 
(interquartile range) 
25,7(22,8-29,4) 26,1(23,4-29,4) 27,9(24,7-31,5) 0,107 
HT: Hormonal Therapy; BC: Breast Cancer; BMI: Body Mass Index, ♯ not in the first generation. P value: Kruskall-
Wallis test. LDL:LDL-C: Low Density Lipoprotein ; BMI: body mass index; T: tertile level. 
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Figure 14: Tumor characteristics-LDL tertiles 
A. Tumor size increases across LDL-C tertiles groups. Line represents the median value of tumor size in each 
LDL-C tertile. B. Frequency of tumor characteristics in LDL-C tertiles groups. 
*1
 LDL T1-T2 (Her2-neu+ 15,5%) 
vs LDL T3 (Her2-neu+ 27,8%): OR 5,015 (1,678-14,988) P 0,002 . 
*2 
LDL T1 (Stage II-III 54,9%) vs LDL T2-T3 
(Stage II-III 69,6%): OR 0,543 (0,313-0,943) P 0,029.  Kruskall-Wallis test. ER: Estrogen Receptor; PR: 
Progesterone Receptor; LVI: Lymphovascular Invasion; LN: Lymph Nodes. 
 
Multivariate logistic regression 
A multivariate logistic regression to the risk of tumor T stage was then modeled. All the 
variables significantly associated at univariate analysis (Additional Table 1) were 
introduced, including age and BMI, even not positively associated, because of its strong 
correlation with lipid profile. It was found that the LDL-C level higher than 117mg/dL is a 
predictor factor to tumor size ≥ 20mm, at diagnosis (Table 9).  
Table 9: Univariate and multivariate logistic regression to the risk of tumor size ≥20mm. 
Variable 
Univariate Analysis 
HR   95% CI    P value 
Multivariate Analysis 
HR     95% CI     P value 
Total Cholesterol T≥2vs T1  1,912 
 
1,113-3,285 0,018 
 
  
 
 
 
LDL-C  (>117mg/dl) T≥2vs 
T1  
2,419 1,394-4,199 0,002 2,468 1,356-4,491 0,003 
Triglycerides T3  1,888 1,092-3,264 0,022  
BMI T≥2vs T1 1,785 0,010-3,155 0,045    
Age T≥2vs T1 0,833 0,430-1,416 0,499    
LDL-C: Low Density Lipoprotein; BMI: body mass index; HR: hazard ratio, CI: confidence interval 
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Discussion  
 
Multiple epidemiological studies exploring causal associations between dyslipidemia and 
breast cancer incidence produced contradictory 
results382,379,383,384,385,348,386,387,377,363,364,369,380. Several methodological aspects may explain 
the diverse conclusions, but biological clues from laboratory411,288,416,491,417,418,419 and in 
vivo pre-clinical studies45,342,44,421, as well as, significant alterations in lipid profile of breast 
cancer patients compared to healthy 
controls390,398,403,404,406,405,407,400,401,374,495,390,398,403,404,406,405,407,402 are very suggestive of a role 
for cholesterol in breast cancer progression. 
In the present study, fasting lipid profile (with discrimination between lipids and 
lipoproteins fractions) was prospectively assessed in a cohort of patients with invasive 
carcinoma, in early stage, before any treatment and with no history of being on lipid 
lowering drugs (including statins, fibrates, oral anti-diabetics, insulin or corticosteroids). 
Population characteristics are similar to other series, concerning to demographic and 
tumor characteristics496,497,498. Slight under-representation of triple negative and HER2 
type cancer have occurred due to the inclusion criteria, as those patients are more likely 
to undergo neoadjuvant chemotherapy. The average lipid profile of breast cancer patients 
in this cohort superimposes those of the sex, age and BMI-matched Portuguese 
population499, 500.  
Results show that systemic LDL-C level above 117 mg/dL is a predictive factor of tumor 
T2 stage or higher, at diagnosis. These level is also positively associated with worse 
prognostic characteristics such as higher histological grade, higher proliferative rate501 and 
more advanced clinical stage (II-III). Patients in the third tercile (LDL-C>144 mg/dl) are 
also more prone to have LVI and lymph node metastasis. This trend seems to be 
transversal to all immunohistochemical breast cancer subtypes, although we found a 
significant increase of HER2 positive cases in patients of the third tertile group.  
Other published studies, also found higher TC levels in breast cancer patients, compared 
to healthy controls403,406 as well as a trend of raised TC, LDL-C levels with higher tumor 
stage403. However, to our knowledge this is the first cohort of breast cancer patients in 
whom the correlation of lipid profile and tumor characteristics was done in a setting of pre-
treatment and with all patients free of lipid lowering drugs. Despite we did not accessed 
variables that may also influence the lipid profile such as smoking habits, type of diet, 
residence area or socioeconomic status, the most important co-variables, BMI, age and 
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lipid lowering drugs were controlled. Furthermore, conversely to previous studies, this 
cohort includes patients in initial clinical stages and with the same histological type, in 
other to better control tumor variables. 
Considering that proliferating cancer cells have an increased demanding of cholesterol 
and intermediates of cholesterol metabolism, the up-regulation of cholesterol biosynthesis 
and or an increased up take from the exterior are expected. Results support the 
hypothesis that high availability of systemic cholesterol promotes tumor growth and 
aggressiveness. However, observed high LDL-C levels may actually reflect a shift in 
cholesterol metabolism (in liver or tumor cells themselves) in patients with aggressive 
tumors, being a consequence of the tumor progression and not a causal factor.  
In cancer cells, cholesterol synthesis has been shown to be increased, due to availability 
of precursors or to increased transcription of biosynthesis enzymes502,503,504. Hidroxi-3-
methyl-glutaril-coA reductase 3 inhibition by statins decreases in vitro cell proliferation, 
attesting that cholesterol biosynthesis should be important to tumor growth503. Elevated 
cholesterol content is characteristic of breast tumors505 and ACAT-1 inhibition, an enzyme 
involved in cholesteryl esterification decreases proliferation and invasion rate411. Although 
strong evidence that cancer cells increases intracellular cholesterol synthesis, this effect is 
not expected to produce hypercholesterolemia and justify the association. 
On the other hand, high LDLR expression was shown in breast tumors compared to 
normal tissue280 supporting that cancer cells are able to uptake LDL-C from the 
bloodstream. In in vitro experiments, HDL-C as well as exogenous triglycerides276 were 
also demonstrated to be consumed by cancer cells through SR-BI416,491,420 .  
In order to support tumor needs, the exogenous cholesterol could be mobilized from body 
storage, through HDL-C or from diet, through hepatic metabolism and LDL-C. Accordingly, 
Zielinski et al399 followed-up a group of patients with advanced breast tumors in remission 
and described a significant raise in plasma cholesterol and triglycerides in most of the 
patients of those who developed disease progression. 
Our results does not exclude the possibility that LDL-C plasma levels are consequence of 
body mobilization, but we saw the same pattern of lipid profile in breast cancer patients 
and age and sex-matched non-cancer Portuguese population499, 500 suggesting that the 
tumor, at this stage, is not changing LDL-C levels. Instead lipid profile of the study 
population may reflect the origin population.  
Therefore, results strongly suggest that a tumor arising in an enriched-cholesterol 
environment has an advantage to progress (Figure 15), revealing that the host metabolic 
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features influence tumor behavior. However, the biological mechanisms underlying this 
association are totally unknown. 
 
Figure 15: Phenotype of breast tumors exposed to high levels of cholesterol-Proposed Model. 
 
We found that tumors of the LDL-C highest tertile are more commonly HER2 positive. 
Membrane cholesterol is specially localized in the lipid rafts domains. Such areas are 
enriched in transmembrane proteins that are key in signaling pathways associated with 
malignant progression: Fas receptor, TNF related apoptosis-inducing ligand, Akt, 
integrins, cadherins and growth factor receptors256 including ERBB2. The last molecule is 
a tyrosine kinases receptor (and oncogene) localized in lipid rafts and it function is highly 
dependent on membrane fluidity506,507. Therefore cholesterol enrichment within the cell 
membrane may alter receptor-signaling. It is possible that ERBB2 receptor ligand-
independent activation is potentiated by cholesterol-enriched environment, explaining 
selection of HER2 positive tumors. 
Estrogen and progesterone are growth factors to ER/PR positive tumors and their 
synthesis requires cholesterol. Recent In vivo studies showed that oxysterol 27-
hydroxycholesterol, also a derivate of cholesterol metabolism and ER-ligand, promotes 
ER positive breast cancer proliferation in mouse models342. In our study, no association of 
LDL-C and ER status was seen thus not supporting a fundamental mechanism ER-
dependent. 
The pro-inflammatory microenvironment induced by high-cholesterol levels, as seen in 
atherosclerosis, in which LDL-C is the most important causative factor508,509, can also play 
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an effect on breast cancer initiation and progression. The use of statins before cancer 
diagnosis was associated to reduced cancer-related mortality457. This effect was 
supposed to be mainly due to the reduction of LDL-C, but statins anti-inflammatory 
mechanism cannot be ruled out.  
Although the molecular mechanism by which systemic cholesterol exert an influence on 
the tumor is unknown, our results show that LDL-C level, at diagnosis is a predictive factor 
of tumor aggressiveness. 
 
Conclusion 
 
We found that LDL-C level at diagnosis is significantly associated with advanced and 
worse prognosis breast tumors and emerges as an important issue to investigate further. 
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Chapter 2 
LDL-cholesterol signaling induces breast cancer proliferation and 
invasion3 
 
Introduction 
 
Cholesterol is an essential structural component of the cell membranes256. Proliferating 
cells, such as cancer cells, are believed to have increased requirements of cholesterol. 
According, cholesterol accumulation is a property of some malignancies510,511 and the 
inhibition of cholesterol storage machinery, in breast cancer cell lines was associated with 
reduced proliferation411. 
To overcome their needs, tumor cells increase lipid biosynthesis272, and may also uptake 
cholesterol from the bloodstream276,288. This ability of cancer cells to use exogenous lipids 
has been considered the link between high fat diets and dyslipidemia with cancer276,411. 
To date, most studies have seek to find a causal relation between cancer incidence and 
lipid levels382,379,383,384,377,369,460, however less studies tried to explore a possible link in 
cancer aggressiveness or progression. Thus, for now, the importance of plasma 
cholesterol in cancer progression remains poorly understood and was the subject of the 
present study.  
We asked whether exposure to a host LDL-C enriched systemic environment promotes 
breast cancer progression by activating key signaling pathways and modulating cell 
behavior. To test this hypothesis we used controlled experimental environments, 
employing well established in vitro and in vivo models. 
                                               
3 Results discussed in this chapter are published at Rodrigues dos Santos C, Domingues G, Matias I, Matos J, 
Fonseca I, de Almeida JM, Dias S LDL-cholesterol signaling induces breast cancer proliferation and 
invasion Lipids Health Dis. 2014 Jan 15;13(1):16. [Highly accessed paper, article is amongst the highest 
ever scored in this journal (ranked #49 of 312).] 
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Material and Methods4 
Cell lines and reagents 
The human breast cancer cell line HTB20 and the mouse breast cancer cell line 4T1 were 
purchased from the American Type Culture Collection. The human breast cancer cell lines 
HTB126, MDA MB 231 were kindly provided by Instituto Português de Oncologia do 
Porto. 
The cell lines were cultured in DMEM (Gibco Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco Invitrogen, 
Carlsbad, CA, USA) and 1% penicillin-streptomycin (Invitrogen life Technologies). Fetal 
bovine serum lipoprotein free (FBSLF) was purchased from Sigma-Aldrich (Germany) and 
human plasma low density (LDL-C) and high density (HDL-C) lipoproteins were obtained 
from Calbiochem (Gibbstown, NJ, USA). Mitomycin C was from Sigma-Aldrich (Germany) 
and Trypsin from (Gibco Invitrogen, Carlsbad, CA, USA). 
Cell proliferation assay  
MDA MB 231, HTB 126, HTB 20 cells (1x 105/mL) were seeded into 24-well plate in 250μl 
DMEM,10%FBS. After overnight incubation, the medium was replaced by 
DMEM,1%FBSLF, for 24h. Then, the medium was aspirated and cells were incubated 
with medium containing HDL-C (100μg/mL) or LDL-C (100μg/mL), at 37ºC in 5%CO2, for 
24h or 48h. The number of living cells was determined by hemocytometer counts (at least 
4 counts/well, in quadruplicates), after Trypan Blue test exclusion. The number of cells is 
expressed as fold change over the control. 
Migration assay 
MDA MB 231 cells were seeded on 24-well plate and grown to confluence in DMEM, 
10%FBS. Upon reaching confluence, the medium was replaced by DMEM, 1%FBSLF, for 
24h. Two-hundred-microliter tips were used to make a denuded area (“wound”) in the 
center of the well. Each well was washed with PBS and treated with HDL-C (100μg/mL) or 
LDL-C (100μg/mL) for 24h. Mitomycin C (0,5μmol/L, from Sigma) was added to the 
medium to block cell proliferation. Serial photographs were taken at 0h, 12h and 24h, and 
cell migration distance was determined by subtracting the values obtained at 0h from 24h 
(at least 4 measurements/well, in quadruplicates). The migration distances are expressed 
as percentage of the wound closure. 
                                               
4
Assistance with RNA extraction and microarray analysis was obtained from Inês Matias. Western blott 
analysis was performed by Germana Domingues. Immunohistochemistry for Ki67 was performed by João 
Matos. The remainder experiments described in this chapter were performed by the candidate. 
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Adhesion assay 
MDA MB 231 cells (1x 105/mL) were seeded into 24-well plate in 250μl DMEM, 10%FBS, 
overnight, and then replaced by DMEM, 1%FBSLF, for 24h.  After 24h, cells were left 
untreated or exposed to LDL-C (100μg/mL), overnight. Then wells were washed with PBS, 
and cells removed with trypsin and reseeded into 24-well plates in 250μl DMEM,10% 
FBS, as defined earlier. After 4h, cells were washed with PBS and adherent counted. The 
cells in the supernatant were also counted. The results are shown as the number of 
adherent or supernatant cells/mL. 
RNA extraction and microarray analysis 
Total RNA was extracted by Trizol method from untreated or LDL-C treated breast cancer 
cells (MDA MB 231) and used to study changes in gene expression. The samples were 
hybridized on an Affymetrix GeneChips at Instituto Gulbenkian de Ciência core facility. 
The gene expression results were analyzed using Chipster 2.2.0 software. A cutoff of 1.5 
fold above or below the house keeping gene expression levels was considered significant. 
IPA Ingenuity Systems (Ingenuity Systems, Mountain View, CA) was used to exploratory 
analysis of interactive networks and relevant biological interactions. 
Protein extraction and western blotting analysis 
Cells were lysed in 50 mM tris, 5 mM EDTA, 2% SDS, pH 6.8 buffer containing protease 
inhibitor cocktail. Lysates were diluted 1:1 in loading buffer (tris–glycerol, 2% SDS, 4% b-
mercaptoethanol, 100 mM DTT) and 300µg protein was loaded on 10% tris–glycine gels. 
Proteins were transferred to 0.2lM nitrocellulose membranes (Hybond-C Extra, GE 
Healthcare Life Sciences, Roosendaal, Netherlands) and subjected to standard 
immunoblotting with the antibodies: Akt (#4685), pAkt (#4060), ERK1/2 (#4695), pERK 1/2 
(#4370),pJNK (#9251) and ß-actin (#A5441),all from Cell Signaling Technology Inc. 
Bands were detected with anti-species HRP conjugate. ImageJ software was used to 
quantify the density of the bands512. 
Statistical analysis 
All results, unless otherwise indicated, are expressed as the mean±standard error of, at 
least, triplicates. Data were analyzed using unpaired two-tailed Student's t test. P values 
of <0.05 were considered statistically significant. 
In vivo models 
 All animal experiments were performed after approval from Ethics Committee of the 
Instituto Gulbenkian de Ciência. Animals were housed and maintained in a barrier facility 
at Instituto Gulbenkian de Ciência. In each experiment, 4-6 week old female mice were 
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injected with breast cancer cells in the right axillary mammary fat pad. Than the test group 
was subjected to a high cholesterol diet (10%fat, 1,25%cholesterol, 0,5%Na cholate diet, 
Ssniff, Germany) and the control group fed the standard (normal) mouse diet, with no 
differences in energy up take values. Food and water were given ad libitum. Elevated 
cholesterol levels were confirmed by standard dosing methods at Clinical Pathology 
Laboratory of the IPOLFG and parallel groups were used to control the diet effect on lipid 
profile. In order to test different tumor types and different host backgrounds the following 
trials were performed: 
BALB SCID/MDA MB 231 (2x106 cells, 4-6 week old female, n=8), 10 weeks; 
BALB SCID/HTB 20 (2x106 cells, 4-6 week old female, n=4), 20 weeks; 
NOD SCID/4T1 (1x106 cells, 4-6 week old female, n=4), 20 days; 
BALB C/4T1 (1x106 cells, 4-6 week old female, n=5), 20 days. 
The animals were sacrificed at different times following tumor inoculation, as referred 
above; mammary tumors, lungs and liver were excised. Tumors were split into two parts, 
one frozen in liquid nitrogen and stored at -80ºC and the other, and other organs, fixed in 
10% neutral buffered formalin.  Photos of the tumor were taken and the large diameter 
measured. Blood was collected, by cardiac puncture, and serum used to determine lipid 
profile (TC, LDL-C, HDL-C and triglycerides). Tumor sizes (large diameter, mm) are 
presented as fold change over the control group. Systemic metastases were searched 
macroscopically during organs collection and microscopically in lungs and liver.   
Immunohistochemistry of tumors was made to Ki67 marker (M7240, Dako), and positive 
cells were counted a Dako Autostainer® using standard protocols, followed by counting 
positive cells in an automated cellular imaging system, at, Department of Pathology at 
IPOLFG.  
An additional trial was done, using statins, in order to test the effect of the reduction of the 
systemic cholesterol on the tumor. Using as mice model NOD SCID /4T1, the test group 
was subjected to a high cholesterol diet (as described above) and treated with simvastatin 
(5mg/Kg in 200μL PBS, 3 days a week, (by gastric tube). Control groups were fed with 
standard (normal) mouse diet and high cholesterol diet and treated with placebo (200 μL 
PBS, 3 days a week, (by gastric tube). The mice were injected with tumor cells 4 weeks 
after starting treatment and treated during 4 weeks more. Animals were sacrificed as 
described before. 
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Statistical analysis 
Values are given as the mean±standard error. Comparisons between control and test 
mouse samples were performed using the Student´s t test. The number of mice used for 
each experiment is indicated in the figure. P values of <0.05 were considered statistically 
significant. 
Results 
LDL-cholesterol stimulation induces breast cancer cell lines proliferation, 
migration and reduces cell adhesion 
We examined the effect of LDL-C on breast cancer cells proliferation and found that the 
number of viable cells increased after LDL-C stimulation in all cell lines, reaching 
statistical significance in MDA MB 231 and HTB 20 at 48h (Figure 16 A). Further 
dissection of LDL-C induced phenotype was performed on MDA MB 231 cells. In detail, 
we also determined the effect of LDL-C in breast cancer cells migration in scratch wound 
healing assays (in the presence of Mitomycin C to inhibit cell proliferation) and found that 
LDL-C induced migration of MDA MB 231 cells, promoting in vitro wound closure. 
Importantly, HDL-C was used as control and did not promote cell migration (Figure 16 B 
and C).Thereafter we tested if cells incubated with LDL-C changed their adhesive 
behavior. As shown in Figure 16D and E, LDL-C pre-treated MDA MB 231 cells, lost their 
adhesion to the matrix compared to control (untreated) conditions.  
Together, these data suggest that LDL-C exposure of breast cancer cells affects their 
adhesive properties, favoring cell migration and proliferation. 
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Figure 16: Proliferation, migration and loss of adhesion induced by LDL-C in breast cancer cell 
lines. 
A. Number of cells (MDA MB 231, HTB 126, HTB 20) after 24h and 48h of LDL-C (100 μg/mg) exposure is 
consistently higher than control (non-treated) condition . B and C, Cells (MDA MB 231) were wounded and 
then cultured for 24h, with LDL-C (100 μg/mL), HDL-C (100 μg/mL) or control conditions. Cell migration into 
the wound was examined by phase-contrast microscopy and migration distance is indicated as the percentage 
of the wound closure at 24h. Representative photos are shown (original magnification 100x C). D and E, 
Number of cells (MDA MB 231) adherent and no adherent cells, at 4h after being removed and reseeded on 
its primary conditions (control and LDL-C100 μg/mL) shows that LDL-C treated cells lose matrix adhesion 
compared to control. Representative photos are shown (original magnification 200x E). P value and the 
number of the experiments are represented in the figure. Columns mean; bars ±SEM. LDL:LDL-Cholesterol; 
HDL: HDL-Cholesterol. 
 
LDL-cholesterol induced gene expression changes in breast cancer cell 
lines 
Having shown that LDL-C induced phenotypic changes on breast cancer cells, next we 
sought to demonstrate a causal mechanistic link between these changes and the 
activation of signaling intermediates and pathways that could explain the altered 
properties. For this purpose we performed Affymetrix microarray analysis of untreated 
versus LDL-C treated breast cancer cells. As shown in Additional Table 3, we found an over 
expression (fold change ≥1,5) of 147 mapped genes and down regulation of 95 mapped 
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genes, at 48h. The great majority of these genes are related to cell survival and 
proliferation pathways. Among genes with altered expression there are the down 
regulation of adhesion molecules genes such as cadherin-related family member3 (-1,53 
fold change), CD226 (-1,52 fold change), Claudin 7 (-1,52 fold change), Ocludin (-1,54 
fold change) and integrinβ8 (-1,49 fold change). Exploratory analysis of the significant 
gene interactions, found an activation of Akt, ERK and JNK networks, all in the 
dependency of the ERBB2 pathway (Figure 17). By western blotting analysis we 
confirmed the increased phosphorylation of Akt and ERK, but not of JNK (Figure 18). 
Observed changes in gene expression and signaling pathways activation on LDL-C 
treated cells corroborate the LDL-C induced phenotype. 
 
Figure 17: Activated cellular networks, at 48h, in LDL treated breast cancer cell line. 
Gene expression analysis of breast cancer cells MDA MB231 exposed to LDL (100 μg/mL), for 48h shows up 
regulation of molecules involved in activation of ERK, Akt and ERBB2 pathways. Grey nodes are genes 
overexpressed, white nodes are predicted genes. Smooth lines represent direct interactions. Dashed lines 
represent indirect interactions. 
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Figure 18: LDL-C induces ERK and Akt protein phosphorylation 
A. Cells (MDA MB 231) exposed to LDL-C show higher expression of phosphorylated ERK and Akt, without 
significant increase in respective total protein. Phosphorylation of JNK is also higher, without reaching 
statistical significance. Epidermal growth factor (EGF) stimulation was used as positive control and induced, 
as expected, increase ERK, Akt and JNK phosphorylation. B. Representative photos of Western blot 
membranes are shown. P value and the number of the experiments are represented in the figure. Columns 
mean; bars ±SEM. LDL:LDL-C: Low density lipoprotein. 
 
High LDL-cholesterol promotes breast cancer growth in animal models 
HD fed mice showed high levels of TC, LDL-C and HDL-C (Figure 19 A) without 
statistically significant differences in triglycerides levels or animal weight (Figure 19 B). 
The values of the mouse lipid profile in each experiment are shown in Additional Table 4. 
These data validate this high fat diet model as a good model to specifically address the 
effects of elevated cholesterol levels. 
HD promoted breast tumor growth in all models tested, with statistically significant 
differences in BALB SCID inoculated with MDA MB 231 and BALB C inoculated with 4T1 
cells (Figure 19 C). Tumors of HD fed mice showed a proliferative ratio that was 20% 
higher than tumors from ND fed mice, assessed by immunohistochemistry (for Ki67 
positive cells) (Figure 19 F and G).  
Lung metastases were observed macroscopically and microscopically in the NOD SCID 
and BALB C/4T1 models. No significant differences were registered the first model, but 
BALB C/4T1 hypercholesterolemic mice showed a higher frequency of lung metastasis, at 
the end of the trial, compared to ND fed mice (Figure 19 E). No liver metastases were 
registered. Two mice of the longest BALB SCID/HTB 20 trial died, one of each group. No 
other mice deaths occurred.  
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Figure 19: Hypercholesterolemic diet induces a breast cancer phenotype characterized by large 
and more proliferative tumors.  
A and B. HD fed mice have raised levels of total cholesterol (TC), low density lipoprotein (LDL-C) and high 
density lipoprotein (HDL-C). There are no statistical significant differences in triglycerides level or animal 
weight, as exemplified to MDA MB 231/BALB SCID trial. (Results of the other experiments are in 
supplementary data.) Animal in the same diet but without tumor cells inoculation were used as control to lipid 
profile parameters. C and D. HD fed mice show large tumors when compared to ND fed mice. The mammary 
tumor large diameter was measured (as exemplified to 4T1 /NOD experiment B) and the differences are 
shown as the fold change over the ND fed mice. E. HD fed mice are more likely to have lung metastasis 
(100%) than ND fed mice (33%). F and G. HD fed mice have more proliferative tumors as confirmed by Ki67 
immune staining. P value and the number of the experiments are represented in the figure. Columns mean; 
bars ±SEM. LDL:LDL-C: Low density lipoprotein. 
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Statins treatment does not reduced systemic LDL level in mice trial   
The treatment with statins did not reduce cholesterol levels of HD fed mice (Figure 20 A). 
Tumor size of HD fed mice treated with statins were lower than HD fed mice not treated 
with statins , but without significant difference, in this trial (P 0,104) (Figure 20 B and C). 
 
Figure 20: Tumor size of hypercholesterolemic diet fed mice treated with statins show no 
significant differences between hypercholesterolemic diet fed and control mice. 
A. HD fed mice have raised levels of total cholesterol (TC) and low density lipoprotein (LDL:LDL-C) and no 
significant differences in high density lipoprotein (HDL:HDL-C) and triglycerides levels compared ND. 
Treatment with statins 5mg/dL, 8 weeks, does not change lipid profile in the HD fed mice. B and C NOD SICD/ 
4T1 mice model fed with HD show no significant differences in tumor size compared to HD fed mice treated 
with statins 5mg/mL. P value and the number of the experiments are represented in the figure. Columns 
mean; bars ±SEM. 
 
Discussion  
Obesity and dyslipidemia have long been linked with a possible increase in the likelihood 
of developing cancer. This possible causal relationship has gained momentum in the light 
of the observed “epidemic“ obesity and the recognized increased incidence of cancer in 
Western countries40. Moreover, the same trend in obesity, dyslipidemia and cancer 
incidence has been seen in Asian with the growing incorporation of Western lifestyles4,210. 
However, few studies have tried to find causal and mechanistic associations between 
increased lipid levels and- not cancer incidence- but cancer behavior. This was tested in 
the present study, using well established in vitro and in vivo models of 
hypercholesterolemia and breast cancer. 
In breast cancer cell lines, representative of different tumor subtypes and stages, we 
found that LDL-C (but not HDL-C) exposure induces cell proliferation, migration and loss 
of adhesion, hallmarks of the process of epithelial to mesenchymal transition183. Others 
have also demonstrated that in some breast cancer cell lines, HDL-C induces 
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proliferation513,514. We saw a discrete effect of HDL-C in ER negative cells proliferation 
(data not shown, not significant), but no influence in migration or adhesion properties.   
Previous studies, also showed that LDL-C induces proliferation513,411 and migration288 of 
ER negative, but not ER positive breast cancer cell lines suggesting that LDL effect is 
dependent on ER status. But, we used an ER, ERBB2 positive breast cancer cell line, 
HTB 20 (BT 474)515, and LDL-C induced similar phenotype changes. 
Gene and protein expression analysis of breast cancer cells stimulated with LDL-C 
revealed that the proliferative effect induced by LDL-C may be dependent on Akt and ERK 
pathways activation. Gene expression analysis also suggested decreased expression of 
adhesion molecules such as cadherin-related family member 3, CD226, Claudin 7 and 
Ocludin, upon breast cancer cells exposure to LDL-C. These findings could explain the 
loss of adhesion in the functional tests, when cells were exposed to LDL-C.  
Our own data shows an association between high plasma LDL-C level and ERBB2 
positive breast cancers516. Also the exploratory analysis of gene expression microarrays 
suggested an upstream activation of an epidermal growth factor receptor (EGFR). Human 
epidermal growth factor receptor-2 (Her-2/neu or ERBB2) is a membrane tyrosine kinase 
and oncogene that is overexpressed and gene amplified in about 20% of breast 
cancers517. Independent investigations have demonstrated that cell cholesterol depletion 
using methyl-N-cyclodextrin, reduces fluidity of the membrane and enhances 
phosphorylation and consequent activation of EGFR downstream cascade251,518,507,519. Orr 
et al507, specifically demonstrated this effect in ERBB2 receptor. Since EGFR could be 
activated in a ligand-independent manner519, we propose as a mechanism that cholesterol 
mobilization across the cell membrane may be the responsible for changes in membrane 
equilibrium/ disorganization leading to ERBB2 activation, rather than the absolute 
cholesterol content itself. As mentioned earlier, this possibility remains to be fully exploited 
in future studies. 
To systematically test the in vitro results, hypercholesterolemia, controlling obesity, was 
induced in mice of different background (including NOD SCID mice, which are non-obese 
mice) with different cells lines (to mimic different tumor subtypes) and data consistently 
showed greater tumor growth in the high LDL-C groups. This is in accordance with the 
results reported by Llaverias et al, in breast and prostate genetic mice models44,520. Our 
xenograft models have the advantage of being more representative of breast cancer 
heterogeneity. 
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Tumors grown in hypercholesterolemic mice have higher proliferative ratios, measured by 
Ki67 immunostaining, which is considered a worse prognostic marker501. Higher frequency 
of lung metastasis was also observed in HD fed mice inoculated with the 4T1 xenogeneic 
breast cancer cell line. In models using human breast cancer cell lines we were not able 
to detect systemic metastasis, either macro or microscopically, perhaps because those 
cells do not induce metastasis in mice (reports are very scarce) or because the length of 
our experiments was not sufficient.  
Thereafter, we tried to reverse the hypercholesterolemic-induced phenotype by treating 
mice with lipid lowering drugs. However we did not achieve systemic LDL-C levels 
reduction with statins, in our model. This is a limitation of our work but such difficulty was 
also found by others521. Rats and mice commonly used in experimental cancer studies are 
generally unresponsive to the hypocholesterolemic effects of statins521. 
In humans, the effect of statins in cancer prevention and treatment remains controversial. 
Two large meta-analyses from 2006 described a neutral effect of satins in cancer445,446. A 
very recent cohort study crossing statins prescription/ pharmacy dispense and cancer 
related-mortality in Denmark National databases457, proved that statins use before 
diagnosis of cancer is associated with reduced cancer-related mortality. Although some 
limitations were found in the study and pointed by the authors and others458, such as lack 
of follow up and co-morbidities information, the association seems to be plausible, in the 
study population. 
The real effect of statins in cancer cells is not well known. Statins decrease intracellular 
cholesterol synthesis by targeting HMGR. Theorically they lower the products of 
mevalonate pathway involved in cell proliferation and by this mechanism prevent tumor 
progression. While this effect  was demonstrated in vitro, there is poor evidence of direct 
action of statins in tumor cells522 when given orally, in vivo, and the effect is supposed to 
be more dependent of cholesterol levels. Therefore, much remains to be learned and 
developed with regards to lipid control in breast cancer setting.  
Taken together, our findings show that breast tumors exposed to a LDL-C-rich host 
macroenvironment may be in survival advantage, which will ultimately result in a more 
aggressive cancer phenotype (Figure 21). Our results are supported by functional studies 
in cell lines and animal models of breast cancer and are in strong accordance with clinical 
data. The study exposes the importance of controlling systemic cholesterol levels in 
breast cancer prevention and treatment revealing LDL-C as a biomarker of tumor 
aggressiveness. 
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Figure 21: Phenotype of breast tumors exposed to high levels of cholesterol-Proposed Model. 
Breast tumors exposed to high levels of LDL-cholesterol are larger and show increased proliferation and 
migration while losing epithelial adhesion properties. 
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Chapter 3 
ABCA1 silencing reduces breast cancer aggressive phenotype 
induced by LDL-cholesterol5 
Introduction 
Altered lipid metabolism has increasingly been recognized as a common property of 
malignant cells. It is modulated by oncogenic signaling pathways and is important for 
initiation and progression of cancer, since cellular proliferation is dependent on sustained 
availability of lipids136, 272. Among lipid metabolism alterations, de novo biosynthesis has 
been posited to play a major role in cancer272 but, there is emerging evidence that 
exogenous lipids may also be incorporated by tumor cells, contributing to malignancy276, 
288. This metabolic feature has been considered an explanation for the association of 
some cancers and high fat diets. 
In fact, we previously revealed that high level of systemic LDL-C, a common consequence 
of high fat diets, is positively associated with large and high grade breast tumors, as well 
as with reduced disease-free survival516. Moreover, cholesterol-enriched 
macroenvironment selects subsets of cells able to up take the exogenous cholesterol and 
thereafter promote cell proliferation, migration and EMT523. 
Cholesterol is a pivotal cell component, especially to membrane microdomains- lipid 
rafts256 and essential to cellular functions as signal transduction, intracellular trafficking, 
polarity and cell migration256.  
However, despite the relevance of cholesterol in regulating such fundamental aspects of 
cell biology, its excessive intracellular accumulation is deleterious and can promote 
dysfunction of cell membrane proteins and domains284, induction of caspase-mediated cell 
death285, 286, organelle disruption and oxidative damage287. Cells that rely on endogenous 
biosynthesis do not accumulate excess of cholesterol because of homeostatic regulation 
of the cholesterol biosynthesis pathway. Cells dependent on exogenous cholesterol are 
more exposed to the environment and, besides repressing endogenous synthesis; they 
need other mechanisms to prevent cholesterol accumulation.   
One mechanism of cellular protection is the esterification mediated by ACAT-1. It was 
already described that some breast cancers show high content of lipids and up regulation 
of ACAT-1288,411. Nevertheless, if cholesterol influx exceeds the capacity of ACAT-1, free 
                                               
5
 Results discussed in this chapter are included in a manuscript in preparation. 
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cholesterol accumulates in the endoplasmatic reticulum membrane where the enzyme 
localizes, compromising ACAT-1 activity524.  
Another protective mechanism is cellular efflux of cholesterol, mainly through ABC 
transporters525. In peripheral tissues, ABCA1 is the main membrane transporter, 
responsible for the efflux of free cholesterol and phospholipids525. If this mechanism is 
used by breast cancer cells and wether it is relevante for tumor progression is not well 
known. 
Systemic cholesterol induces an aggressive phenotype in breast cancer cells by selecting 
clones prone to use the available cholesterol. We hypothesized that the perturbation of 
cholesterol flux equilibrium, namely ABCA1 efflux mechanism, might disrupt the 
hypercholesterolemic induced aggressive phenotype.  
 
Material and Methods6 
Cell lines and reagents 
The murine breast cancer cell line 4T1 was purchased from the American Type Culture 
Collection and the human breast cancer cell lines HTB20, MDA MB 231 were kindly 
provided by Instituto Português de Oncologia do Porto. 
Cells lines were cultured in DMEM (Gibco Invitrogen, Carlsbad, CA, USA) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS, Gibco Invitrogen, Carlsbad, CA, USA) 
and 1% penicillin-streptomycin (Invitrogen life Technologies). Lipoprotein deficient serum 
from fetal calf (LPDS), Glyburide, Mitomycin C and DMSO were purchased from Sigma-
Aldrich (Germany), human plasma low density (LDL-C) and high density (HDL-C) 
lipoproteins were obtained from Calbiochem (Gibbstown, NJ, USA), and Trypsin from 
(Gibco Invitrogen, Carlsbad, CA, USA). 
The antibodies used were: Akt (#4685), pAkt (#4060), ERK1/2 (#4695), pERK 1/2 
(#4370), pJNK (all from Cell Signaling Technology Inc; ABCA1 (ab18180, Abcam); LDLR 
(ab30532, Abcam) Ki67 (M7240, Dako) and ß-actin (#A5441, Sigma-Aldrich); Alexa 
Fluor® 488 (A-21202) and 594 (A-21203) from Invitrogen life Technologies.   
                                               
6
Assistance with RNA interference experiments was obtained from Jacinta Serpa and Ana Costa. Western 
blott analysis was performed by Germana Domingues. Immunohistochemistry was performed by João Matos 
and reviewed by Isabel Fonseca. The remainder experiments described in this chapter were performed by the 
candidate. 
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Human samples analysis 
A total of 44 patients with breast invasive carcinoma, NOS493, treated at Multidisciplinary 
Breast Unit of the IPOLFG during the year of 2011 and enrolled in a published cohort516 
were studied concerning ABCA1 expression in primary breast tumor. Patient samples 
were selected from 14 consecutive patients of each LDL-C tertile group of the studied 
population (each tercile group represents groups of patients with increasing systemic LDL-
C levels).  
ABCA1 (1:100; ab18180 from Abcam) staining was performed in breast cancer samples, 
using testis tissue as positive control. Measurements of ABCA1 expression was based on 
topographic score (0 to +3) of antibody staining tissue distribution accessed under 
microscopy by two independent observers. Technicians and pathologists were blinded to 
the lipid profile status of the study participants. This study was approved by the Ethics 
Committee of IPOLFG. 
Cell proliferation assay  
MDA MB 231 and HTB 20 cells (1x105/mL) were seeded into 24-well plate in 250μl 
DMEM,10%FBS. After overnight incubation, the medium was replaced by 
DMEM,1%LPDS, for 24h or 48h.  Then, the medium was aspirated and cells were 
incubated in different conditions: Control (DMEM+1%LPDS), LDL-C 
(DMEM+1%LPDS+LDL-C100μg/mL), DMSO (DMEM+1%LPDS+0,01%DMSO), GLY 
(DMEM+1%LPDS+Glyburide 200μM/mL), LDL-C+GLY(DMEM+1%LPDS+ LDL-C 100 
μg/mL+ Glyburide 200μM/mL), at 37ºC in 5%CO2, for 24h or 48h. The number of living 
cells was determined by hemocytometer counts (at least 4 counts/well, in quadruplicates), 
after Trypan Blue test exclusion. The number of cells is expressed as fold change over the 
control. 
Apoptosis and cell death 
Apoptosis of MDA MB 231 cells were detected after treatment with glyburide, or control for 
48h. Phosphatidylserine exposure on the surface of apoptotic cells was identified by flow 
cytometry (BD FACS CaliburTM, BD Biosciences) after staining with Annexin V-FITC 
(Biolegend) and propidium iodide (PI,50µg/ml). In parallel the number of death cells was 
evaluated in the cell proliferation assays of MDA MB 231 and HTB 20 cells, by using 
Trypan Blue test. 
Migration assay 
MDA MB 231 cells were seeded on 24-well plate and grown to confluence in 
DMEM,10%FBS. Upon reaching confluence, the medium was replaced by DMEM, 1%, for 
 106 
 
24h. Pipette tips (200 µl) were used to make a denuded area (“wound”) in the center of 
the well. Each well was washed with PBS and treated with the same conditions as in the 
cell proliferation assay. Mitomycin C (0,5μmol/L, from Sigma) was added to the medium to 
block cell proliferation. Serial photographs were taken at 0h, 12h and 24h, and cell 
migration distance was determined by subtracting the values obtained at 0h from 24h (at 
least 4 measurements/well, in quadruplicates). The migration distances are expressed as 
percentage of the wound closure. 
Cholesterol measurements  
The measurement of intracellular and culture medium cholesterol content was made by 
using the Amplex® Red Cholesterol assay Kit (Invitrogen) on thin layer 
chromatography526.  
Quantification of mRNA levels 
RNA was extracted by Trizol (Sigma) method from untreated or treated breast cancer 
cells. cDNA was sinthetized with Superscript II (Invitrogen, Carlsbad, CA) by using 
random-sequence hexamers primers (Roche Applied Science, Indianapolis, IN). Real-time 
PCR was performed with Power SYBR Green PCR Master Mix in 7900HT Fast Real-Time 
PCR System (both from Applied Biosystems, Foster City, CA). Amplification of 18S RNA 
was used for sample normalization.  
RT-PCR data were analyzed by DataAssist software (Applied Biosystems Foster City, CA) 
using RNA 18S as endogenous control. The final results are expressed as fold relative 
differences in gene expression between the studied samples and the control sample 
(calibrator). The following are the primer sequences used; 18S RNA forward 
GCCCTATCAACTTTCGATGGT reverse CCGGAATCGAACCCTGATT; ABCA1 RNA 
forward AACGCCCTCACCAAAGACCCT reverse AGGGCGTGTCTGGGATTGGG; 
HMGR RNA forward CCAAACCCCGTAACCCAAAG reverse 
AGCGACTATGAGCGTGAACAA; LDLR RNA forward GCTTGTCTGTCACCTGCAAA 
reverse AACTGCCGAGAGATGCACTT. 
Western blotting analysis 
Treated and untreated cells were collected at 48 hours and lysed with RIPA buffer (20mM 
Tris pH 7.5, 150mM NaCl, 5mM KCl, 5mM MgCl, 1% Triton X-100, protease inhibitor 
cocktail and 1mM sodium orthovanadate). Equal amounts of proteins (100μg/lane) were 
subjected to 12% SDS–polyacrylamide gel electrophoresis (SDS-PAGE) (Mini-Protean 
TGX precast gel, BioRad, US). Proteins were transferred onto nitrocellulose membrane 
(Hybond-C Extra, GE Healthcare Life Sciences, Roosendaal, Netherlands) and subjected 
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to standard immunoblotting with primary antibodies against to ABCA1 (1:1000), Akt 
(1:1000), pAkt (1:1000), ERK1/2 (1:1000),pERK 1/2 (1:2000), pJNK (1:1000) and ß-actin 
(1:5000). 
Small interfering RNA 
Cells (MDA MB 231) were seeded into 24 wells plate (2x104 / well) and transfected with 
ON-TARGET plus non-targeting Pool (D-001810-10-05, Dharmacon; therefore named 
control, scramble) and with ON-TARGET plus SMART pool, Human ABCA1 (L-004128-
00-0010, Dharmacon). After transfection, cells were incubated for 48h, at 37ºC in 5% CO2 
atmosphere in control and LDL-C conditions.   
Immunofluorescence  
Cells treated and untreated, cultured over a glass slide and were tested to the ABCA1 
expression by Immunofluorescence. Primary antibody was incubated at room temperature 
for 1h; secondary antibody was incubated at room temperature for 2h. Slides were 
mounted with Vectashield mounting medium with DAPI (Vector Laboratories, Burlingame, 
CA). 
In vivo models 
 All animal experiments were performed after approval from Ethics Committee of the 
Instituto Gulbenkian de Ciência. Animals were housed and maintained in a barrier facility 
at Instituto Gulbenkian de Ciência. Mice model were established by injecting 4T1 cells 
(1x105) in the right axillary mammary fat pad of 4-6 week old female mice, Balb/c. Then, 
animals were subjected to a high cholesterol diet (10%fat, 1,25%cholesterol, 0,5%Na 
cholate diet, Ssniff, Germany) and the other group fed the standard (normal) mouse diet, 
with no differences in energy up take values. Food and water were given ad libitum. 
Elevated cholesterol levels were confirmed by standard dosing methods (at Pathology 
Laboratory of IPOLFG) and parallel groups were used to control the diet effect on lipid 
profile. Five days after tumor inoculation, Glyburide (10mg/kg) was administered through 
intraperitoneal injection in alternate days regimen. Glyburide was prepared with glyburide 
0,5mg/ml, DMSO 0,5%, Ethanol10%, PBS 39,5%, PEG 400 50%. The vehicle solution 
was used as placebo in the control group.  
The animals were sacrificed 20 days after tumor inoculation. Mammary tumor, lungs and 
liver were excised. Tumors were split into two parts. One part frozen in liquid nitrogen and 
stored at -80ºC.The other part, lung and liver were fixed in 10% neutral buffered formalin. 
Photos of the tumor were taken and the volume measured (side x side x side, mm2). 
Blood was collected, by cardiac puncture, and serum used to determine lipid profile (TC, 
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LDL-C, HDL-C and triglycerides) and glycemia. Lung metastases were assessed by 
microscopic evaluation of serial sections.  
Statistical analysis of experimental data 
Values are given as the mean±standard error. Comparisons between control and test 
samples were performed using unpaired two-tailed Student's t test. P values of <0.05 
were considered statistically significant. The number of mice/experiments used for each 
trial is indicated in the figure. P values of <0.05 were considered statistically significant. 
Statistical analysis was performed using Graph Pad Prism version 5.00 for Windows, 
Graph Pad Software, San Diego California USA. 
 
Results 
Exogenous LDL-cholesterol induces ABCA1 expression  
We started by observing a significantly elevation of ABCA1 mRNA expression in LDL-
cholesterol treated cells compared to non-treated cells (Microarray analysis, data not 
shown). ABCA1 gene expression differences were confirmed by RQ-PCR, revealing that 
ABCA1 gene expression in LDL-C treated cells is 4,5 fold higher than control cells, P 
0,004 (Figure 22 A). 
Differential expression of ABCA1 protein was demonstrated by Western blot analysis of 
LDL-C treated  MDA MB 231 cells (Figure 22 B) confirmed by immunofluorescence to 
MDA MB 231 (Figure 22C) and also observed on HTB 20 (Figure 22 D) breast cancer cell 
lines, representative of different breast cancer subtypes. 
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Figure 22: Exogenous LDL-cholesterol induces ABCA1 expression. 
 A. Total amount of mRNA of ABCA1 was measured by RT-PCR using mRNA derived from MDA MB 231 
cells treated with LDL (100 ug/dl) and from control non treated cells. ABCA1 gene is overexpressed in LDL 
treated cells, at 48h (P 0,004). B, C and D. ABCA1 protein expression was detected by western blot and by 
immunofluorescence in MDA MB 231 treated and non-treated cells and by immunofluorescence in HTB 20 
treated and non-treated cells. Representative photos suggest a correspondent overexpression of ABCA1 in 
LDL-C treated cells Immunofluorescence photos (X40). P value and the number of the experiments are 
represented in the figure. Columns mean; bars ±SEM. LDL:LDL-C: Low Density Lipoprotein.  
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Systemic level of LDL-C correlates with ABCA1 expression 
In order to study ABCA1 expression in human breast cancer tumors, we analized ABCA1 
expression in human samples of breast tumors of patients with increasing levels of 
systemic LDL-C levels and found that ABCA1 protein is present in almost all studied 
breast tumors, but expression is higher in tumors of patients with elevated LDL-C levels 
(Figure 23) 
Of interest, exploratory correlations of ABCA1 with tumor immunohistochemical subtypes 
did not show significant differences. However, is important to note that the number of 
sample was small and not designed to measure differences. 
 
Figure 23: ABCA1 expression in human breast tumors 
ABCA1 expression is higher in primary tumors of patients patients with elevated levels of systemic 
LDL-C (LDL2 and LDL3 in which LDL-C≥117mg/dl). Representative photos of each group are 
shown. P value and the number of the experiments are represented in the figure. Columns mean; 
bars ±SEM. LDL:LDL-C: Low Density Lipoprotein. 
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ABCA1 inhibition reduces LDL-cholesterol-induced proliferation and 
migration and increases apoptosis of breast cancer cells 
Having shown that exogenous LDL-C induces proliferation and migration of breast cancer 
cell lines523 which courses with overexpression of ABCA1 (Figure 22), we sought to 
demonstrate the effect of ABCA1 inhibition on this phenotype. For this purpose we used 
glyburide, which is a selective inhibitor of ABC transporters527,528,529.  
Inhibition of ABCA1 reduces cell proliferation (Figure 24 A and B) and cell migration 
(Figure 24 C and D). DMSO was used as vehicle solution to glyburide and because of that 
control DMSO condition is shown. Neither vehicle nor the inhibitor drug produces 
significant effect on cell death (Figure 25 A and B). However ABCA1 inhibition significantly 
increases apoptosis in LDL-C exposed cells treated with glyburide, when compared to 
non-treated cells (Figure 25 C).  
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Figure 24: ABCA1 inhibition reduces LDL-induced proliferation and migration of breast cancer cell 
lines.  
A and B. LDL-C exposure induces cell proliferation. Glyburide treatment reduces the number of cells when 
exposed to LDL-C, with significant difference in MDA MB cells at 48h (P 0,0182) and an evident trend in HTA 
20 cells, at the same time point. C and D. Cell migration into the wound was examined by phase-contrast 
microscopy and migration distance is indicated as the percentage of the wound closure at 48h. . LDL-C 
induces cell migration and treatment of LDL-C- exposed cells with glyburide significantly decreases (P 0,003) 
the ability of MDA MB cells to migrate. Representative photos of wound healling assays are shown (original 
magnification 100xC). P value and the number of the experiments are represented in the figure. Columns 
mean; bars ±SEM. LDL:LDL-C: Low Density Lipoprotein; GLY: Glyburide.  
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Figure 25: Apoptosis and cell death. 
A and B. Breast cancer cells (MDA MB 231 and HTB 20) were cultured in control (DMEM+1%LPDS) or in 
LDL-C enriched medium (DMEM+1%LPDS+LDL-C100μg/mL) and then treated with glyburide (GLY 
(DMEM+1%LPDS+Glyburide 200μM/mL), LDL-C+GLY(DMEM+1%LPDS+ LDL-C 100 μg/mL+ Glyburide 
200μM/mL), at 37ºC in 5% CO2, for 48h. DMSO was used as vehicle to glyburide and so, control condition 
with DMSO (DMEM+1%LPDS+0,01%DMSO)is also shown. The number of inviable cells determined by 
hemocytometer counts (at least 4 counts/well, in quadruplicates) by Trypan Blue test, shows that treatment 
with glyburide does not produce differences in cell death, at 48h. C. Apoptosis was measured in MDA MB 231 
cells, cultured in similar conditions after staining with Annexin-PI. Annexin positive cells were counted by 
Fluorescence –activated cell sorting. The number of cells is expressed as fold change over the control. P 
value and the number of the experiments are represented in the figure. Columns mean; bars ±SEM.  
LDL:LDL-C: Low Density Lipoprotein; GLY: Glyburide.  
 
To specifically demonstrate the ABCA1 down regulation and because ABCA1 protein 
expression and mRNA levels are discordant in different cells and tissues530, we 
investigated the effect of glyburide in ABCA1 mRNA expression by RT-PCR, as well as 
protein expression by immunofluorescence and Western blot analysis. Results showed 
that glyburide produces an important down expression of ABCA1 transcription and visibly 
decreases the expression ABCA1 the protein levels (Figure 26). 
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Figure 26: Glyburide decreases ABCA1 transcription and expression. 
 A. MDA MB 231 cells were cultured in LDL-C free and LDL-C enriched medium and treated with glyburide, 
for 48h. Total amount of ABCA1 mRNA was quantified by RT-PCR and proved to be overexpressed in cells 
cultured with 100ug/ml LDL-C compared to control, and decreased when these cells are treated with 
glyburide. B and C ABCA1 protein expression was detected by western blot and by immunofluorescence and 
results suggest a reduction of protein expression when cells were treated with glyburide. Immunofluorescence 
photos (X40). P value and the number of the experiments are represented in the figure. Columns mean; bars 
±SEM. LDL:LDL-C: Low Density Lipoprotein; GLY: Glyburide. 
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siRNA ABCA1 inhibition prevents LDL-C-induced phenotype of breast 
cancer cells 
Because the mechanisms of action glyburide are not completely understood, we wanted 
to be sure that the observed effect in tumor cells phenotype treated with glyburide is on 
the dependent of ABCA1 inhibition. So we specifically down regulated the ABCA1 gene 
expression by using small interfering RNA. Transfected cells exhibited down regulated 
ABCA1, confirmed by reduced ABCA1 mRNA (Figure 27 A) and protein expression 
(Figure 27 B). Functional tests showed reduction of proliferation rate (siScramble LDL 
0,941±0,148 fold change over control vs siABCA1 LDL 1,774±0,251 over control, P 0,029) 
and migration (siScramble LDL 73,5%±9,678 vs siABCA1 LDL 47,24%±15,11, P 0,026) in 
cells siABCA1 transfected compared to those transfected with siScramble. Differences 
produced by siABCA1 are equivalent to those obtained with glyburide inhibition. We thus 
concluded that ABCA1 inhibition by glyburide is responsible for the phenotype 
modifications (Figure 27 C, D and E). 
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Figure 27: Down regulation of ABCA1 by siRNA specifically reduces LDL induced proliferation and 
migration of MDA MB 231 cells. 
 A Effect of siRNA on mABCA1 expression in MDA MB 231 was evaluated by RT-PCR. Cells transfected with 
siABCA1 have lower levels of mRNA compared to those transfected with scramble, especially when cultured 
in LDL-C enriched medium (P 0,029). B. Transfected cells and controls were grown on glass coverslips for 
immunochemistry staining. Representative photos (40 x magnifications) suggest ABCA1 protein down 
expression in siABCA1 transfected cells, growing in LDL-C enriched medium. C. After transfection, MDA MB 
231 cells were cultured in LDL-C enriched medium or LDL-C free medium. After 48 h, the number of viable 
cells was evaluated by hemocytometer counts (at least 4 counts/well, in quadruplicates), after Trypan Blue 
test exclusion. Number of cells is expressed as fold change over control. D and F. After transfection, PC-3 
cells were incubated with the medium containing 10% FBS for 24 h, and medium was switched to serum-free 
medium. After 24 h, cells were wounded and then cultured for 48 h with or without LDL-C (100 µg/mL). Cell 
migration into the wound was examined by phase-contrast microscopy (representative photos of experiments 
are shown with original magnification 100xC). P value and the number of the experiments are represented in 
the figure. Values are expressed as percentage of wound closure. Columns mean; bars ±SEM. LDL:LDL-C: 
Low Density Lipoprotein. 
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ABCA1 inhibition increases cellular cholesterol content 
Knowing that ABCA1 acts mainly in cholesterol efflux, we wonder if the observed 
phenotype changes in glyburide treated 
cells were due to cholesterol homeostasis 
perturbation. In fact, we confirmed that 
ABCA1 blocking, either with glyburide or 
siRNA, leads to intracellular cholesterol 
accumulation (Figure 28 A and B). The 
cholesterol concentration in the culture 
medium was lower in the glyburide treated 
cells, although without statistically significant 
differences, corroborating the intracellular 
cholesterol accumulation effect of ABCA1 
inhibition (Figure 28 C). 
 
Figure 28: ABCA1 inhibition increases cellular 
cholesterol content.  
A and B. Cholesterol content of breast cancer cells 
was measured by chomatography of cells lisates with 
use of Amplex® red  cholesterol assay kit and showed 
an enrichement of LDL-C exposed cells compared to 
control cells, which is significantly higher when cells 
were treated with glyburide. C. The cholesterol 
concentration of cell culture medium was measured by 
the same method and revelead an increase in 
cholesterol content at 48h, in the LDL-C enriched 
conditions, although showing a modest decrease 
when cells were treated with glyburide. Note that in A 
and B, cholesterol concentration is given by cell, in C 
cholesterol concentration is given by culture sample. P 
value and the number of the experiments are 
represented in the figure. Values are expressed as percentage of wound closure. Columns mean; bars ±SEM. 
LDL:LDL-C: Low Density Lipoprotein; GLY: Glyburide. 
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According to the intracellular cholesterol accumulation hypothesis, HMGR and LDLR 
transcriptions are repressed in cells exposed to glyburide as well as in cells with ABCA1 
silencing, both exposed to LDL-C (Figure 29). 
 
Figure 29:ABCA1 inhibition decreases LDLR and HMGR expression. 
A and B. Effect of ABCA1 silencing on cellular cholesterol metabolism was measuring mRNA expression of 
LDLR and HMGR evaluated by RT-PCR. LDLR mRNA expression is enhanced by exogenous LDL-C 
availability but reduced when ABCA1 is inhibited. Conversely HMGR mRNA expression is decreased in the 
repressed in presence of LDL-C and do not change or is even reduced when ABCA1 is inhibited. LDL:LDL-C: 
Low Density Lipoprotein; GLY: Glyburide. 
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Glyburide ABCA1 inhibition reduces ERK protein phosphorylation 
We had previously demonstrated that cells death is not significantly increased when 
ABCA1 is inhibited, although apoptosis is slightly increased. Mechanistically, we tested 
the eventual modifications in proliferative cell signaling pathways and found a reduction in 
ERK phosphorylation upon ABCA1 inhibition, suggesting that ERK-cell signaling pathway 
may be mediating this effect (Figure 30).  
 
 
Figure 30: ABCA1 inhibition by glyburide reduces ERK protein phosphorylation. 
A. MDA MB 231 cells were incubated with LDL-C free medium or LDL-C enriched medium and then treated or 
not with glyburide. After 24 h, whole cell lysate was analyzed by western blotting after treatment for 15 min 
(ERK1/2),30 min (Akt) and 10 min (pJNK). The graph shows the ratio of pERK1/2 to ERK1/2, pAkt to Akt and 
pJNK in each sample relative to βactin lane. B. Representative photos of western blot membranes are shown. 
P value and the number of the experiments are represented in the figure. Columns mean; bars ±SEM. 
LDL:LDL-C: Low Density Lipoprotein; GLY: Glyburide. 
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In vivo, glyburide reduces tumor growth and lung metastasis incidence 
We and others have previously shown that hypercholesterolemic diet induces breast 
cancer growth and increased incidence of metastasis44,523.  
In this experiment we used an immunocompetent mice model injected with mouse breast 
cancer cell line 4T1, exposed to hypercholesterolemic or normal diet. Test groups, treated 
with glyburide, show smaller tumors compared to non-treated groups, reaching statistically 
significance in the hypercholesterolemic fed mice (HD gly treated tumor volume mean is 
0,82±0,126 fold lower than HD non treated group, P0,003). Glyburide treated groups also 
showed reduced incidence of lung metastasis when compared to non-treated groups 
(Figure 31 A and B). Lipid profile and glycemia, at the end of the trial, did not show 
differences between glyburide treated and non-treated groups (Figure 31 C and D). 
 
Figure 31: Glyburide reduces tumor growth and lung metastasis incidence. 
A. BALB/c 4T1 mice model treated with glyburide (10mg/kg) show reduction of tumor size compared to non-
treated mice, reaching significance in the HD fed group. B. BALB/c 4T1 mice HD fed show higher lung 
metastasis incidence which is decreased with glyburide treatment. C. Hypercholesterolemic diet (HD) fed mice 
have increased levels of low density lipoprotein (LDL-C) compared to normal diet (ND) fed mice but no 
significant differences to glyburide treated group. No significant differences in total cholesterol (TC), in high 
density lipoprotein (HDL), triglycerides and glucose levels were registered in HD compared ND, neither when 
treated with glyburide. D. Different diets or glyburide treatment did not produce significant weight differences. 
P value and the number of the experiments are represented in the figure. Columns mean; bars ±SEM. 
LDL:LDL-C: Low Density Lipoprotein; GLY: Glyburide 
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Discussion 
 
It is was previously shown that LDL-C induces phenotypic changes in breast cancer cell 
lines, characterized by increased proliferation, migration and loss of adhesion523. It is 
believed that tumor cells require cholesterol to proliferate, and those with the ability to up 
take and accumulate exogenous cholesterol would be in selective advantage, especially 
when the macroenvironment (systemic) is cholesterol-enriched.  Accordingly, numerous 
studies have shown increased levels of cholesterol in tumors compared to normal 
tissue531,532,533,534 and breast cancer cells expressing high levels of LDLR and ACAT-1 
were shown to be more aggressive411,288,535,536. 
Interestingly, we found that LDL-C-selected cells abundantly express ABCA1 receptor. 
ABCA1 is the main ABC transporter responsible for the cellular efflux of free cholesterol 
and phospholipids537,538,539. 
ABCA1 is a protein belonging to a large family of conserved transmembrane proteins 
transporting a variety of substrates, including lipids, ions, amino acids, peptides, sugars, 
vitamins, steroid hormones, and drugs across cell membranes540. 
Although data on the expression and localization of cholesterol transporters in mammary 
tissues is scarce541, ABCA1 expression was identified by immunohistochemistry in the 
epithelium of normal as well as in neoplastic human breast tissues542. ABCA1 
overexpression was also reported in prostate cancer543 and melanoma544, and ABCA1 
somatic mutations were implicated in colon cancer initiation545. Our data showed an 
overexpression of ABCA1 in breast tumors of patients with higher systemic LDL-C levels 
suggesting a modulation of ABCA1 tumor expression by the systemic host environment.  
We hypothesized that for tumors growing in LDL-cholesterol-enrich macroenvironment; 
ABCA1 expression is a marker of cell dependency on exogenous cholesterol. ABCA1 is 
the mechanism by which these cells avoid intracellular cholesterol cytotoxicity and 
maintain the cholesterol-enriched microenvironment to the surrounding cells to proliferate.  
In fact, block ABCA1 expression attenuates the LDL-cholesterol-induced phenotype. We 
demonstrated that ABCA1 inhibition reduces cell proliferation and migration, slightly 
increases apoptosis with no significant cell death. These changes go along with reduction 
of ERK phosphorylation exposing a modification of ABCA1 dependent cell signaling 
pathways. 
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Supporting our findings, Adlakha et al546, recently demonstrate that ABCA1 is post-
transcriptionally regulated by miRNA-128-2, a pro-apoptotic molecule, being the ABCA1 
protein negatively expressed in the presence of this miRNA. In a mice trial, levels of 
miRNA-128-2 were reduced upon high-fat diet as compared with normal diet in several 
tissues. Conversely, mRNA levels of ABCA1 were increased. The authors speculate if diet 
modulates mi-RNA-128-2 expression, reducing pro-apoptotic stimulus and also leading to 
ABCA1 expression. In this case ABCA1 expression would have a protective effect against 
excessive cholesterol loading of endoplasmatic reticulum membrane that triggers unfolded 
protein response which eventually lead to the induction of apoptosis547,548. 
Conversely, Smith et al290 interpreted their own results considering ABCA1 as an anti-
cancer molecule. ABCA1 loss-of-function mutations lead to intracellular cholesterol 
accumulation and consequently to cholesterol metabolism instability and cancer initiation. 
However they do not considered different micro or macroenvironment, namely 
hypercholesterolemic environment in which the excess of cholesterol would be 
deleterious, driving the need of ABCA1. Taken together, results suggest that cholesterol 
metabolism is fundamental to cancer cells and ABCA1 is pivotal to cellular regulation.  
Thereafter we intended to explore the mechanism by which ABCA1 would be involved in 
tumor aggressiveness.  
To silence ABCA1 we used glyburide, a sulfonylurea family drug that inhibits ABC 
transporters528,538. Although the precise molecular mechanism of ABCA1 inhibition by 
glyburide is not known, we demonstrated the reduction of ABCA1 mRNA as well as 
ABCA1 protein (not quantified,) suggesting a transcriptional inhibition; and, in accordance, 
the specific inhibition of ABCA1 by siRNA interference produced exactly the same results. 
Then we used glyburide in all experiments to avoid transfection process, transient 
inhibition and to reproduce the ABCA1 inhibition in in vivo models. Others have also found 
an anti-tumor effect of glibenclamide, an analogue of glyburide, in in vitro 
experiments549,550. 
Our first hypothesis was that ABCA1 expression avoids excessive cholesterol 
accumulation. In fact ABCA1 inhibition leads to intracellular cholesterol accumulation, 
although cells repress LDLR and HMGR transcription, which is accompanied by cell 
proliferation and migration reduction. Concomitantly to intracellular cholesterol 
accumulation ABCA1 silencing reduces microenvironment cholesterol content and may 
decreases LDL-C signaling to neighbor cells to proliferate and invade. Nevertheless, we 
cannot exclude the fact that ABCA1 itself might act as a signaling molecule to surrounding 
cells, controlling their proliferation and consequently tumor growth. 
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On the other hand, ABCA1 is known to localize mainly in the plasma membrane. The 
translocation of phospholipids and cholesterol across the cell membranes implicates 
constant membrane and meso-domain organization modulating receptor-mediated 
signaling events, namely through lipid raft anchored proteins such as EGFR, ERBB2 or 
ER551,291. Inhibition of such movement, by inhibition of ABCA1 efflux may also explain 
reduction in cell proliferation and migration. In line, we already described a higher 
proportion of ERBB2 positive tumors in breast cancer patients with high levels of LDL-C at 
diagnosis516. It was as also shown that inhibition of cholesterol transport and ABCA1 
degradation with serdemetan, a tryptamin compound with antiproliferative activity, reduces 
lipid raft signaling pathways in hematologic malignant cell lines552. 
Considering the importance of LDL-signaling to tumor aggressiveness we tested if the 
inhibition of LDLR expression, a major LDL-cholesterol acceptor, would avoid the LDL-
cholesterol signal. However, transcriptionally reduction of LDLR did not replace the 
expected phenotype (Additional figure 1 and 2). A possible explanation is that others 
receptors, not studied may be involved, such as oxidized LDL receptor 1553 or scavenger 
receptor class B type I491. Indeed, we and others554,553,536 found high expression of other 
receptors-biological redundancy, in breast cancer cell lines exposing even more the 
relevance of cholesterol to tumor cells (data not shown). These findings turn the 
identification of ABCA1 role of uppermost importance, once it seems to be a more specific 
target to control cholesterol induced phenotype.  
Although the mechanism by which ABCA1 potentiates tumor aggressiveness in 
cholesterol enriched environment and how its inhibition produces antitumor effect maybe 
complex, it confirms the importance of cholesterol metabolism in breast cancer and 
reveals ABCA1 as an important therapeutic target.   
A mice model trial using glyburide showed that glyburide-treated mice have smaller 
tumors and lower incidence of lung metastasis, particularly in HD fed mice. We assume 
that in vivo glyburide effect occurs in cancer cells as in in vitro. Despite systemic effects, 
indirect effect on tumor cells, cannot be excluded, we showed that there were no 
differences in lipid profile, glycemia or mice weight at the end of the trial. Moreover, 
glyburide is a safe drug widely used in diabetes control 555. 
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Figure 32: ABCA1 as a marker of LDL-C induced phenotype-Proposed Model 
 
Patients with primary tumors with high ABCA1 score were seen to have more elevated 
LDL-C plasma levels. This fact points ABCA1 receptor as a marker of tumor 
aggressiveness and supports our hypothesis of LDL-C induced phenotype marker. The 
results from mice trial suggest an advantage in directly targeting this phenotype marker 
(Figure 32).  
Conclusion 
Results confirm the importance of cholesterol metabolism to breast cancer 
pathophysiology exposing the modulation of tumor behavior by the host systemic 
metabolism. 
ABCA1 emerges as a cell marker of cholesterol dependency which can be explored as a 
biomarker as well as a specific therapeutic target. 
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Chapter 4 
Plasma level of LDL-cholesterol, at diagnosis is a breast cancer 
prognostic factor 7 
Introduction 
 
A tumor has been defined as a group of cells with autonomous capabilities able to survive, 
proliferate, develop neovascularization (angiogenic potential) and invade other organs 
(metastatic potential)84.  
Cancer cells metabolism has intriguing scientists for a long time (since Otto Warburg) but 
a little is known about this subject. Recently, reprogramation of cellular metabolism has 
been on the focus as an emerging hallmark of cancer, either as a way to accomplish the 
other demands of  tumor cells or as the initial cause of the malignant transformation556. 
However, cancer cells living in an organism interact with the macrosystem and must be 
under the influence of systemic metabolism. In fact, some metabolic disorders have been 
linked to specific cancer behavior, including obesity40,557 and diabetes61. On the other 
hand, the role of dyslipidemia, other common metabolic disorder, has generated great 
controversy, namely concerning to its impact on cancer incidence. Recently, we provided 
experimental523 and clinical516 evidence that the systemic cholesterol metabolism has not 
a neutral role in breast cancer pathophysiology. Data show that cells use the exogenous 
cholesterol to proliferate and undergo EMT and, according; patients with higher systemic 
LDL-C levels at diagnosis have larger and aggressive tumors. By prospectively following a 
cohort of patients with breast cancer diagnosed at stage I-III, we intended to validate that 
systemic cholesterol metabolism influences tumor behavior.  
 
 
                                               
7 Results discussed in this chapter are published at Rodrigues dos Santos C, Fonseca I, Dias S, 
Mendes de Almeida JC. Plasma level of LDL-cholesterol at diagnosis is a predictor factor of 
breast tumor progression. BMC Cancer. 2014 Feb 26;14:132 (highly accessed paper).  
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Methods8 
Study population and data collection 
Study population and study design were previously described in chapter 1 and are briefly 
shown here (Figure 33). All women, who underwent for operable breast cancer at the 
Breast Unit of IPOLFG from January to December 2011, were prospectively assembled. 
Inclusion criteria: 1) 
invasive ductal carcinoma 
(currently named invasive 
carcinoma NOS78), 
confirmed by biopsy; 2) 
surgery as the first 
treatment with R0 
resection; 3) informed 
consent. Exclusion criteria: 
1) previous treatment 
(chemotherapy, 
radiotherapy, 
hormonotherapy); 2) 
hereditary breast cancer 
(confirmed by genetic 
analysis) or 3) taking lipid-
lowering, anti-diabetic 
drugs (statins, fibrates, oral 
anti-diabetics, insulin) or 
corticosteroid in the 
previous year. The study 
was approved by the Ethics 
Committee of the IPOLFG. 
Demography, risk factors 
and clinical examination were recorded in the first interview. Treatment was determined by 
the clinicopathological stage and patient characteristics according to the institutional 
protocols (following NCCN guidelines492), without changes related to the study (Additional 
                                               
8  The data collection was performed in collaboration with Breast Unit clinicians. The remainder tasks 
described in this chapter were performed by the candidate. 
 
 
Figure 33: Study Fluxogram 
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Table 2) . Fasting lipid profile was measured at diagnosis, along with routine preoperative 
exams. 
Follow up, after surgery and adjuvant treatment (when appropriate), was scheduled every 
6 months for 2 years and annual thereafter. Mammography was performed 1 year after 
surgery and then repeated yearly.  
Biospecimen collection. Pathological and Immunohistochemistry assays 
Fasting lipid profile was measured at diagnosis, along with routine preoperative exams as 
described earlier (Chapter 1).  
Hormonal receptors were measured using standardized immunohistochemistry. HER2 
was scored according to the WHO guidelines493 from 0 to 3+. All cases with 2+ score were 
reevaluated using chromogenic in situ hybridation.  Immunohistochemical staining for Ki67 
was performed in a Dako Autostainer® (Dako, Glostrup, Denmark) using standard 
protocols, followed by counting positive cells in an automated cellular imaging system 
(ACIS® II, Dako, Glostrup, Denmark I).   
Statistical analysis 
Continuous variables are presented as mean (standard deviation) or median (interquartile 
range) if they have normal distribution or not, respectively. For categorical variables 
absolute values and frequencies are shown. Spearman rank correlations coefficients were 
calculated to examine correlations between continuous variables.   
Patient subgroups were defined by LDL-C levels tertiles. Tumor characteristics (T stage, 
N Stage, immunohistochemical subtypes) and patient characteristics (BMI and age (by 
tertiles)) were studied as categorical variables.   
Kaplan-Meier curves were used to determine overall survival (OS) and disease-free 
survival (DFS) rates with use of log rank tests. Cox proportional hazards models were 
used to estimate hazard ratios with 95% confidence intervals (CI), relating LDL-C level to 
DFS. Multivariate Cox model was adjusted to tumor T stage, N stage and subtype.  
To assess the internal validity of our results we examined the association of lipid profile 
with BMI and age. The association of BMI and tumor characteristics, as well as OS and 
DFS adjusted to BMI were also determined. 
For statistical purposes, cases were censored at the date of disease progression 
confirmation, death or at June 9th, 2013, whichever came first. 
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Likelihood ratio P values are reported to whole variables in the model. All P values are 
two-tailed.  
The statistical analysis was done using IBM SPSS Statistics for Windows, Version 
19.0(Armonk, NY: IBM Corp. Released 2010). 
Results 
 
During follow up, 1 woman had local disease relapse, 16 women had systemic tumor 
progression and 7 died. Other 2 women died of unconfirmed disease (Figure 33). 
Survival and Cox Regression Model  
At 25 months of  follow up the DFS in LDL T1, LDL T2 and LDL T3  groups was  100%, 
90,6% and 88,3%, respectively (log rank test 0,013) (Figure 34 A). OS had no statistically 
significant differences between LDL-C tertiles groups (Figure 34 B). 
 
Figure 34: Overall and disease-free survival in LDL-C tertiles groups. Kaplan–Meier curves. 
A. At 25 months, overall survival is 100 % in LDL T1, 92,8%  in LDL T2 and 97,2% in LDL T3 (Log rank test P 
0,066). B. At 25 months, disease-free survival is 100% in LDL T1, 90,6% in LDL T2 and 88,3% in LDL T3 (Log 
rank test  0,013).  
 
The association of BMI and tumor characteristics, as well as OS and DFS adjusted to BMI 
were also determined and differences of DFS across LDL-C tertiles still significant (Figure 
35). 
 129 
 
 
 
 
F
ig
u
re
 3
5
: 
O
v
e
ra
ll 
a
n
d
 d
is
e
a
s
e
-f
re
e
 s
u
rv
iv
a
l 
in
 L
D
L
-C
 t
e
rt
ile
s
 g
ro
u
p
s
 a
d
ju
s
te
d
 t
o
 B
M
I 
K
a
p
la
n
–
M
e
ie
r 
C
u
rv
e
s
 f
o
r 
o
v
e
ra
ll 
s
u
rv
iv
a
l 
a
n
d
 d
is
e
a
s
e
 f
re
e
 s
u
rv
iv
a
l 
to
 e
a
c
h
 B
M
I 
te
rt
ile
 a
re
 s
h
o
w
n
. 
A
t 
2
5
 
m
o
n
th
s
 o
f 
fo
llo
w
 u
p
 d
is
e
a
s
e
-f
re
e
 s
u
rv
iv
a
l 
s
h
o
w
s
 d
if
fe
re
n
c
e
s
 a
c
ro
s
s
 L
D
L
-C
 t
e
rt
ile
s
, 
B
M
I 
a
d
ju
s
te
d
 (
L
o
g
 
ra
n
k
 t
e
s
t 
P
 0
,0
1
8
).
 B
u
t 
o
v
e
ra
ll 
s
u
rv
iv
a
l 
is
 n
o
t 
d
if
fe
re
n
t 
in
 L
D
L
-C
 t
e
rt
ile
s
 (
L
o
g
 r
a
n
k
 t
e
s
t 
0
,1
5
7
).
  
 
 130 
 
Cox regression model to DFS, adjusted to tumor T and N stages, and breast cancer 
immunohistochemical subtypes, revealed that LDL-C≥117 mg/dL, at diagnosis, is 
associated with poor disease-free survival (HR 0,129; CI 0,017-0, 978, P 0,048)(Table 10).  
Table 10: Cox multivariate regression model for disease-free survival 
Variable HR                     95% CI                  P value 
Tumor T Stage  (≥T2) 0,822 0,264-2,565 0,736 
Tumor N Stage (≥N1) 0,551 0,201-1,515 0,248 
LDL-C (> 117 mg/dL) 0,129 0,017-0,978 0,048 
Luminal A (yes) 0,599 0,072-5,017 0,637 
Luminal B (yes) 0,532 0,047-6,026 0,610 
Triple Negative (yes) 0,128 0,015-1,111 0,062 
HER2 type (yes) 
a 
-- -- -- 
a. Degree of freedom reduced because of constant or linearly dependent covariates 
LDL-C: Low Density Lipoprotein; T and N: TNM stages; HR: hazard ratio, CI: confidence interval 
 
Discussion 
 
All of the women included in the study were treated with curative (R0) surgery plus 
radiotherapy and or systemic therapy according to NCCN guidelines492. 
Curative surgery means that all macroscopic tumor (with clear margins) and clinical 
metastatic lymph nodes were removed. Radiotherapy had been shown to reduce local 
recurrence, and very recently was demonstrated to have also impact in late overall 
survival558. Chemotherapy and hormonotherapy have proved impact on survival559 
because are expected to eliminate distant subclinical micrometastasis.  
We previously shown that aggressive tumors were more common in patients with high 
LDL-C levels at diagnosis560 and here we demonstrate that these patients also have 
reduced DFS at 2 years of follow-up. LDL-C level appeared as an independent factor 
associated with worse prognosis, besides classical prognostic factors or tumor subtype. 
For operable breast cancer, 2 years of follow up may be considered short, but is also 
reported that disease relapse has a peak of incidence in the first 2 years after 
diagnosis561,562. As a limitation we could not avoid the possible influence of adjuvant 
treatment either in lipid profile or disease progression, once no modifications to the routine 
protocols were introduced. Nevertheless the strong association of LDL-C level and tumor 
size before treatment favors the LDL-C as a putative prognostic biomarker. It is also not 
possible to exclude the common association of cholesterol levels, obesity and the 
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variance in health awareness before diagnosis. However results were adjusted to BMI 
and, during follow up, all women were evolved in the same program of surveillance and 
health control.   
Elevated LDL-C is a well established cardiovascular risk factor but the significative 
differences in DFS of LDL-C tertiles groups and not OS, which would include 
cardiovascular causes of death, supports the independent risk for tumor-related event. 
Moreover, the adjustment to BMI, still show differences in DFS across LDL-C tertiles 
groups. 
The longitudinal correlation with LDL-C level at diagnosis favors a primordial selection; 
however the continuous effect of elevated LDL-C on micrometastasis could not be 
excluded because lipid profile was not systematically accessed after breast cancer 
treatment. The different metabolic patterns of the primary tumors found in chapter 3 
supports that cancer cells are not independent of the macrosystem and that the 
modulation of systemic metabolism could have impact on tumor cell metabolism and 
behavior: high systemic LDL-C levels may select for aggressive clones.  
On the other hand, cholesterol could also promotes other systemic alterations favoring 
tumor dissemination, independently of the tumor cells malignant potential, such as local or 
systemic inflammation, endothelium permeabilization, lymphatic concentration and 
flux563,564. 
Results expose that cholesterol metabolism, and specifically LDL-C levels, influence 
tumor behavior being a prognostic biomarker and an accessible therapeutic target. 
Being hypercholesterolemia a global prevalent feature, measurable and treatable, its 
management in breast cancer would have a major impact. Taken together, results 
strongly supports that plasma cholesterol levels must be evaluated and controlled in 
breast cancer patients and their effect should be analyzed in clinical protocols. 
 
Conclusion 
 
In conclusion, results expose that cholesterol metabolism, and specifically LDL-C levels, 
influence tumor behavior and is a prognostic biomarker and an accessible therapeutic 
target.  
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Final Discussion 
 
Our working hypothesis in this thesis was that a tumor is not an independent entity in an 
organism. Rather, it influences and must be influenced by the systemic (metabolic) 
environment.   
Despite the assumption that cachexia is a consequence of tumor spread and its metabolic 
needs, very little is known about the relationship of systemic metabolism and tumor 
behavior. Clinical and epidemiological studies have been providing evidence that obesity 
and diabetes, common metabolic features of Western societies, are associated with 
higher incidence and worse cancer prognosis. Some metabolic environments may 
potentiate tumor development, by acting directly on tumor cells or by promoting systemic 
modifications that favors tumor spread or reduce the host ability to antitumor defense. 
Although dyslipidemia, namely hypercholesterolemia, is also extremely prevalent, the role 
of systemic lipid metabolism in cancer is unclear and is still under intense scrutiny.  
Lipids are essential for vital cell functions, and therefore many steps of lipid metabolism, 
have been conserved over time and across the species. It is expected that tumor cells 
also make use of this well established property in nature. 
For these reasons, we wanted to know how the high prevalence of dyslipidemia correlates 
with tumor pathophysiology and how its control can change the natural history of the 
disease, using breast cancer as a model. Despite improvements in detection and 
treatment, it is the most common tumor in women remaining one of the most important 
causes of death worldwide. Moreover, several aspects of breast cancer biology, suggest a 
putative dependency of lipid metabolism. Breast epithelial cells themselves are dependent 
on the absorption of lipids from circulation for milk production; the majority of breast 
cancers are stimulated by steroid hormones, which are cholesterol metabolism derived; 
breast cancer is highly prevalent in regions with high incidence of dyslipidemia and 
interestingly we found an overlap in the pattern of global distribution of breast cancer and 
cholesterol levels in the population. 
Hence, the central question of this thesis was to study the role of systemic 
cholesterol metabolism in breast cancer development. 
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First, we reviewed the literature and observed that  
1) Epidemiological studies on breast cancer incidence and dyslipidemia are contradictory 
and although first reports associate cancer with low levels of cholesterol, this association 
is today accepted as a reversal causation. It means that the low levels detected in 
circulation reflect cholesterol consumption by the tumor. The unequivocal evidence of 
dyslipidemia as a risk factor for breast cancer similarly to what was shown to 
cardiovascular diseases, is very unlikely to be achieved by human studies, namely 
because of the long time course for tumor development. 
2) Laboratory (in vitro/ in vivo) findings support the causal influence of cholesterol in 
breast cancer pathogenesis. However, it should be noted that in vivo studies are very 
recent and were not available at the beginning of this project. 
3) Knowing that statins are commonly used to hypercholesterolemia control, we searched 
for evidence of the effect of lipid lowering drugs in breast cancer incidence. We concluded 
that studies were designed to assess cardiovascular endpoints and conclusions to 
oncologic measures are scarce. Nevertheless, ongoing trials on breast cancer prevention 
with statins should add some new and important information. 
4) Breast cancer patients usually have altered lipid profiles and modifications in that profile 
occur during different tumor stages, suggesting that the interaction of the tumor with the 
host systemic lipid metabolism is not constant over time. 
Thus, the available data indicate that the metabolism of systemic cholesterol influences 
breast cancer pathophysiology. Being a causal relationship so hard to demonstrate 
because of the need for lengthy studies and the impossibility to control all variables that 
interfere with the lipid profile over this period, we tried to focus on the role of cholesterol in 
breast tumor progression. 
The widespread use of screening mammography allowed the identification of subclinical 
tumor lesions considered early breast tumors. In clinical terms (human) this is the earliest 
tumor stage we can identify to study the natural history of the disease. So, we designed a 
prospective study including women with early breast tumor, with the most frequent 
histologic type (invasive carcinoma, NOS) and determine the lipid profile at diagnosis and 
before any therapy that could modify tumor characteristics. We also controlled the intake 
of drugs that could modify the lipid profile, including statins, fibrates, insulin, oral 
antidiabetics or corticosteroids. Likewise we controlled the individual variables which could 
interfere with lipid profile such as age, parity, menopausal status and BMI. Initial analysis 
clearly shows that LDL-C, and no other lipid profile variables, correlates with tumor size 
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and patients with high LDL-C levels have more aggressive tumors. Meaning these tumors 
have classical worse prognosis characteristics: high proliferative index, less differentiated 
and higher prevalence of HER2 positive tumors. 
These findings, together with the fact that the most common dyslipidemia type is 
high LDL-C with low HDL-C, lead us to go further on the understanding of the LDL-
C signaling mechanisms. 
In vitro exposure of breast cancer cells to exogenous LDL-C enriched medium intended to 
mimic systemic LDL-C influence on tumor cells. We initially used increasing LDL-C 
concentrations and observed a dose dependent effect until a noxious level (data not 
shown) and subsequently reproduced all the experiments with a concentration of 
100µg/ml, considering that interstitial LDL-C concentration is approximately 1/10 of LDL-C 
plasma concentration565. 
The cells exposed to higher concentrations of LDL-C developed a more aggressive 
phenotype, characterized by increased proliferative and invasive capacity; in agreement 
with the findings of the clinical study. Gene expression analysis of these cells revealed 
that exposure to LDL-C also induces genotypic changes. In other words, the more 
aggressive behavior of these cells seems to be induced by increased transcription of 
genes involved in cell proliferation and survival. It was also demonstrated the activation of 
cell signaling pathways related to cell proliferation and survival as Akt and ERK. 
To further corroborate these results, we used breast tumor orthotopic animal models (with 
different backgrounds and different types of cell lines) to demonstrate that dyslipidemia 
induced by cholesterol-enriched diet also recreates a phenotypic expression of increased 
aggressiveness in breast tumors. 
Although the clinical association of higher LDL-C levels and more advanced and 
aggressive tumors does not exclude a correlation of reverse causality; meaning that the 
highest serum LDL-C levels may correspond to a reaction to larger and more proliferative 
tumors rather than to be the cause of these phenotypes; studies in vitro and in vivo 
strongly support the hypothesis of LDL-C induces aggressive phenotype. These data also 
favor the notion that tumors are not metabolically independent of the organism and the 
modulation of the systemic environment can be used for prevention and treatment of 
breast tumors. 
After showing that systemic LDL-C promotes breast cancer progression, it was 
critical to understand how to prevent such effect. 
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Thus, the most direct way to reduce this worse prognosis phenotype would be to prevent 
dyslipidemia and or to treat dyslipidemia when diagnosed. The most widely used drugs in 
the treatment of hypercholesterolemia are statins. As an exploratory strategy of this 
approach to breast cancer we conducted a pilot trial with simvastatin in animal model. 
However, one problem in pre-clinical evaluation of statins is precisely the inability to 
reduce cholesterol levels in animals commonly used as models such as mouse. 
Therefore, despite the trend towards smaller tumors in the group treated with statins, this 
cannot be associated with lowered levels of LDL-C. It is known that statins can have side 
effects with benefit and in this case with an impact on tumor growth, such as the anti-
inflammatory properties. But we must also consider that the effect of statins may occur 
either in the liver with consequent reduction in systemic cholesterol levels, and in tumor 
cells themselves, leading to reduced synthesis of cholesterol and all pro-proliferative 
products derived from the mevalonate pathway (as demonstrated recently in in vitro and 
preliminary clinical results). Nelson et al342 also described a positive effect of atorvastatin 
in breast tumors volume in mice models, but do not show the cholesterol measurements. 
Furthermore, the threshold for considering dyslipidemia diagnosis and tretament values 
are widely studied for the prevention of cardiovascular events, but nothing is known about 
the limit values for cancer events. This was the reason that led us to not consider a 
threshold value for dyslipidemia in the study group (considering the cardiovascular limits, 
80% of women with breast cancer were advised to lipid lowering treatment) but rather a 
relative subgroup analysis which resulted in the demonstration of differential effects with 
higher values compared to the lower. Specifically, we found differences in behavior of the 
tumor to LDL-C levels greater than 117mg/dl. However tumor response to LDL-C levels is 
not straight forward, i.e. above very high LDL-C levels tumor agressiveness was not 
increasing, leading to assume that there is a saturation point value above which cell 
response no longer exist. Another possible explanation is that very high LDL-C level is 
harmful to cells whose cholesterol metabolism depends on exogenous supply (such as 
observed in vitro) and again the systemic metabolic environment selects tumors with 
different metabolic profiles attenuating the phenotypic expression of aggressiveness. 
This dependency on the exogenous supply was also our main interpretation for the 
overexpression of cholesterol exporters observed in the gene expression (microarrays) 
analysis. 
The high expression of ABCA1 (the main exporter of intracellular free cholesterol) in 
tumors exposed to high concentrations of LDL-C was one of the most intriguing findings. 
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For proliferative cells with high demanding of cholesterol and well adapted to a medium 
enriched in cholesterol, dispense of such a metabolite seems to be counterintuitive. We 
considered as the most plausible interpretation that this was a defense mechanism for 
cells that depend on the external environment to avoid excessive accumulation of 
cholesterol. We had previously found that too much cholesterol was toxic. However, while 
the inhibition of cholesterol export promoted cellular accumulation and reduced cell 
proliferation, this did not promote significant cell death. 
It was recognized (namely by the pivoteal contribution of Otto Warburg) that tumor cells 
even in the presence of oxygen reprogram the metabolism of glucose for less apparently 
efficient way of producing energy, the so-called "aerobic glycolysis" in which only 4 ATP 
molecules are generated per glucose molecule, instead of the 36 resulting from the 
oxidative phosphorylation. This process also leads to the production of lactic acid, which 
has been incriminated in the promotion of carcinogenesis. Some authors have identified 
various tumor cell populations with different metabolic needs namely with preference for 
lactic acid, and this metabolic switch is interpreted as a form of symbiosis between 
different tumor populations (Warburg effect). 
Similarly it is possible that cholesterol export to the interstitial space is a way of perpetuate 
the LDL-C signal induced to the surrounding cells. Similarly to the ability to incorporate 
glucose which has been used to clinically detect metabolic activity of tumor cells through 
the PET scan, the ability to incorporate LDL-C may also be useful for cancer detection 
and ABCA1 may serves as a marker of this metabolic feature and an approachable target 
to stop cancer cell communication. 
As an obvious way to stop this communication we prevented the internalization of LDL-C 
through the LDLR, which had no significant impact on the phenotype LDL-C induced. 
Although LDLR is known to be the main LDL-C receptor, there are others receptors 
documented, as SRBI or OLR that might keep the amount of cholesterol and 
communication. In any case from the systemic point of view, the blockage of LDLR would 
lead to an accumulation of circulating LDL-C with atherosclerotic consequences. The 
other way to stop this communication would be to block signaling through inhibition of 
ABCA1, which reduced cell proliferation and invasiveness. ABCA1 inhibition appears 
relatively specific in this chain and a better therapeutic target. We also had the opportunity 
to demonstrate that tumors of patients with high levels of LDL-C have overexpression of 
ABCA1, supporting the ABCA1 as biomarker of exogenous cholesterol dependency and a 
potential therapeutic target.  
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Blockage of this receptor was obtained in vitro and in vivo with a drug which 
pharmacokinetic and pharmacodynamics profile is well known in clinical practice –
glyburide (glibenclamide family). Even though in a pre clinical setting, this is an important 
contribution to the expansion of therapeutic armamentarium to breast cancer. The 
chemoprevention with other oral antidiabetic (metformin) is also in advanced stages of 
clinical studies and apparently with good results. The mechanism of action of 
glibenclamide is different from the mTOR pathway inhibition elicited by metformin and 
emerges as another potential and accessible therapeutic tool. Furthermore, statins by 
reducing HMGR and thus the intracellular concentration of cholesterol has the potential to 
also inhibit the expression of ABCA1 and may constitute another parallel benefit of statins, 
independent of plasma cholesterol levels. This potential action, provide additional support 
to ABCA1 inhibition. 
Like us, other groups recently identified ABCA1 as a player in breast cancer. Supporting 
our findings, Adlakha et al546, demonstrate that ABCA1 is post-transcriptionally regulated 
by miRNA-128-2, a pro-apoptotic molecule, being the ABCA1 protein negatively 
expressed in the presence of the miRNA. In a mice trial, levels of miRNA-128-2 were 
reduced upon high-fat diet as compared with normal diet in several tissues. Conversely, 
mRNA levels of ABCA1 were increased. The authors speculate if diet modulates miRNA-
128-2 expression, reducing pro-apoptotic stimulus and also leading to ABCA1 expression. 
In this case ABCA1 expression would have a protective effect against excessive 
cholesterol loading of endoplasmic reticulum membrane that triggers unfolded protein 
response which eventually lead to the induction of apoptosis547,548. Smith et al290 found 
that ABCA1 loss-of-function mutations lead to intracellular cholesterol accumulation which 
favors cancer initiation and considered ABCA1 as an anti-cancer molecule. Even though 
apparently contradictory to our observations, these findings support that cholesterol import 
or intracellular enhanced biosynthesis are pro-cancerigenous and so corroborates our 
data. The authors do not explored the setting of excessive cholesterol accumulation, due 
to ABCA1 loss of function, which would have the opposite outcome. Nevertheless, 
reaffirms that ABCA1 is an important and relatively specific player in the fundamental 
cholesterol metabolism of cancer cells. 
Particularly important in our studies was the follow-up of a population of patients with early 
breast tumors. At 2 years follow-up was possible to demonstrate that the levels of LDL-C 
at diagnosis correlated with tumor size at presentation and is an independent prognostic 
factor for DFS. 
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Several limitations should be considered in this analysis as the criteria for selection, the 
time of observation, adjuvant therapy impact, and possible changes in lipid profile. 
Because of selection criteria, only patients with initial surgical treatment were included. 
Knowing that triple negative tumors and HER2 type tumors are generally larger and have 
greater probability of lymph node metastases at diagnosis are more likely referred for 
neoadjuvant chemotherapy which led to an underrepresentation of these tumor types in 
the population. Although we had not found differences in lipid profile between different 
tumor types in the analysis of the population and a recent article demonstrating indirect 
activation of ER by cholesterol metabolites342, our experimental results show a greater 
effect of cholesterol availability on ER negative cells (MDA MB 231 and HTB 126 versus 
HTB 20). ER positive and ER negative cell lines seem to have differential lipid metabolism 
and needs and it is recognized that ER positive cells have impaired cholesterol 
biosynthesis compared to ER negative. 
Wang et al 283 found that differential expression of lipid metabolism genes may be involved 
in the risk for subtypes of breast cancer and are expressed at higher levels in the 
contralateral breast of ER negative cases leading to potential biomarkers to ER negative 
breast cancers. So the exogenous lipid dependency may be more crucial to RE negative 
cells. This is especially important because ER negative cancers have less therapeutic 
options. The demonstration that lipid metabolism modulation, namely 
hypercholesterolemia control would help in ER negative breast cancer prevention and 
treatment is a finding with expected high impact. 
In the natural history of operable breast tumors 2-year follow-up is too short, knowing that 
these are tumors with a very good prognosis, with a low rate of events and late recurrence 
(up to over 20 years). However, is also recognized that there is a peak of recurrence in 
this period and we can conclude that at least for early recurrence / progression there is a 
strong association with LDL-C levels in the diagnosis. 
Patients were treated according to the institution protocol and therefore subject to local 
adjuvant (radiotherapy) and systemic (chemotherapy/ hormonotherapy) therapy. 
Especially the latter is recognized to have impact on survival and this effect could not be 
excluded from the analysis. Furthermore, is known that tamoxifen and aromatase 
inhibitors interfere with lipid profile and even contribute for the control of dyslipidemia. One 
can speculate how the positive effect of its action also depends on this lipid profile 
modulation. Strictly speaking, a prognosis factor can only be validated in a population 
without other interventions; however it is not acceptable to deny the benefit of current 
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therapeutics to test new prognostic factors. Instead, they must be evaluated in the current 
treatment scenario. 
Nevertheless, even after the adjustment to important factors as tumor intrinsic prognostic 
markers and BMI, plasmatic LDL-C level at diagnosis still predictive of reduced DFS. 
From biological point of view these data strengthen the hypothesis that systemic 
metabolic environment in early stages of tumor development can select tumor 
characteristics. The immunohistochemical evaluation of a pilot sample to the key points of 
intracellular cholesterol metabolism in vivo, further corroborate this hypothesis suggesting 
the adaptation of the tumor to the environment that we had observed in vitro, including the 
overexpression of ABCA1 in cases of tumors grown in enriched-cholesterol environments 
. 
Despite this apparently direct effect of systemic metabolism of cholesterol in the primary 
tumor, we cannot eliminate the possible systemic influences of hypercholesterolemia in 
the body, which can also be facilitators of tumor progression and dissemination. 
Together, results strongly support an effect of systemic LDL-C in breast tumor progression 
and ABCA1 expression appears as a marker of tumor responsiveness to systemic LDL-C. 
This observation recalls the effect of systemic estrogen. Similarly the reduction in 
estrogen levels (e.g. ovarian castration or with aromatase inhibitors) or blocking of specific 
hormone receptors (e.g. tamoxifen) inhibits this proliferative effect, also the control of LDL-
C, or blocking cellular effector molecules may prevent its impact and need to be exploited 
clinically.  
 
In summary the results lead us to propose as the final model that breast tumors 
require cholesterol availability to proliferate and progress. If these tumors develop 
in a cholesterol-enriched environment, the well adapted tumors will be selected and 
dominate. The contribution of other cholesterol effects in the body for the 
enhancement of the progression and spread of tumors is still under evaluation. 
Results also support and impose a trial to test the effect of hypercholesterolemia 
control in breast cancer patients.  
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Importance of the findings and future perspectives 
 
The importance of our findings can be considered at two levels. The first, in a biological 
point of view, reveals that one tumor is not a collection of independent cells in the body. 
Conversely, it modifies the organism leading to overall degradation, but is primarily 
influenced by the host characteristics. Although this influence is often neglected, mainly 
because of the difficulty studying this issue, it likely extends to all dimensions of the body. 
Here we showed how systemic metabolism features and specifically, host cholesterol 
metabolism may influence tumor progression. Second, and extremely relevant, is the 
demonstration that a highly prevalent condition such as hypercholesterolemia may be 
among the risk factors for the progression of the most common and high mortality 
associated cancer in women. For prevalent pathologies, a risk or worsening factor even 
though not major has a giant scale effect. Presently, nobody doubts of the connection 
between smoking and cancer, but obesity and all its comorbidities are starting to replace 
tobacco as the main risk factor for malignancy. The demonstration of a correlation 
between two diseases as prevalent as breast cancer and dyslipidemia provides important 
information for the management of public health data. 
For now, our results clearly implicate cholesterol in the pathophysiology of breast cancer; 
disclose a predictive value of LDL-C level at diagnosis and expose the need to control 
hypercholesterolemia in women with breast cancer, once women with elevated LDL-C 
levels have a higher risk of cancer progression and cancer-related death.  
As future prospectives it is mandatory to conduct a clinical trial to evaluate the effect of the 
control of hypercholesterolemia in patients with breast cancer as a secondary prevention 
strategy. In parallel, more models must be developed (exprimentals and clinical) to clarify 
the role of cholesterol in tumor initiation and to understand if there is also a role for 
cholesterol control in primary prevention.  
Not of less importance and presently ongoing is the study of the effects of systemic 
metabolism in the organism, namely by producing changes that enhance tumor spread or 
metastasis in target organs. 
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Additional Tables  
 
Additional Table 1: Univariate logistic regression to the risk of 
tumor Size ≥20mm 
Variable 
Univariate Analysis 
HR   95% CI    P value 
N 
Total Cholesterol  T1  0,491 
 
0,285-0,845 0,010 
 
244 
Total Cholesterol  T≥2 
T1vsT2.T3 
1,912 1,113-3,285 0,018 244 
Total Cholesterol T3 1,489 0,869-2,550 0,146 244 
Total Cholesterol Q1 0,555 0,312-0,070 0,081 244 
Total Cholesterol Q4 1,351 0,763-2,395 0,301 244 
HDL-C T1 1,458 0,849-2,504 0,171 241 
HDL-C T≥2 0,686 0,399-1,178 0,171 241 
HDL-C T3 0,739 0,430-1,268 0,271 241 
HDL-C Q1 1,231 0,690-2,195 0,482 241 
HDL-C Q4 0,686 0,390-1,207 0,190 241 
LDL-C T1 0,413 0,238-0,718 0,002 243 
LDL-C T≥2 2,419 1,394-4,199 0,002 243 
LDL-C T3 1,556 0,904-2,677 0,133 243 
LDL-C Q1 
 
0,305 0,167-0,557 <0,0001 243 
LDL-C Q4 1,709 0,952-3,069 0,071 243 
Triglycerides T1 0,951 0,555-1,629 0,855 241 
Triglycerides T≥2 1,051 0,614-1,800 0,855 241 
Triglycerides T3  1,888 1,092-3,264 0,022 241 
Triglycerides Q1 0,989 0,552-1,772 0,970 241 
Triglycerides Q4 1,628 0,898-2,953 0,107 241 
BMI T1 0,560 0,117-0,990 0,045 221 
BMI T≥2 1,785 1,010-3,155 0,045 221 
BMI T3 1,438 0,823-2,512 0,201 221 
Age T1 1,453 0,848-2,487 0,173 244 
Age T≥2 0,688 0,402-1,179 0,173 244 
Age T3 0,833 0,430-1,416 0,499 244 
LDL-C: Low Density Lipoprotein; HDL-C: High Density Lipoprotein, BMI: Body Mass 
Index, T: tertile level, Q: quartile level; CI: Confidence Interval. 
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Additional Table 2: Breast Cancer Treatment 
Treatment 
 No. of 
Patients 
% 
Surgery 
   
   Mastectomy 
 
64 26,2 
   Breast Conserving  
 
180 73,8 
Chemotherapy 
 
165 67,6 
Trastuzumab 
 
29* 11,9 
Radiotherapy 
 
191 78,3 
Endocrine Therapy 
 
171 70,1 
* 13 cases Her2 Type; 16 cases Luminal B type 
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 Additional Table 3: Gene expression of LDL-C treated MDA MB 231 
 
Molecules in Network Score 
Focus 
Molecules Top Functions 
Up regulated 6h  
   ANGPTL4,FFAR3,GPR152, 
KIR2DL3,MAL2,MTRF1L,POLR3G, 
RN7SK,ROPN1,SLC25A20,SPRR2G 28 12 
Organismal Development, Lipid 
Metabolism 
CISH,CPT1A,IL24,PDGFD, 
PRLR,RETNLB,TNIP3 25 11 
Cancer, Reproductive System 
Disease, Cell Morphology 
TMEM229A 3 1 
Embryonic Development, Organ 
Development, Organismal 
Development 
LGALS9C 3 1 
Digestive System Development and 
Function, Embryonic Development, 
Tissue Morphology 
GRAMD1B,MAPK1 3 1 
Organ Morphology, Nucleic Acid 
Metabolism 
PCDHA8 3 1 
Embryonic Development, Organ 
Development, Organismal 
Development 
LCE2C  3 1 
Cell Death and Survival, Cellular 
Assembly and Organization, Cellular 
Development 
PCDHA13 3 1 
Cell Cycle, Embryonic Development, 
Renal and Urological System 
Development and Function 
GGT2 3 1 Drug Metabolism, Protein Synthesis 
S100Z 2 1 
Cancer, Carbohydrate Metabolism, 
Cardiovascular System Development 
and Function 
XCL2 2 1 
Reproductive System Disease, 
Cellular Movement, Cell Signaling 
Down regulated 6h 
   BHLHE40,BTG1,CCNG2,FASN, 
HMGR,IDI1,INSIG1,KRT80, 
LIFR,MVK 17 11 
Cellular Growth and Proliferation, 
Cellular Development, Cell Cycle 
CLDN7 2 1 Cancer, Cell Cycle, Cell Morphology 
TP53INP1 2 1 
Endocrine System Disorders, 
Gastrointestinal Disease, 
Inflammatory Disease 
AIM2 2 1 
Cell-To-Cell Signaling and 
Interaction, Inflammatory Response, 
Gastrointestinal Disease 
NPY1R 2 1 
Energy Production, Molecular 
Transport, Nucleic Acid Metabolism 
Up regulated 48h 
   AKR1C3,ASS1,ELF3,HIST1H4A, 
KRT7,KRT81,MT1E,MT1F,MT1X, 
RARRES3,TGFB3,TIMP3,WNT5A 15 13 
Cancer, Gastrointestinal Disease, 
Cellular Development 
ALOX5AP,C15orf48,CABLES1, 
CD74,CRISPLD2,EPAS1,GPR56, 
HLADRA,KIAA1199,PHB2, 
S100A2,S100A4,TACSTD2 15 13 
Cancer, Gastrointestinal Disease, 
Dermatological Diseases and 
Conditions 
HES1,ITGB4,LPCAT3,PBX1, 
PTGS1,STAT5B,TNFSF10 5 6 
Cell Death and Survival, Cellular 
Development, Cellular Growth and 
Proliferation 
ANGPTL2 1 1 
Connective Tissue Disorders, 
Developmental Disorder, Skeletal 
and Muscular Disorders 
SIX1 1 1 
Cellular Development, Cellular 
Growth and Proliferation, Tumor 
Morphology 
Down regulated 48h    
CSF2,DHCR7,DHCR24,EGR1, 
HMCR,IDI1,IL11, 
IL24,INSIG1,MVK,KRT15 20 11 
Cellular Development, Cellular 
Growth and Proliferation, Lipid 
Metabolism 
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Additional Table 4: Lipid Profile in Mice Trails 
 
 
 
Normal Diet Hchol Diet 
 
Normal Diet Hchol Diet 
 
Tumor 
 
Control 
Mice model/ 
Weight/Lipid 
Profile 
variable 
MDA MB231 
BALB SCID 
N=8 
MDA MB231 
BALB SCID 
N=8 
P value 
MDA MB231 
BALB SCID 
N=5 
MDA MB231 
BALB SCID 
N=5 
Weight (g) 19,6(±1,79) 19,9(±2,87) 0,6389 20,92(±1,50) 19,9(±1,85) 
TC (mg/dl) 126,8(±0,73) 372,3(±107,66) 0,0095 102,1(±17,42) 356(±84,79) 
LDL (mg/dl) 11,8(±25,19) 79,8(±17,29) 0,0095 9,7(±4,41) 66(±23,29) 
HDL (mg/dl) 40,3(±17,44) 106,8(±55,78) 0,0114 36,8(±8,76) 117,2(±42,23) 
Triglycerides 
(mg/dl) 
166,8(±47,77) 200(±34,33) 0,2571 271(±79,92) 114,7(±26,54) 
 
HTB 20 
BALB SCID 
N=3 
HTB 20 
BALB SCID 
N=3 
P value 
HTB 20 
BALB SCID 
N=2 
HTB 20 
BALB SCID 
N=2 
Weight (g) 19,9 (±1,90) 19,4(±1,82) 0,700 19,6(±1,06) 17,0(±2,12) 
TC (mg/dl) - 345,5(±34,05) 
 
125 262 
LDL (mg/dl) 16,5(±14,85) 82(±3,46) 0,200 13,5(±2,12) 111(±14,14) 
HDL (mg/dl) - 120(±11,728) 
 
- - 
Triglycerides 
(mg/dl) 
121 123,5(±3,54) 
 
142 - 
 
4T1 
NOD SCID 
N= 4 
4T1 
NOD SCID 
N=  
P value 
4T1 
NOD SCID 
N=2 
 
4T1 
NOD SCID 
N=2 
 Weight (g) 19,1(±2,85) 20,2(±2,17) 1,000 21,1(±0,40) 23,3(±0,85) 
TC (mg/dl) 95,67(±22,9) 278,7(±58,11) 0,0071 199,0(±173,95) 333,5(±99,70) 
LDL (mg/dl) 17,3(±4,04) 105,3(±47,16) 0,0323 5(±5,65) 50,5(±23,33) 
HDL (mg/dl) 23(±7,94) 53,7(±16,92) 0,0468 48(±43,84) 54,5(±34,65) 
Triglycerides 
(mg/dl) 
93,7(±49,17) 157(±58,39) 0,2240 250(±207,89) 317,5(±135,06) 
Hchol: Hypercholesterolemic ;TC: Total cholesterol; LDL: LDL-C: Low Density Lipoprotein; HDL:HDL-C: 
High Density Lipoprotein. Values are represented by mean±SD. P value : Student t test. 
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Additional Figures  
 
 
Additional figure 1: LDLR expresion in human breast tumors 
A. LDLR staining (1:100; ab30532 from Abcam, liver as positive control) was performed in breast cancer 
samples of 14 consecutive patients of each LDL-C tertile group of the studied cohort population (each tercile 
group represents groups of patients with increasing systemic LDL-C levels).  
Measurements of LDLR expression was based on topographic score (0 to +3) of antibody staining tissue 
distribution accessed under microscopy by two independent observers. Measurements of both markers were 
made based on topographic score (0-+3) of antibody tissue distribution and cell intensity accessed under 
microscopy by two independent observers. LDLR expression was observed in primary tumors of all patients 
without significant variations. B. Representative photos of each group are shown. P value and the number of 
the experiments are represented in the figure. Columns mean; bars ±SEM. LDL:LDL-C: Low Density 
Lipoprotein.  
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Additional figure 2: Inhibition of LDLR does not prevent the accumulation of intracellular 
cholesterol and LDL-C induced phenotype 
If the cholesterol induced phenotype is dependent on LDL-C signaling, we asked if reduction in LDL-
cholesterol up take would produce phenotype attenuation, by reducing intracellular cholesterol. To this aim we 
performed functional tests of proliferation and migration in cells transfected with siRNA for LDLR, a major LDL-
cholesterol acceptor. We could demonstrate inhibition of LDLR expression(A), but this did not significantly 
reduce cell proliferation(B) and migration (B) induced by the presence of LDL-C. 
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